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Chapter 1
Diagnosis of Breast cancer
Breast cancer is a major health issue in the Netherlan ds,even though mortality has been reduced 
by approximately 23.5% due to the national bi-annual mammography screening program in all 
women between 50 and 75 years of age [1] and improvements in therapy. The incidence of 
breast cancer has gradually increased at an estimated rate of 1.2% per year [2].
Breast cancer accounts for nearly one third of newly detected malignancies in women (32,8%) 
and is still the cause of death for almost 5% of all women who annually die (4.7% 2008) [2,3]. 
Trends in breast cancer incidence rate and breast cancer mortality are depicted in figure 1. 
Consequently, optimization of diagnosis and treatment to further reduce the mortality and 
morbidity of breast cancer is essential.
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Fig 1 : Trends in breast cancer incidence (A) and breast cancer mortality (B) as provided by the Dutch 
National Cancer Registration. Reported rates are European Standardized Rates (ESR)
Currently, detection of breast cancer leans on three supporting pillars. The first is physical 
examination, either by the patient herself, the general practitioner or a dedicated surgeon. 
Although physical examination is known to be a very insensitive technique [4,5], a large 
proportion of tumors is first detected by palpation [6,7]. Mammography is the second and 
probably most important pillar of breast cancer detection due to its value in mass screening 
[1,4,8], even though sensitivity is only about 70% [9]. Ultrasound, the third pillar, has currently 
little value in screening for breast cancer, due to the fact that it is very operator dependent 
and time consuming [10]. Nevertheless the technique is invaluable in the evaluation and 
assessment of palpable breast lesions as it can clearly differentiate cystic from solid lesions. 
Moreover, ultrasound guided biopsy is the easiest way of obtaining histologic material from 
solid lesions, which is indicated in virtually all lesions that are not typically benign.
Nevertheless, diagnosis consists of more than just detecting a cancer. According to Merriam 
Websters dictionary, diagnosis is "1 a : the art or act of identifying a disease from its signs and 
symptoms b : the decision reached by diagnosis". In more medical terms, the 1b explanation 
translates to staging, because virtually all treatment protocols define the optimal treatment
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procedure by the actual disease stage. Consequently, adequate treatment of any disease can 
only start after a good and complete diagnosis. Basically, knowing what you treat determines 
how you treat it, or: if your diagnosis is insufficient, so will your treatment be.
Unfortunately, this simple approach raises two major problems:
1) It is unclear how much you need to know to provide optimal treatment
2) It is unclear how to deal with new information when treatment protocols are 
based upon less than perfect staging
Mammography and ultrasound in tumor staging:
Current staging in breast cancer is based upon the same pillars as tumor detection: clinical 
examination, mammography and ultrasound [11]. This is historically determined; there is no 
evidence available that these techniques are the best staging methods. However, many studies 
have shown that mammography and ultrasound are both better in assessment of the size of 
malignancies than clinical examination. Until recently this approach was thus accepted as the 
standard of care.
Breast MRI
In 1971 Raymond Damadian showed that relaxation in NMR experiments differed between 
normal and malignant tissue [12]. This basic knowledge made the prospect of imaging magnetic 
relaxation of tissues worthwhile. The first magnetic resonance images were produced by Paul 
Lauterbur in 1972. He showed that using magnetic gradients it was possible to locate the origin 
of a radio signal emitted by nuclear spins within an excited body [13]. From here onwards, the 
field of magnetic resonance imaging has rapidly grown. Image quality, tissue differentiation 
and imaging speed have largely improved over the years.
The first in vivo MR imaging study of the breasts has been reported by Ross in 1982 [14]. This 
study, as well as subsequent work from El Yousef and colleagues [15-19], showed the potential 
of breast MRI to detect breast lesions. However, image contrasts between normal tissue and 
malignant lesions were poor and hence only large lesions were detected. In general, the 
sensitivity of breast MRI at this time was comparable to that of mammography at a much higher 
expense.
The value of breast MRI changed radically when gadolinium containing contrast agents were 
for the first time administered to detect breast cancer (fig 2) [20]. These contrast agents (at 
first only Gd-DTPA, later also several other gadolinium chelates such as Gd-DOTA, that was 
used for most patients in the studies described in this thesis) are diamagnetic and shorten 
the T1 relaxation time of surrounding tissue [21]. This results in enhancement at T1-weighted 
images. Contrast agents are given as a bolus and remain mainly intravascular. Diffusion to
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the extravascular extracellular space (the contrast agent does not cross the cell membranes) 
occurs only slowly due to the tight endothelial lining of capillaries [22,23]. In tumors over 2 
mm, however, diffusion of nutrients is no longer sufficient to support growth [24], and vascular 
growth factors are up-regulated. Consequently, new vessels are formed in and around the 
tumor. The quality of these new vessels is much poorer than that of normal vessels. They are 
wide, tortuous and the endothelial lining of the vessel wall is often defect, hence these vessels 
are leaky. In other words, contrast agents can exit the capillaries easier, and rapidly accumulate 
in the extravascular extracellular space. Based on this physiological principle, most tumors over
2 mm in size enhance on T1-weighted imaging, and in practice, most do.
Fig 2: Coronal T1 weighted breast MRI o f both breasts. In the left breast a 3.6 cm ILC is present. The 
tumor is hardly visible without contrast (AA), but clearly enhances after contrast administration (Bí), 
although differentiation from tatty tissue is still difficult without unenhanced images. Subtraction 
o f the unenhanced IM RI trom the contrast enhanced MRl nulls the fat signal and cleariy shows the 
enhancing tumor (C).
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Since 1986, many studies have evaluated breast MRI in different cohorts of women. The 
results are similar in all studies. Sensitivity for malignant breast lesions is higher than with 
mammography, ultrasound, and clinical examination. A recent meta-analysis estimated the 
overall sensitivity to be 90% [25].
A minor drawback is, that other entities that result in leaky microvasculature, will also enhance. 
Among these most notably inflammation and fibroadenoma [26]. The latter is a benign and 
very common breast lesion, that may resemble carcinoma. Consequently, specificity of MRI is 
only 72%. This implies, that histological confirmation of all MRI detected lesions is required.
Breast MRI in preoperative staging
The high sensitivity of breast MRI when used in a screening setting results in an increased 
detection of cancers. However, MRI screening is currently only indicated in high risk patients, as 
it has not been tested in other populations [27,28].
MRI is therefore often performed in patients with known primary tumors to accurately stage the 
tumor. However, the value of MRI in this setting is heavily disputed because all studies currently 
performed have regarded breast MRI solely as a diagnostic modality.
Different from studies of therapeutic agents that require a systematic review of randomized 
controlled trials, the highest quality of evidence for diagnostic tests (according to the center 
for evidence based medicine in Oxford (CEBM)) is reached by a systematic review of validated 
cohort studies with a good reference standard [29]. The main reason for the difference is that it 
is well possible to subject a patient to multiple diagnostic tests (with or without results blinded 
to the other test) and hence perform a matched cohort analysis, whereas it is impossible to 
subject the same patient to different treatment regimes.
Unfortunately this is conflicting with the levels of evidence for diagnostic tests as proposed 
by Fryback and Thornbury [31-33]. They describe six levels of evidence ordered in an one-way 
hierarchical model (fig 3). Evidence of efficacy at a certain level of the model implies efficacy of 
all lower levels, but does not imply anything about higher levels. Using the quality criteria for 
diagnostic studies of the CEBM, only evidence up to the fourth level can be generated.
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Fig 3: One-way hierarchical model o f the levels o f evidence o f diagnostic tests, according to Fryback 
and Thornbury. Evidence o f improvement at one level implies positive results at all lower levels, but 
does not imply anything about hierarchically higher levels.
At the bottom of the model in diagnostic radiology is the technical capability to obtain 
adequate images, which is mainly the domain of physicists. It goes without saying that breast 
MRI (especially at 1.5T) has met these demands, even though new developments continue to 
be tested. The second level describes diagnostic accuracy and is an area that includes most 
radiological studies. At this level the sensitivity and specificity of the modalities are tested and 
weighted. In the preoperative setting, this does no longer regard the actual tumor detection 
(the presence of the tumor is already established), but instead includes the staging capabilities 
of the various imaging modalities. Hence, the quality of predicting the pathological size of 
the tumor, and the detection of additional lesions in the affected breast are major endpoints. 
Once again, many well-documented studies have shown that breast MRI is better in tumor size 
estimation and detection of additional lesions than either mammography and ultrasound [34]. 
The third and fourth level of evidence are highly connected and describe the impact of a 
diagnostic test on, respectively, diagnostic thinking and therapeutic management of a patient. 
Since breast MR often detects more extensive cancer spread, its effects at the third and fourth 
level are predictable: a surgeon who initially thought that his/her patient had a small breast 
cancer, suddenly realizes that the tumor burden is much larger (3rd level), consequently the 
proposed therapy shifts from local excision to a wider local excision or even mastectomy (4th 
level). These effects at the 4th level have been well studied and a recent meta-analysis showed 
that breast MRI revealed significant additional information in 16% of patients (3rd level), which 
resulted in a conversion to more extensive surgery in 11.3% of patients, including 8.1% change 
from local excision to mastectomy [34].
Actually, it is possible that in preoperative staging the 3rd and 4th level are more connected
12
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than they should be. Sometimes it may be useful to know that additional tumor foci are present 
without altering surgical treatment. Already in the 70s, when breast conserving therapy was 
investigated as replacement for mastectomy, it was known that in many patients tumor was left 
in situ. The high rate of local recurrence without radiotherapy and, consequently, the need of 
radiotherapy in all patients after breast conserving surgery are also mere acknowledgements of 
the fact that surgery in many patients is debulking rather than curative. On the other hand, local 
recurrence rates after breast conserving therapy (6-10%) are still higher than recurrence rates 
after radical mastectomy, though this appears not to affect overall survival.
The rather dogmatic resection of the visible tumor load on mammography is proven effective, 
but there is still room for improvement. Nevertheless, it is by no means sure that MRI detected 
additional tumor foci also need to be resected when curation can also be expected from 
radiotherapy and chemotherapy.
Consequently, the fifth level of diagnostic evidence includes patient outcome. The quality of the 
diagnostic test is no longer rated in relation to the quality of another diagnostic test, but instead 
it is regarded as part of the therapy. In the evaluation of diagnostic modalities patient outcome 
is generally neglected. Vice versa, most therapeutic trials start only after diagnosis is established 
and neglect the fact that the modalities used to come to a diagnosis are serious contributors to 
the eventual outcomes [35]. Level 5 evidence is only sparsely available for diagnostic modalities 
because validated cohort studies evaluating diagnostic modalities are, as stated before, unable 
to provide this kind of evidence. Instead, modalities that have already proven their value at 
the 4th level and thus substantially influence therapeutic management should be assessed 
as new therapeutic options. They consequently should be tested in randomized controlled 
trials. Although this is understandable from a methodological point of view, serious ethical 
objections to such study designs arise when new diagnostic modalities have been shown to be 
substantially better than conventional diagnostic modalities. This seriously limits evaluation of 
diagnostic tests in patient outcome.
In preoperative staging of breast cancer with MRI the principal outcome parameters to be 
tested are mortality and disease related morbidity (local and distant recurrence). However, since 
these are long term outcome parameters and the effect of better staging is probably small in 
respect to the effect of radiotherapy and adjuvant chemotherapy, studies with large numbers of 
patients need to be performed. For practical purposes, the rate of incomplete tumor resection 
may be chosen as a surrogate short term outcome parameter. The rationale for this outcome 
parameter is easy to understand: regardless of the value of the detection of additional distant 
lesions on MRI, incomplete tumor excision is followed by re-excision. Tumor extension of the 
index lesion is more accurately measured using MRI. Therefore, it should be easier to excise 
the tumor completely at the first attempt and hence less re-excisions will be necessary. Such 
a study basically tests the capability of radiologists and surgeons to transfer the knowledge of 
preoperative acquired imaging to the operating room.
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In order to test the value of preoperative breast MRI at the 5th level, we designed the PREOP study. 
The goal of this study was to investigate whether or not the performance of preoperative MRI could 
reduce the rate of re-excisions necessary for initial incomplete surgery. Moreover the study would 
allow long term follow-up of the cohorts to observe differences in recurrence and survival. First, 
the performance of preoperative MRI was defined to be an experimental modality. Patients with 
breast cancer who were to undergo primary surgical resection were randomized to preoperative 
MRI or no preoperative MRI. Nevertheless, according to the study design, all patients underwent 
preoperative MRI, but the images were only interpreted and reported in 50% randomly selected 
patients. The MR images in the remaining 50% of patients were not interpreted, but saved outside 
of the PACS system for retrospective comparison of the cohorts at the end of the study.
The study was approved by the ethical committee of the UMC St Radboud and all patients 
provided informed consent. However, patients in whom staging with conventional methods was 
inconclusive (virtually all patients with more than 50% fibroglandular tissue at mammography 
and virtually all patients with tumors over 2 cm at mammography), were offered preoperative MRI 
outside of the study protocol, due to ethical objections within the multidisciplinary treatment 
team. Moreover, large international studies [36] showed that preoperative MRI detected additional 
tumors in the contralateral breast in 3.1- 19% of patients that are not treated if not reported [36­
39]. This latter finding subsequently resulted in the Eusobi (European Society of Breast Imaging) 
recommendation to perform preoperative breast MRI in all patients [27]. Consequently, due to 
serious ethical and methodological objections of the performer (R.M. Mann) and the principal 
investigator (C. Boetes), both authors of the Eusobi guideline, the PREOP study was stopped after 
accrual of only 8 patients.
Nowadays, some evidence has become available that shows that the transfer of knowledge from 
the preoperative MRI to the operation room is more difficult than expected. In a study by Pengel 
et al. overall no significant reduction in the rate of tumor positive surgical margins was observed 
(MRI -19,4%, MRI + 13,8%, p=0.17). Nevertheless, they did observe a reduction in the rate of 
tumor positive surgical margins from 8,1% to 1,6% in the subgroup of invasive ductal carcinomas 
(p=0.02), and consequently preoperative MRI may prevent some re-excisions in this population 
[40]. However, in a similar study by Bleicher et al. no effect of preoperative MRI was noted except 
for a higher rate of mastectomies in the MRI+ group. This group was thus truly unable to use the 
MRI information to the benefit of the patient [41]. Studies evaluating the long term outcomes 
after implementation of preoperative MRI are equally sparse. The two available studies show 
conflicting results: While Fischer et al. documented both a reduction in local recurrence and a 
reduction in metachronous contralateral breast cancers, Solin et al. did not detect any differences 
[42,43].
It may not be surprising that, since efficacy of preoperative breast MRI has not been shown 
at the fifth level, and in fact has hardly been investigated, no studies have yet assessed level 
number 6, the societal level. This is the cost-effectiveness of the diagnostic test from a societal 
viewpoint, the top of the pyramid.
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Despite the fact that many small studies investigated breast MRI at the lower levels of the 
hierarchical pyramid of Fryback and Thornbury, structured reviews of the available data, 
providing higher quality evidence according to the CEBM, were lacking at the time of initiation 
of this thesis. Moreover, evidence for the value of preoperative breast MRI at higher levels of the 
pyramid is not available. Consequently, it is essential to further increase the level and quality of 
evidence for the performance of breast MRI.
Invasive lobular carcinoma
Invasive lobular carcinoma (ILC) is the second most common form of breast cancer reported in 
5-20% of patients. Its relative frequency has been increasing in the last decades. This is probably 
related to the increased use of complete hormone replacement therapy in perimenopausal 
women [44,45]. The reduced use of this therapy in recent years may already have resulted in a 
small decrease of the incidence of ILC [46]. ILC derives its name from the old assumption that 
the tumor arises from the lobules of the glandular tissue [47], whereas the more common form 
of breast cancer, invasive ductal carcinoma (IDC), arises from the milk ducts. Since most breast 
cancers, including IDC and ILC, have been shown to arise from the terminal ductal lobular units, 
these common breast cancers are somewhat inappropriately named [48,49].
The main difference between IDC and ILC is their growth pattern with ILC tending to grow more 
diffusely. The 'classic type' lobular carcinoma consists of relatively small, uniform cells that grow 
in a loosely cohesive fashion, forming lines of cells infiltrating the healthy tissue -  so called 
Indian files (fig 4). Often formation of webs around healthy ducts referred to as targetoid growth 
is reported. Moreover, skip lesions i.e. areas of tumor separated from the index lesion by normal 
breast tissue are more common than in IDC [50,51]. Moreover synchronous and metachronous 
contralateral carcinomas are more often observed in ILC compared to IDC [52].
The genetic basis for these differences is probably due to a mutation in the E-cadherin gene 
(CDH1). E-cadherin is strongly related to cell-cell cohesion and affects morphology and motility 
of cells. Hence a lack of E-cadherin expression may be the cause for the disjointed growth of 
ILC [50,51,53]. Apart from the lack of E-cadherin expression, biologically classic ILC resembles 
low grade IDC. Similarly, the more aggressive subtype pleiomorphic invasive lobular carcinoma 
resembles high grade IDC.
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Fig 4 : Ten times enlarged HE-stain o f an ILC. Note the relative uniformity and the lin ear arrangement 
o f the small round cancer cellsi (Courtesyof Dr. P. Bult, RUNMC Department o f  pathology)
There are only a few other documented differences between IDC and ILC. ILC are generally 
larger at detection than IDC and are more often estrogen and progesterone receptor positive.
Furthermore, ILC metastasizes to locations that are extremely rare for IDC, such as the gastro­
intestinal tract, the retroperitoneum, the gynecological organs and the leptomeninges (fig 5, 
fig 6) [54,55]. However, the most common metastatic sites for ILC are the lungs, the liver and 
bones (fig 6, fig 7).
Outcomes are not very different with a 5 year disease free survival of 85.7 vs. 83.5% for ILC and 
IDC respectively [52]. Some studies suggest even a slightly better outcome for ILC than IDC, 
regardless of the often larger size of ILC at diagnosis [56,57]. Currently, there are no differences 
in treatment based on the histopathological differentiation between IDC and ILC [11].
16
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Fig 5: Axial T1 weighted MRI images o f the brain after intravenous administration o f 15 m l Gd-DOTA 
in a 62 year old patient 5 years after detection and treatment o f a pT2N3a ILC, who presented with 
nausea, vomiting and confusion. Note the diffuse leptomeningeal enhancement (arrows), which 
was later shown to be meningeal carcinomatosis (diffuse ILC metastasis) by lumbar puncture.
Fig 6: Postcontrast axial CT images o f a 59 year old woman, 3 years after detection and treatment 
o f a pT3N2a ILC, who presented with bilateral hydronephrosis, caused by a large irregular 
retroperitoneal mass (arrows) obstructing both ureters. Histology was obtained, showing diffuse 
metastasis o f ILC. The hydronephrosis was treated with bilateral nefrostomy (inset A). Also note the 
multiple hypodense liver metastases and sclerotic metastases in the vertebral bodies (inset A and B).
17
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Fig 7: Images o f a 47 'year old woman, presenting with a T4 ILC. She underwent whole body MRI 
to screen for distant metastaseo The whole body STIR acquisition (len) and the post contrast (15 
ml Gd-DOTA) T1 weighted VIBE acquisition (right) show a large metastasis central in the liver, with 
tentral necrosis. The patient undorwent nemadjuvant chemotherapy, to which she reoponded very 
well, 6 months later the life r metastasis was no longer visible and the primary tumor wa f  surgically 
removed.
The thesis
Despite the relative small differences between IDC and ILC, ILC presents a major diagnostic 
challenge. The tumors are, due to their diffuse growth pattern, more difficult to detect than IDC. 
The diffuse infiltrative growth pattern is also the most likely explanation for why ILC tends to 
be larger than IDC. Moreover, the growth pattern of ILC makes mammography and ultrasound 
unreliable at staging, thus causing high rates of tumor re-excision and leading to a common 
preference by both patients and surgeons to perform mastectomy. Fortunately, studies have 
shown, mastectomy rates for ILC are decreasing [58,59].
Since breast MRI has shown to be better at tumor staging compared to conventional tumor 
staging using clinical examination, mammography and ultrasound, the use of MRI may be 
especially valuable in the preoperative staging of the subgroup of patients with ILC. However, 
whether staging with MRI is beneficial for patients with ILC is still unknown.
18
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The principal goal of this thesis is to increase the quality and level of scientific evidence regarding 
the use of breast MRI in patients with ILC in order to provide a general recommendation for the 
use of breast MRI in these patients. This recommendation should be supported by high quality 
evidence up to level 4 and at least some level 5 evidence, because nowadays the use of new 
diagnostic modalities can no longer be recommended or disencouraged without taking patient 
outcomes into account. To reach this goal, we defined sub goals as listed below:
- Summarize and qualify the available evidence for breast MRI in ILC up to the fourth level
- Detect the gaps in the available evidence for breast MRI in ILC up to the fourth level
- Fill the gaps in the available evidence for breast MRI in ILC up to the fourth level
- Evaluate the performance of preoperative breast MRI in patients with ILC at the fifth level
- Define a standard for performance of high quality breast MRI in general
The final recommendation is provided in the general discussion and conclusions (Chapter 10). 
This recommendation is based on all available evidence currently present and although it leans 
heavily on the other works in this thesis, it does not neglect the valuable contributions of other 
investigators prior to or during the period I have been working on this thesis. Consequently, I 
hope to provide a recommendation that can be considered as "state of art", rather than a more 
limited conclusion of the results of this thesis only, which are in itself just pieces of the puzzle.
Outline of the thesis
In Chapter 2 the differences between invasive ductal and invasive lobular cancer are discussed 
in depth from a radiological point of view.
Chapter 3 discusses the evidence to support the use of preoperative MRI in ILC at the start of 
the present work. It provides a global overview that should be regarded as an introduction to 
the subject.
In the systematic review in Chapter 4, the available evidence for the performance of MRI in 
patients with ILC is structured and analyzed. We used meta-analytic techniques to increase 
the scientific value whenever possible and tried to identify the gaps in the currently available 
evidence.
Chapter5 is a sidestep that explains the use of very rapid imaging and subsequent analysis to 
obtain quantitative enhancement parameters, that cannot be derived from more conventional 
imaging with a high spatial resolution and a relative poor temporal resolution.
Some of these rapid techniques, as well as conventional imaging and CAD applications are 
subsequently used in Chapter 6 to evaluate the actual differences between IDC and ILC on MR 
imaging, since no studies actually compared the two types of cancer directly.
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In Chapter 7 the correlation between MR measured tumor size and size at histopathology was 
re-addressed, on one hand because the available data were too sparse and too heterogeneous 
to allow meta-analysis, on the other hand because we tried to identify a cause for the sometimes 
observed overestimation of tumor size on breast MRI.
These results culminated in Chapter 8 in a study to the only thing that really matters, namely 
whether the patient actually benefits from preoperative imaging with MRI in case of ILC. For 
reasons explained above, the rate of re-excisions and the rate of mastectomies were addressed 
in a retrospective cohort study stratified by the use of preoperative MRI.
Chapter 9 provides guidelines for the use of breast MRI. Technical demands are described and 
indications are discussed. Although partly based on the results of above mentioned studies, the 
guideline was printed before some of the studies above appeared in press, hence statements 
on the use of preoperative MRI in patients with ILC are still rather conservative.
In the general discussion and conclusions presented in Chapter10, the current evidence 
for the use of preoperative breast MRI in ILC is revisited, a general advice is formulated and 
shortcomings are discussed. Chapter 11 provides a Dutch translation of these findings. A short 
note also addresses the general role of breast MRI in the near future; in Appendix 1 a specific 
feature of breast MRI in the future is discussed in more detail.
20
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Differences in incidence
Invasive ductal carcinoma (IDC) is by far the most common type of malignant breast lesions. 
Various authors report the fraction of IDC between 70 and 90% of all breast cancers [1,2]. The 
second most common form, invasive lobular carcinoma (ILC) is therefore much less prevalent 
and is reported to constitute between 5 and 20% of all breast cancers. However, incidence rates 
of ILC have been increasing over the past decade, possibly due to the extensive use of complete 
hormone replacement therapy (CHRT). This is nowadays well recognized and the use of CHRT 
has decreased, but the effect on the incidence of ILC is not (yet) visible [2]. Other types of breast 
cancer, e.g. medullary carcinoma, tubular carcinoma or mucinous carcinoma, are even more 
rare and will not be further considered in this article.
Pathologic differences
The terms 'ductal' and 'lobular' are used to describe the behaviour and growth pattern of the 
tumor. Although, one would expect a ductal carcinoma to arise in the ductuli of the breast and 
a lobular carcinoma in the lobules, most tumors arise at the terminal ductal-lobular unit [3] and 
'ductal' and 'lobular' are thus not indicators of the site of origin.
The pathologic features of IDC are highly variable. This is mainly the result of the fact that IDC is 
a diagnosis 'by exclusion'. In other words, a breast tumor is called IDC when no specific histologic 
features that would classify it as a specific type of breast cancer are present [4]. A typical IDC 
grows as a mass and produces a strong desmoplastic reaction in the surrounding tissue. 
Macroscopic examination of the pathology specimen shows a gray-white mass, sometimes as 
hard as rock, due to the extensive desmoplastic reaction of the surrounding tissue [5]. Invasive 
ductal carcinomas that consist of tumor cells only, with little or no desmoplastic reaction, are 
tan and much softer. Microscopic histopathology in these tumors is also highly variable and 
different histopathologic features can be present in a single case. Often necrosis is present, 
which can be extensive. The appearance of the cells ranges from almost normal epithelial breast 
cells to severe pleiomorphism and nuclear atypia and mitotic activity ranges from normal to 
marked. Ductal carcinoma in situ (DCIS) is often found in and around IDC, and is frequently 
regarded as the precursor lesion of the invasive carcinoma [6]. Although, in some cases DCIS 
is the prominent feature of the lesion with only minimal invasive components, in other lesions 
DCIS may be completely absent.
The distinguishing feature between IDC and ILC lesions is the typical growth pattern of ILC. 
Although some ILC have an appearance very similar to the classic pattern of IDC at gross 
pathology, often no evident mass can be seen and the specimen will only have an odd rubbery 
consistency while even in other ILC no macroscopic abnormality can be found [4]. 
Microscopically, the classic form of ILC is characterized by uniform, small round cells with small 
regular nuclei with only little mitotic activity that invade the stroma in a single-file pattern 
around the ducts. This is known as Indian filing and is probably the main reason for the fact
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that these tumours are often much larger than initially appreciated. The infiltration of the 
surrounding tissue in these tumors often cause (almost) no desmoplastic stromal reaction. 
Cohesion of the cells in ILC is often very loose due to the typical loss of the adhesion molecule 
E-Cadherin. This is also one of the most prominent differences between ILC and IDC, because in 
the latter this molecule is (in varying degrees) present [7]. Apart from the classic form, several 
variants of ILC are recognized: some are characterized by a different growth behaviour, while 
others have a similar growth behaviour but a different cellular appearance. In some ILC several 
variants are present and these are consequently designated as 'mixed' [4].
As in earlier series in the literature only the classic form of ILC was recognized, the currently 
reported increase in the incidence rates may also be partly contributed to the recognition of the 
variant types of ILC [4]. Both IDC and ILC lesions are pathologically very heterogeneous entities. 
Histologic grading is performed for both types of cancer. Tumor grade is usually lower (i.e. more 
benign) for ILC than for IDC lesions; also the mitotic activity index (MAI) is usually lower for 
ILC than for IDC lesions. Furthermore, the biological characteristics between the two groups 
are different and usually more benign in ILC. Invasive lobular carcinomas more often express 
estrogen and progesterone receptors and more often exhibit a normal expression of p53 and 
HER-2/Neu [1].
Diagnostic differences
The patient presentation is generally slightly different between patients presenting with ILC and 
patients presenting with IDC. Patients presenting with IDC have a mean age of around 60 years. 
Patients presenting with an ILC are generally a little older [1,8,9]. Invasive ductal carcinomas 
are generally smaller at the time of presentation than ILC, especially the fraction of patients 
presenting with a tumor larger than 5 centimeter is much larger in patients presenting with ILC. 
Furthermore, ILC are more often multifocal or even multicentric than IDC and many studies also 
report a higher incidence of contralateral carcinoma than in IDC [10,11] although numbers are 
ranging from 3 to 30%. However, even though the tumors are usually larger, the frequency of 
tumor positive axillary lymph nodes in patients with ILC is only slightly higher [1,8,9,11]. 
Patients with IDC usually present themselves with a palpable mass or an abnormal mammogram. 
The mass is often well palpable due to the common fibrotic reaction. Invasive ductal carcinoma 
on mammography is usually seen as a mass that is either spicular or ill-defined although 
roughly circumscribed masses do also occur, especially in patients carrying a BRCA mutation. 
Asymmetric opacity or architectural distortion is present in only 10-15 % of patients [12]. 
Microcalcifications are present in 30-50% of IDC's and are caused by necrosis and debris [12]. 
Lesion opacity of IDC is usually higher than that of normal fibroglandular breast tissue (Fig 1).
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Fig 1: Cranio-caudal mammogram o f the left breast. There is a large hyperdens mass, with an 
irregular border visible in the medial part o f the breast. Lesion density and confosmationare typical 
for the presence o f a large IDC.
Patients with ILC present with similar features. However, due to the more diffuse growth pattern 
of these tumors, palpation is often more difficult and it is often very difficult to palpate the 
margins of the abnormality. The mammographic abnormalities are often also much more subtle 
than with IDC, approximately 50% is seen as a distinct spicular mass, whereas the only signs of 
malignancy are architectural distortion or asymmetric opacity in 40-60% [12,13]. Most studies 
confirm that microcalcifications are not typically present in ILC and when present they are usually 
caused by surrounding DCIS or sclerosing adenosis and not by the ILC [12,14]. Furthermore 
the opacity of the lesions is often equal to or lower than the opacity of the surrounding 
fibroglandular tissue, making them even more difficult to observe. Commonly, ILC are only 
visible on one mammographic view, usually the cranio-caudal (CC) view.
In both IDC and ILC the sensitivity of mammography is largely dependent on breast density. 
However sensitivity for ILC is due to the more subtle changes usually lower than for IDC and has 
been reported to be as low as 34% [15]. The actual sensitivity for ILC is probably between 80 and 
90% and only slightly lower than the sensitivity for IDC, but up to 30% of findings are classified 
as equivocal (BI-RADS 3) [13,16]. Invasive lobular carcinomas are hence overrepresented in 
studies of false negative mammograms [17]. False negative imaging of ILC occurs in 8-21% of 
cases (Fig 2).
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Fig 2: Medio-lateral oblique mammogram o f the left breast. Architectural distortion is visible in the 
upper part o f the breast. Note the absence o f a well defined mass and the relative equal opacity o f 
the lesion compared to the normali fibroglandular tissue in the lower part o fthe breast. This lesion 
proved to be ILC at histopathology.
Estimation of the size of breast cancer is ver y difficult with mammography a nd un derestimation 
of lesion extent is common. The size? of IDC is more correctly measured than the size of ILC 
[18,19].
With ultrasound, both IDC and ILC are readily detected [15]. Detection of IDC is only marginally 
better than sensitivity for ILC, although early reports of the sensitivity of ultrasound in cases 
of ILC are as low as 68% [20], newer transducers perform much better and a sensitivity of up 
to 98% has been reported [21]. Both IDC and ILC are classically characterized by hypoechoic 
lesions with an irregular, poor-defined margin and posterior shadowing. However, high grade 
IDC have a well-defined margin in 11% and posterior shadowing is only present in 30% of 
cases [22]. Invasive lobular carcinomas are much more likely than IDC to be hyperechoic and 
are much less often taller than wide [23]. Larger ILC, that have a distinctive infiltrative pattern, 
are harder to recognize and sometimes shadowing only may be the sole recognizable feature 
[21]. In many instances ultrasound is only used to obtain a histologic specimen by means of 
ultrasound guided biopsy. The technique can also be used for size estimation. Several authors 
report better results than with mammography [20,24], while others found mammographic size 
estimation more accurate [19,25]. All authors, however, show that ultrasound underestimates 
tumor size, more so with larger tumor size.
Magnetic resonance is by far the most sensitive modality for the evaluation of breast lesions. 
It has a very high sensitivity overall [26,27] and various small studies have shown that this also 
holds true for ILC [25,28]. Approximately 85% of all IDC present as a mass. The margin is usually
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spiculated or irregular, often, due to central necrosis, enhancement is more prominent at the 
border of the lesion and internal enhancement is heterogenous. The presence of an extensive 
intra ductal component can be seen as ductal enhancement. Only 60% of all ILC are presented 
as a mass. Architectural distortion and especially asymmetric segmental, regional or diffuse 
enhancement may be signs of ILC. Furthermore some lobular lesions present with multiple 
small foci of enhancement [29]. Additional lesions, unobserved by other imaging modalities, 
are commonly found in both IDC and ILC [30]. However, the incidence of unobserved additional 
lesions is much higher in ILC patients (30-40%) [31]. Furthermore, unexpected contralateral 
carcinomas are more commonly found in patients with ILC than in patients with IDC.
The basic principle of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) of the 
breast is that contrast exits the neovascular capillaries in the tumor easier than normal vessels. 
These 'leaky' vessels are produced in response to vascular growth factors produced by the 
tumor in periods of hypoxia, especially vascular endothelial growth factor (VEGF), also known 
as vascular permeability factor (VPF), is held responsible for the neovascular proliferation. Due 
to the nature of ILC, which grows in single strands along pre-existing ductuli, these tumors are 
generally less hypoxic than IDC and consequently require less neovascularisation. Moreover, 
VEGF expression in lobular carcinoma is not as high as in ductal carcinoma and although mean 
vascular density is not very different between the two types of breast cancer, vascular neogenesis 
may be governed by other mechanisms in ILC than in IDC, causing less 'leaky' vessels [32].
This results in a different enhancement pattern in ILC than in IDC. The classic pattern of 
malignancy, with rapid increase of signal intensity followed by early wash out of the contrast 
and hence decrease of the signal that is often observed in IDC is frequently not present in ILC 
[33]. Instead, slow enhancement, with no apparent wash-out can be present and ILC can thus 
easily be regarded as enhancing fibroglandular tissue on DCE-MRI. This is also the cause of most 
described false negative MRI evaluations in cases of ILC (Fig 3, Fig4).
Size estimation of breast lesions with MRI is accurate. Various authors mention pearson's 
correlation coefficients between 0.8 and 0.9 for measurement of ILC [25,34], while size estimation 
for IDC is generally even more accurate [19]. However, overestimation of lesion size, generally 
due to the presence of DCIS, LCIS or sclerosing adenosis, occurs in up to 10% of cases, while 
underestimation of lesion size occurs in equal proportion [25].
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Fig 3: Subtracted MIRI image. In the left breast a large ID)C is present with strong enhancement 
and typical early wash-out or contrast (curves respectively ptesent percentages tlower curve) and 
arbitrary units (upper curve)), indicative o f the malignant nature o f the lesion.
Fig 4: Subtracted MIRI image. In the right breast subtle asymmetric regional enhancement is seen. 
The patient presented with a palpable abnormality o f the breast. Histology showed ILC.
Differences in treatment
The difficulties in size estimation of ILC with conventional imaging initially resulted in a more 
aggressive treatment of ILC than IDC. Even with equal sizes, mastectomy was more often 
performed in IDC than in ILC. However, breast conserving therapy (BCT) has become increasingly 
accepted for ILC as well [35]. Nevertheless, the chance of positive margins, especially in series 
w here no MRI is performed is higher for ILC than for IDC and conversion to mastectomy after 
initial BCT is much more common in ILC than in IDC [36,37].
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Radiotherapy after initial BCT is essential in both IDC and ILC. The occurrence of recurrent 
disease is even more reduced in patients with ILC than in patients IDC and is more or less equal 
for both types of tumor after 10 years [38].
Patients with ILC that are treated with neoadjuvant chemotherapy are less likely to respond to 
treatment [39] and are less likely to achieve a complete pathological response (i.e. no evidence of 
tumor in the pathological specimen after surgery) than patients with IDC. However, recurrence 
free and overall survival are higher for patients with ILC. In patients with ILC the prognostic 
consequence of pCR is thus not as strong as it is in patients with IDC [40].
Differences in prognosis
The metastatic pattern of IDC and ILC is somewhat different. While both tumors metastasize 
to bone, lung, pleura and liver, metastases to the gynaecological organs, the gastro-intestinal 
space, the retro-peritoneal space and the leptomeningen are much more common in patients 
with ILC [11,41].
Long term prognosis for operated ILC and IDC is very similar, even after BCT for early stage 
disease [42]. Several studies indicate that the recurrence free survival and overall survival for ILC 
is slightly better than for IDC, although most do not show histologic type to be an independent 
prognostic factor. The risk of mortality is however lower for patients presenting with ILC [8].
Conclusion
Invasive ductal and lobular carcinoma differ in their pathological origin, this causes differences 
in presentation and diagnosis as well as in treatment and prognosis. In general lobular 
carcinoma's are more difficult to detect and size estimation is harder, making adequate staging 
and treatment more difficult. MRI is very helpful in adequately assessing ILC.
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Introduction
Invasive lobular carcinoma of the breast (ILC) presents a well recognised diagnostic problem. 
The incidence, clinical presentation and the pathological findings f this disease will be discussed 
briefly. The mammographic and ultrasound findings are shown and the use of contrast 
enhanced magnetic resonance imaging in this disease is presented against this background.
Incidence
Invasive lobular carcinoma is the second most common form of malignancy of the breast. 
Between 10 and 15 % of all malignancies of the breast are ILC. A recent report on its incidence, 
based on the documentation of 190458 women with breast cancer in the SEER database (The 
Surveillance, Epidemiology, and End Results data from the American National Cancer Institute), 
showed that the proportion of ILC steadily increased from 9.5% to 15.6% between 1987 
and 1999. This might be due to the increase in use of combined estrogen and progesterone 
replacement therapy (CHRT) for prevention of menopausal complaints in this period. It has 
been shown that CHRT increases the risk on ILC 2 to 4-fold, while it has only little impact on the 
risk of the most common form of breast cancer, invasive ductal carcinoma (IDC). Although this 
knowledge has led to the decreased use of CHRT, its effects on the proportion of ILC are not yet 
visible [1].
Presentation
Patients presenting with an ILC are generally older than those presenting with an IDC. Patients 
often present with a palpable mass or apparent changes of the breast, others may show a 
mammographic abnormality consisting of a mass or an architectural distortion. However, 
findings at palpation or mammography can be very subtle and ILC is easily missed. The tumors 
are generally slightly larger in patients with ILC than in patients with IDC and the chance of ILC 
presenting as a tumor larger than 5 cm is 50% greater than the chance of IDC presenting as such 
(14% vs. 9%) [2,3]. However, axillary lymph nodes are not more often positive.
Invasive lobular carcinomas are characterised by multifocality and multicentricity in the 
ipsilateral breast and are more often bilateral than other types of invasive breast cancer (15%), 
although data on the amount of contralateral breast cancer vary widely [2,4].
Metastatic spread of ILC is different from that in IDC. Metastases to lungs, liver, and brain are 
more common in IDC, while ILC metastases are also found in bone marrow, the leptomeningen, 
the peritoneal cavity, the retroperitoneal space, and the gynaecologic organs [5,6]. Tumor 
characteristics of ILC are generally more benign than those of IDC, receptor status of the 
estrogen and progesterone receptors is more often positive and p53, Her-2/Neu and epidermal 
growth factor expression is more often normal. However, disease free and overall survival are
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not significantly different from IDC, and are mostly dependent upon tumor stage and age at 
diagnosis [2].
Pathology
Pathology of ILC may mimic an IDC, showing a firm gray-white mass. However, no visible 
mass may be present and although the breast tissue may have a rubbery consistency there 
may also be no visible or palpable evidence of malignancy without microscopic examination 
[7]. Histopathologically, the classic form of ILC is characterised by small round cells, that are 
relatively uniform. The cells are only loosely cohesive due to a typical loss of expression of the 
adhesion molecule E-cadherin [8]. They invade the surrounding stroma in a single file pattern 
(Indian filing), resulting in linear strands along the ductuli. Some cause hardly any desmoplastic 
stromal reaction. These features make them difficult to observe [9].
Other forms of ILC are the solid form where the tumor cells grow in confluent sheets, and the 
alveolar form where tumor cells grow in groups of 20 or more cells connected by delicate 
fibrovascular tissue. Some other variants have been described, including a tubulolobular variant 
where small tubules with rounded contours are formed concurrent with the classic appearance, 
a pleiomorphic variant where the tumor cells are generally larger and show more nuclear 
variation but grow in the typical (classic) pattern and a signet ring cell variant with a prominent 
portion of cells with a signet ring appearance caused by large intracytoplasmatic lumina [10].
A mixed type is described when no single form comprises > 80% to 85% of the lesion.
The classic form is present in 30-77% of patients, most others have either a solid form lesion 
nor a mixed type. Furthermore, low grade ductal carcinoma in situ (DCIS) is often present 
around ILCs [7]. However, the pathological diagnosis of ILC is difficult and poorly reproducible. 
Specialised breast pathologists are better able to reproduce such a diagnosis, but even then 
reproducibility of the diagnosis is no more than moderate with kappa- scores between 0.4 and 
0.6. Furthermore, 3% of all breast malignancies have both features of ILC and IDC and cannot 
readily be assigned to either [11].
Mammography
The specific growth pattern of ILC hampers the value of mammography. Sensitivity is reported 
between 50% and 85%. Up to 25% of mammograms is reported to be normal or of low suspicion. 
The false-negative rate for ILC is higher than for any other type of invasive breast cancer [12,13]. 
Its appearance on mammograms is variable. Approximately 60% of lesions are reported as a 
mass, most are spiculated others are ill-defined and some are even reported as well-defined 
masses (fig 1). Architectural distortion is seen in 20% to 30% of cases (fig 2), asymmetric 
density of the breast in 10-15% and no tumor is seen in 5% of cases. Other findings include skin 
retraction, nipple retraction and cutaneous thickening of the skin. In 10% of patients
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Fig 1: ILC presenting as small mass on CC and MLO mammograms o f a right breast (arrows)
Fig 2: An area o f architectural distortion retromammilair in a right breast (circles), representing a 
large ILC. Size determination is very difficult.
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microcalcifications are found, although these are not always associated with the ILC but may 
occur in surrounding ductal carcinoma in situ (DCIS) or sclerosing adenosis [14]. A difficulty 
is that detectable ILCs on mammography are of a relatively low radiographic opacity, similar 
to or even less opaque than normal fibroglandular breast tissue. Many visible lesions are thus 
reported as benign. Furthermore, ILC is often visible in only one radiologic view, usually cranio- 
caudal [14-16]. Size determination with mammography is difficult. The size of > 50% of all ILCs 
is underestimated, therefore mammography is unable to accurately measure the extent of ILC 
[16,17].
Ultrasound
Early reports on the use of ultrasound in ILC mention low sensitivity, comparable to the 
sensitivity of mammography. However, more recently high resolution ultrasonography has 
been reported to yield a much higher sensitivity, up to 98% [15].
Invasive lobular carcinoma appears most commonly as hypoechoic masses with or without 
shadowing in 58% and 27%, respectively. Larger ILC may have a distinctive infiltrative pattern, 
which is harder to recognize and sometimes shadowing only may be the sole recognizable 
feature. A significant advantage of imaging with ultrasound is the possibility of easy acquisition 
of histologic material by an ultrasound guided biopsy. The correlation of pathological size and 
size measured with ultrasound is however poor. Several authors mention Pearson's correlation 
coefficients between 0.19 and 0.67. The size is, as with mammography, usually underestimated 
[17-20].
Goal of MRI in the Assessment of Invasive Lobular Carcinoma
Mammography is characterized by its rather poor sensitivity and inability to accurately measure 
the size of an ILC not an appropriate modality for the assessment of ILC. Ultrasound seems 
to have a high sensitivity and provides an easy way to obtain histologic confirmation of the 
diagnosis. However, ultrasound is unable to provide an accurate assessment of tumor size. The 
typical growth pattern of ILC makes radical surgery difficult and the secondary mastectomy 
rate is generally higher than for IDC [13]. Accurate assessment of tumor size is thus the most 
important feature that should be provided by MRI. Furthermore, its sensitivity should at least 
equal that of ultrasound.
Magnetic Resonance Imaging
Magnetic resonance imaging of the breasts is generally performed with a dedicated double 
breast coil in at least a 1.0 T MRI device. Images are obtained in a 3D matrix prior to and after
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the administration of a gadolinium based contrast agent. This contrast agent is administered 
intravenously and leaves the plasma through the new formed "leaky" vessels within, and 
surrounding the tumor. Standard pulse sequences are aimed at the visualization of contrast 
and are therefore T1 weighted. Morphologic features are either examined on high resolution 
subtraction images generated from pre- and post-contrast FLASH-series (Fast Low Angle SHot), 
or on series that are fat-saturated or are generated by selective excitation of non fat-bound 
protons only as is the case in the RODEO (ROtating Delivery of Excitation Off-resonance) pulse 
sequence. Several large prospective studies have shown that MRI has a high sensitivity of 
around 95% and is more accurate in the determination of disease extent than ultrasound and 
mammography [21-23]. However, these studies did not explicitly state the value of MRI in cases 
of ILC. Other authors have, however, presented specific results for ILC in smaller retrospective 
studies. Direct comparison with ultrasound shows that MRI has a higher sensitivity, although 
the sensitivity of ultrasound in these studies was not nearly equal to the earlier mentioned 
results [17,24]. In 40% of patients MRI is able to show more extensive tumor burden [25] and 
Pearson's correlation coefficient with pathologic size has been reported to be between 0.81 and
0.97 [17,19,20]. Tumor size estimation has been shown to be accurate in 75% of cases, over and 
underestimation occurs in equal proportions.
The pattern of the lesion on MRI correlates well with pathology and is characterized by either a 
solitary mass with irregular margins in 30% (fig 3) or by multiple small enhancing foci (60%) with 
or without enhancing strands between these foci (fig 4), corresponding to clusters of tumor cells 
connected by single strand invasion or by normal tissue; sometimes only enhancing strands are 
visible [26]. The standard practice of imaging both breasts at once reveals contralateral breast 
tumors in a number of cases.
Fig 3: A large mass on a subtracted high resolution MR image in a right breast representing a very 
large ILC, note the long spiculae at the superior margins o f the tumour suggesting linear spread 
<along the ductuli.
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Fig 4: Multiple small enhancing foci on a subtracted high resolution MR image in the right breast, 
representing a large multicentric ILC in the right breast.
Dynamic Sequences in Breast Magnetic Resonance Imaging
Standard breast MRI consists mainly of T1 weighted imaging with a high spatial resolution prior 
to and after an intravenously administered unspecific extracellular gadolinium based contrast- 
agent. Contrast enhancement is the principal parameter that determines the visibility of any 
breast lesion in breast MRI. Typically, exchange of contrast from the intravascular space to the 
extravascular extracellular space and vice versa is much faster in malignant than in benign 
lesions. This results in different kinetic profiles for different types of lesions, and even distinct 
differences between the different histological types of breast cancer. A typical malignant 
pattern shows rapid early enhancement followed by rapid wash-out of the contrast agent. 
Some researchers use rapid pulse sequences immediately after the administration of the 
contrast agent to document the outflow of the contrast agent from the tumor vessels. These 
"dynamic" acquisitions provide information on the contrast enhancement profile and hence 
on tumor vasculature. As they document the rather fast transition of contrast agent from the 
plasma to the extravascular extracellular space a temporal resolution of only several seconds is 
needed. Consequently spatial resolution is diminished in these sequences.
These contrast enhancement kinetics are mainly dependent on the expression of vascular 
endothelial growth factor (VEGF), also known as vascular permeability factor (VPF). This factor 
is a cytokine that stimulates neovascularization by increasing the microvascular permeability 
for plasma proteins. This is more important than the vascular density within the tumor [27]. 
Quantitative and qualitative analyses of the contrast enhancement profile for ILC are however 
less specific as in IDC. Enhancement is often only marginally faster than in healthy tissue and 
atypical slow enhancement and absence of wash-out may occur (fig 5). This is probably due to
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Fig 5: The dynamic profile o f three different ILC. The colours within the tumour represent relative 
enhancement. Relative enhancement increases as colours change from blue trough green and 
yellow to red. Tumour A is a very large ILC wiih a typical malignano enhancement pattern and a 
dynamic curve showing rapid initial enhancement and subsequent wash-out o f the contrast agent. 
Tumoui B shows a tess malignantpattern with a plateau phase in the dynamic rurve ahter initial rrpiV 
enhancement. Tumour C shows no rapid enhancement and no subsequent wash-out. Although the 
tumour is tradily vitible on MRI it may thus be reported as enanrivg breasl rissue because the typical 
malignant pattern is absent.
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the specific growth pattern of ILC, which does not need extensive neovascularization and thus 
produces only few leaky vessels [26,28,29]. Furthermore, expression of VEGF is less extensive 
in lobular carcinoma than in ductal carcinoma even though the vascular density is not really 
different. This might be reflected in the substantial lower and less specific enhancement profiles 
found for invasive lobular carcinoma [30].
False-Negative Imaging on Magnetic Resonance Imaging
Even though sensitivity of contrast enhanced MRI for ILC is high, various authors reported false 
negative findings. This might be due to the difficulties described above, regarding enhancement 
profiles for ILC. There may be no apparent enhancement at all or enhancement is attributed 
to normal glandular tissue and the absence of a contrast enhancement profile suggestive of 
malignancy leads to a false benign classification. [20,31]. Especially ILC growing in a single 
file pattern without a discrete mass are easily missed. Furthermore, microscopic disease after 
excision biopsy may be missed [25].
Conclusion
Magnetic resonance imaging has several advantages over mammography and ultrasound 
in the assessment of ILC. The sensitivity of contrast enhanced MRI is much higher than the 
sensitivity of mammography and although sonography has been shown to have a high 
sensitivity, comparative studies favour MRI. Magnetic resonance imaging is better capable of 
accurate assessment of tumor size than any other imaging modality, even though substantial 
under or over-estimation still may occur. Magnetic resonance imaging often detects a more 
extensive tumor burden and may detect unsuspected contra-lateral lesions. However, findings 
are often subtle and a typical malign enhancement profile may be absent, therefore false 
negative findings still do occur. In cases of ILC where breast conserving therapy is proposed, 
contrast enhanced MRI of both breasts appears mandatory.
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Chapter 4
Abstract 
Purpose
The clinical diagnosis and management of invasive lobular carcinoma of the breast (ILC) presents 
difficulties. Magnetic resonance imaging (MRI) has been proposed as the imaging modality of 
choice for the evaluation of ILC. Small studies addressing different aspects of MRI in ILC have 
been presented but no large series to date. To address the usefulness of MRI in the work-up of 
ILC, we performed a review of the currently published literature.
Materials and Methods
We performed a literature search using the query "lobular AND (MRI OR MR OR MRT OR 
magnetic)" in the Cochrane library, Pubmed and scholar.google.com, to retrieve all articles that 
dealt with the use of MRI in patients with ILC. We addressed sensitivity, morphologic appearance, 
correlation with pathology, detection of additional lesions, and impact of MRI on surgery as 
different endpoints. Whenever possible we performed meta-analysis of the pooled data.
Results
Sensitivity is 93.3% and equal to overall sensitivity of MRI for malignancy in the breast. 
Morphologic appearance is highly heterogeneous and probably heavily influenced by 
interreader variability. Correlation with pathology ranges from 0.81 to 0.97; overestimation 
of lesion size occurs but is rare. In 32% of patients, additional ipsilateral lesions are detected 
and in 7% contralateral lesions are only detected by MRI. Consequently, MRI induces change in 
surgical management in 28.3% of cases.
Conclusion
This analysis indicates MRI to be valuable in the work-up of ILC. It provides additional knowledge 
that cannot be obtained by conventional imaging modalities which can be helpful in patient 
treatment.
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Introduction
Invasive lobular carcinoma (ILC) is the second most common histologic type of breast 
carcinoma after invasive ductal carcinoma (IDC). In most series ILC constitutes between 5 and 
15% of all breast cancers, whereas IDC constitutes between 70 and 90% of all breast cancers 
[1-5]. Probably due to the use of complete hormone replacement therapy (CHRT) the lobular 
breast cancer component has continuously increased over the past decade from 9.5% in 1987 
to 15.6% in 1999 [3].
Patients are, according to most series, a little older than patients presenting with IDC, especially 
the fraction of patients presenting with ILC younger than 40 is smaller [1,5,6]. Furthermore, the 
mean tumor size of ILC is slightly larger than in patients with IDC and patient presentation with 
a tumor larger than 5 cm occurs more often in cases of ILC [1,5,7].
Histopathologically, ILC are clearly defined: Invasive lobular carcinomas are constituted from 
small, relatively uniform cells, very similar to normal endothelial cells. Characteristically, 
these cells are only loosely cohesive and infiltrate the stroma in single cell file strands along 
ductuli. This growth pattern, present in 30-77% of cases [8], is also known as "Indian filing". It 
is probably caused by a typical loss of the adhesion molecule E-cadherin. Often there is very 
little desmoplastic stromal reaction [8,9]. The biological characteristics of ILC are usually less 
alarming than those of IDC: more tumors contain estrogen receptors (ER) and progesterone 
receptors (PR), while expression of Her2/Neu and p53 are more often normal and axillary lymph 
nodes are not more often positive, even though ILC are overall larger in size than IDC [1,7].
Probably due to the diffuse infiltrative growth pattern, ILC is frequently missed on mammography 
[5]. Detection is also compromised because ILC often has a density less than or equal to normal 
fibroglandular breast tissue on mammography [5,10].
For correct treatment of ILC, adequate staging is important. Both mammography and ultrasound 
tend to underestimate lesion size and are therefore not optimal for staging purposes [5,11]. This 
may in part be the reason that higher failure rates of breast conserving therapy (BCT) in ILC than 
in IDC are reported [2,11,12]. Various authors therefore propose magnetic resonance imaging 
(MRI) as the modality of choice for the evaluation of ILC. Several small studies addressing the 
different aspects of the use of MRI in ILC have been presented, but no large series to date. 
Therefore many questions regarding the use of MRI in ILC remain unanswered.
- The sensitivity of MRI for breast lesions is approximately 95-98%, however, 
whether this holds true for ILC as well is not clear [13].
- The morphologic aspects of ILC are not yet well defined, nor is the dynamic behavior 
of contrast agents in these tumors clearly documented.
- Moreover, whether the MRI findings are similar to pathologic findings and can thus be 
used for accurate staging still needs to be established.
- Finally, the impact of MRI on surgical treatment of ILC should be evaluated.
To answer these questions we performed a thorough review of the existing literature regarding 
the use of MRI in case of ILC and performed meta-analysis whenever possible. We subsequently
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reviewed the literature on other imaging modalities for this indication in order to evaluate the 
use of MRI from a clinical perspective.
Materials and Methods 
Search strategy
We performed a literature search for articles that specifically dealt with the use of MRI in 
patients with histologic proof of ILC published before the 1st of April 2006. The Cochrane Library, 
MEDLINE and the in-progress citations as provided by PubMed were searched using the query: 
"lobular AND (MR OR MRI OR MRT OR magnetic)". These databases were further searched using 
the "Related Articles" function in PubMed. The same query was used to browse the web using 
scholar.google.com.
Furthermore, the references of all retrieved articles were mannually searched for relevant cross­
references. Articles in all languages were accepted. All retrieved articles were then compared 
and from overlapping series of patients only the most recent publication was accepted.
Many different search terms were used for literature review of other imaging modalities. 
However, only Pubmed was used as search engine.
Endpoints
The study was thus undertaken to answer the following four questions.
1. What is the sensitivity of MRI for ILC?
2. What are the visual characteristics of ILC on MRI?
3. Are the findings on MRI equal to the findings at pathology?
4. What is the impact of MRI on surgical management of ILC?
Whenever studies allowed direct comparison between MRI and other imaging modalities, these 
modalities were also analyzed. Sensitivity was defined as the number of lesions visible on MRI 
divided by the total number of ILC detected at pathology. We regarded morphology, dynamic 
curve analysis of contrast behavior, and quantitative dynamic analysis of contrast behavior 
as three different aspects of tumor appearance and these were thus analyzed separately. A 
principal distinction between mass-like and non-mass-like lesions was made in the analysis of 
morphology. Based on the BIRADS lexicon [14], we defined architectural distortion, regional, 
segmental, ductal, multifocal or diffuse enhancement, and multiple enhancing foci as descriptors 
of non-mass lesions. Nodular or focal enhancement, well-defined, round, irregular or spiculated 
masses, and dominant masses with small enhancing foci were defined as descriptors of mass­
like lesions. Correlation between the findings on MRI and pathology was evaluated for relative 
tumor size (unifocal versus multifocal disease and single quadrant versus multicentric disease) 
and absolute tumor size. The impact on surgical management was derived from all changes 
implemented, based solely on MRI findings. The numbers of correct and incorrect changes were 
tabulated.
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Eligibility Criteria
All studies that presented a series of at least 10 patients with histologic proof of pure ILC, with or 
without concurrent DCIS and / or LCIS, were considered eligible. A quality analysis of the study 
had to be possible, otherwise no abstracts were accepted. Patients with mixed carcinomas of 
ILC and IDC were excluded. Studies that presented data on both ILC and mixed carcinomas had 
to allow extraction of the relevant data for ILC only. Every study considered eligible according to 
these eligibility criteria was then evaluated for all the study endpoints. Specific eligibility criteria 
for the various considered endpoints are described below.
Detection:
Studies had to be based on a pathology database and all subsequent patients with ILC who 
underwent a MRI had to be included. The total number of ILC confirmed at pathology had to be 
clearly stated as well as the number of lesions found with MRI.
Morphology:
Studies describing the appearance of ILC visible on MRI were eligible. Separation between mass 
and non-mass like lesions had to be possible.
Dynamic curve analysis o f contrast behavior:
Studies that described the enhancement versus time curve were eligible. However, as time to 
peak and shape of the final phase of the enhancement curve were our main endpoints, these 
had to be described.
Quantitative analysis o f contrast behavior:
Studies performing quantitative analysis of the contrast-enhancement parameters were eligible. 
Relative correlation with pathology:
Studies presenting data on the unifocal versus multifocal correlation or single quadrant 
involvement versus multicentric involvement were eligible.
Absolute correlation with pathology:
Studies comparing sizes measured on MRI with those measured at pathology and presenting a 
correlation coefficient or sufficient raw data to calculate such a value were eligible.
Detection o f additional lesions:
Any study describing additional lesions apart from the index lesion detected by MRI only with 
subsequent acquisition of histologic proof of malignancy was considered eligible. Lesions in 
the ipsilateral breast and the contralateral breast were evaluated separately.
Impact on surgical treatment:
Studies mentioning all changes in surgical strategy based on MRI findings were eligible. 
Statistics
The quality of all included studies was assessed using the QUADAS tool [15]. The latter is a list 
of 14 items created for quality assessment of studies to diagnostic accuracy. Although not all 
the included studies specifically evaluate diagnostic accuracy, this tool was judged to be the 
most appropriate available. Data of all the studies were collected according to the inclusion 
and exclusion criteria. When at least five studies presented the same type of data or at least 
100 patients were included in a smaller series of studies with similar data, we considered
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meta-analysis and heterogeneity analysis was performed. Dichotomous data with a binomial 
distribution (e.g. sensitivity) were transformed to the log odds scale because this scale has 
a normal distribution and is a good approximation to the exact binomial distribution. A 
disadvantage of this transformation, however, is that the confidence intervals are a little wider 
and values in the middle of the distribution (e.g. sensitivity closer to 50%) are more heavily 
weighted in meta-analysis than values close to the upper or lower level. Pearson's correlation 
coefficient was transformed to Fisher's Z for the same reason [16].
We calculated Cochran's Q coefficient and the I2-statistic to assess heterogeneity. Cochran's Q is 
a form of the x2 test and provides information about the applicability of pooling the data. The I2- 
statistic provides a quantitative measure of the amount of heterogeneity and has an upper limit 
of 100%. Values of the I2-statistic of 25%, 50% and 75% can be interpreted as low, moderate and 
high heterogeneity, respectively [17]. Meta-analysis of the data using a random effects model 
was performed when the Q-coefficient showed no significant heterogeneity (p>0.05).
In cases where meta-analysis was feasible, the estimate and the 95% CL are expressed. When 
meta-analysis was not feasible due to severe heterogeneity, only the range of values found in 
the different studies is mentioned. All calculations were performed using R version 2.3.1 (The 
R project for Statistical Computing, www.r-project.org) and the meta package (G. Schwarzer, 
cran.r-project.org).
Results 
Studies
We identified 21 separate studies that dealt with MRI and ILC [18-38]. We further identified 4 
studies that did not deal specifically with ILC and MRI. However, they did present their data in 
such a fashion that relevant information for ILC only could be extracted for at least 10 patients 
[39-42]. Four studies were case-reports and were dropped from the cohort [20,21,29,37]. 
The study by Bazocchi et al. [18] was excluded because only eight patients underwent MRI. 
Leung et al. [27] and Newstead et al. [42]only published their findings in abstract form and 
were consequently excluded. Table 1 gives an overview of the included studies and their 
characteristics, including the QUADAS score.
The applied scan protocols in the included studies are diverse. In general, most studies 
presented herein used a 1.5T MRI scanner, although some authors had at least some of their 
included patients scanned using 1.0T machines [33,34,40]. Most protocols were based on T1 
weighted images made with either a normal FLASH 3D sequence or a FLASH 3D sequence with 
fat-suppression [19,20,23,24,26,31,33-36,38,40,41] or a RODEO sequence with water selective 
excitation [25,30,32]. A number of authors also used T2 weighted sequences [22,23,31,38,40,41]. 
Other differences in scan protocols involve the voxel sizes and temporal resolution. Some 
authors emphasize high spatial resolution [32,39] while others prefer high temporal resolution 
[26] and yet again others performed both types of sequences in succession [30,38]. Furthermore, 
single breast coils [30,32,36,41,43] and double breast coils (all others) were used and sometimes
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compression was applied to the imaged breast [31,36,39]. In most reported studies the scanning 
protocols evolved over time and are thus not identical for all imaged patients.
Table 1: Characteristics o f the included studies
Author
Pub.
Year
Study 
type N
Age
mean
Age
min.
Age
max. Field
Scan
seq.
Uni/
Bilat
Com
Pres­
sion
Mean Quadas
size Score
Rodenko GN [32] 1996 1 20 60 38 84 2 1 1 0 X 11
Sittek H [34] 1998 1 23 X X X 1 2 2 0 X 11
Weinstein SP [36] 2001 1 17 53 32 69 2 2 1 1 1,7 12
Kim SJ [41] 2001 1 12 54a 24a 88a 2 2 1 0 2,1a 12
Trecate G [35] 2001 1 28 X 32 81 2 2 2 0 X 9
Francis A [24] 2001 2 22 X X X 2 2 2 0 3,7 12
Qayyum A [30] 2002 1 13 55 46 84 2 1 1 0 X 11
Munot K [28] 2002 1 20 61 39 78 2 3 2 0 X 11
Yeh ED [38] 2003 1 19 59 42 79 2 2 2 0 4,1 11
Kneeshaw PJ [26] 2003 1 21 57 43 72 2 2 1 0 X 11
Quan ML [31] 2003 1 62 53 X X 2 2 3 1 X 10
Bedrosian I [39] 2003 1 24 53a X X 2 0 0 1 X 10
Schelfout K [33] 2004 1 26 57 41 74 3 2 2 0 X 11
Diekmann F [22] 2004 1 17 X X X 0 0 0 0 X 10
Boetes C [19] 2004 1 34 55 35 78 2 2 2 0 4,9 10
Berg WA [40] 2004 2 29 X X X 3 2 2 0 X 13
Kepple J [25] 2005 1 29 62 51 67 2 1 3 0 X 9
Fabre Demard N [23] 2005 1 34 X X X 2 2 2 0 X 11
Pub. Year -  Year o f publication o f the original article
Study type -  1 = retrospective cohort study, 2 = prospective cohort study
N -  Number o f patients included
Age mean -  mean age o f all included patients, X = not mentioned
Age min., Age max. -  Age o f respective youngest and eldest patient included in the study, respectively 
Field -  Strength o f magnetic field, 0 = unknown, 1 = 1T, 2 = 1.5T, 3 = both 1T and 1.5T 
Scan seq. -  Type o f scan sequence used, 0 = unknown, 1 = RODEO, 2 = FLASH 3D, 3 = other 
Uni/Bilat -  Unilateral or bilateral imaging o f the breast, 0 = unknown, 1 = unilateral, 2 = bilateral,
3 = both unilateral and bilateral depending on the patient
Compression -  Compression applied to the breast, 0 = No, 1 = Yes
Mean size -  Mean size o f the lesions in centimeters, X = not mentioned
Quadas score -  Number o f items valid on QUADAS scorings list
a Valid for whole study population only, not for subpopulation o f patients with ILC
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Lesion detection
Eight studies provided sufficient data to calculate sensitivity of MRI for ILC 
[19,23,24,26,28,33,34,40]. Sensitivity ranged from 83% to 100%. Cochran's Q was 6.48 (p=0.49), 
I2 was 0%, indicating homogeneous studies and hence data pooling could be performed. Mean 
sensitivity was 93.3% (95% CI 88% - 96%). Only the studies by Francis et al. [24] and Berg et al.
[40] provided prospective data and are therefore able to show sensitivity in clinical practice. 
They showed a sensitivity of 95% and 97%, respectively, and were statistically not different from 
the retrospective studies (2-sided T-test, p=0.78). Seven of these studies also provided data on 
mammography (Q 31.79 (p<0.001), I2 = 81%), six on ultrasound (Q 10.92 (p=0.05), I2 = 54%) 
and five on clinical examination (Q 29.63 (p<0.001), I2 = 87%). Sensitivity of ultrasound could 
also be computed through meta-analysis and was 83% (95% CI 71 - 9196), although moderate 
heterogeneity was present. The provided data for mammography and clinical examination were 
too heterogeneous for meta-analysis and ranged from 34 - 91% and 28%-94%, respectively. 
Figure 1 shows the results of each independent study and the overall results.
Fig 1: Forestplot o f the sensitivity o f the respective modalities for ILC (MMG = 
mammography, US = ultrasound, CE = clinical examination), the horizontal lines 
represent 95%confidence intervals. /Modalities presented on the right ofthe authors 
name have not been tested in the appropriate study. The diamonds at the bottom 
represent the pooled estimates and their 95% confidence intervals for MRI and US 
respectively. Because mammographyaad ctinical examination were toa heterogeneous 
for meta-analysis no pooled estimate is presented for these modalities.
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Morphology
Seven studies described lesion morphology on static MRI images [23,30,32,33,36,38,41]. However, 
Kim et al. [41] studied morphologic appearances of masses only and therefore did not include 
non-mass-like lesions. Information provided by their study is therefore only used to evaluate the 
appearance of masses and not for the principal distinction between mass and non-mass lesions. 
The terminology used in the literature to describe the lesions is highly variable. Only Yeh et al. 
[38] consistently used the terminology of the BIRADS lexicon [14]. The six eligible studies that 
presented data on morphologic appearance described a total of 133 tumors. However, results are 
highly variable. The incidence of a mass-like lesion ranged from 31 -  95% (Q 16.44 (p<0.01), I2 = 
70%). Table 2 shows the appearance of ILC on MRI for all individual studies.
Table 2: Morphologic appearance o f ILC on MRI
Author Number of Tumors Non-Mass-like Mass-Like
Rodenko GN [32] 20 1 (5) 19 (95)
Weinstein SP [36] 18 8 (44) 10 (56)
Qayyum A [30] 13 9 (69) 4 (31)
Yeh ED [38] 20 11 (55) 9 (45)
Schelfout K [33] 27 6 (22) 21 (78)
Fabre Demard N [23] 35 11 (31) 24 (69)
Numbers between parenthesis represent percentages.
Fabre Demard et al. [23] did not specify the lesions beyond the description "mass-like". Other 
authors used many different terms to further describe lesions. In the study presented by Rodenko 
et al. [32], 5 pre-defined shapes were used, but they described all 19 mass-like lesions as spicular 
enhancing masses. In the other studies most lesions are described as spiculated masses as well. 
Schelfout et al. [33] recognized a dominant mass with multiple enhancing foci in eight cases and 
Yeh et al. [38] described even a round focal mass. In the 12 mass-like cases described by Kim et al.
[41] 10 had an irregular shape and 8 were spiculated. Therefore, among the 76 masses, a total of 
65 tumors were described as an irregular or spiculated mass. This appears to be the most common 
type of mass-like presentation in ILC.
Kinetics
Only two studies reported on the dynamic curve appearance of ILC [34,35]. The most apparent 
similarity between findings was that maximum enhancement is often delayed and wash-out 
is present in only a minority of lesions. Sittek et al. [34] reported that maximum enhancement 
was not reached before two minutes after contrast administration. Trecate et al [35] noted that 
a classic pattern of rapid signal increase was only present in 4 of 12 pure ILC, whereas a delayed 
pattern was observed in the other 8 cases.
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Two other studies reported on quantitative contrast behavior analysis in ILC [30,38]. Qayyum 
et al. [30] reported on a parameter called K21, analogue to the Ktrans parameter as described 
by Tofts et al [44]. Yeh et al. [38] evaluated the extraction flow product (EF), which is a similar 
analogue but respects the possibility that contrast leakage from the vessels is limited by 
flow instead of being limited by the permeability surface area product. Both studies did not, 
however, include sufficient patients to produce meaningful results, other than a high variability 
in the values of these parameters and the presence in some tumors of enhancement very much 
like enhancement in normal breast tissue. It was noted that K21 values appeared to be an order 
of magnitude less in ILC than in IDC lesions.
Correlation
Several authors evaluated correlation of the MRI findings with pathology [19,24-26,28,32,33,40]. 
Three studies compared unifocality and multifocality between MRI and pathology [26,32,33] 
(table 3). Overall 5 of 67 cases (7%) were regarded as multifocal, whereas they appeared unifocal 
at pathology and, vice versa, two cases (3%) in one study appeared unifocal at MRI, but were 
multifocal according to pathology.
Table 3: Relative correlation o f unifocality versus multifocality for MRI versus pathology
Number of
Author patients M
Rodenko GN [32] 20
Kneeshaw PJ [26] 21
Schelfout K [33] 26
Total 67
9
9
14
11
10
17
11
f MF 
ÌI PATH
Over­
estimated
Under­
estimated
9 2 1
! 11 1 0
! 10 2 1
5 2
UF = unifocal, MF = multifocal, PATH = pathology
Overestimated = Disease was classified as multifocal on MRI, but was unifocal on pathology. 
Underestimated = Disease was classified as unifocal on MRI, but was multifocal on pathology.
Overestimation of multifocality based on mammography in 63 patients from these studies 
occurred in two patients (3%), whereas underestimation occurred 25 times (40 %) and the 
lesion was not visible on mammography in another four patients (6%).
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Two of these studies further analyzed single quadrant versus multicentric involvement of the 
affected breast [32,33] (table 4). In the study by Rodenko et al. [32] two cases of single quadrant 
disease were erroneously classified as multicentric on MRI.
Table 4: Relative correlation o f single quadrant versus multicentric involvement for MRI versus 
pathology
Number of SQ SQ MC MC Over- Under-
Author patients MRI PATH MRI PATH estimated estimated
Rodenko GN [32] 20 9 11 11 9 2 0
Schelfout K [33] 26 21 21 5 5 0 0
Total 46 2 0
SQ = single quadrant, MC = multicentric, PATH = pathology.
Overestimated = Multicentric involvement was seen on MRI, but involvement o f only one 
quadrant was shown on pathology.
Underestimated = Involvement o f only one quadrant was seen on MRI, but on pathology 
multicentric involvement was shown.
Mammography in 42 of these patients resulted in overestimation of disease extent in one 
patient and underestimation in 15. Again, no lesion was visible in four patients.
Berg et al. [40] further showed a series of 12 patients that underwent MRI. Correct size estimation 
was performed in seven patients. In one patient an additional focus was missed and in four 
patients overestimation occurred due to foci of LCIS.
Absolute correlation of MRI and pathologic size measurement was performed by six authors 
[19,24-26,28,32]. Rodenko et al. [32] found a Kappa coefficient of 0.77, which represents 
substantial agreement. The other authors presented Pearson's correlation coefficients ranging 
from 0.81 to 0.97 (Q 10.90 (p = 0.03), I2 = 63%). Correlation coefficients for other modalities 
were substantially more variable. Presented correlation coefficients in table 5 are optimized by 
excluding cases where no abnormalities were seen from the calculations.
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Table 5: Correlation o f tumor size measured by various modalities compared to pathology
MRI ■ MMG m■ US ■ CE
Author N PCC K N PCC K N PCC K N PCC K
Rodenko GN [32] 20 0.773 15 -.081
Munot K [28] 20 0.97 10 0.66 14 0.67
Kneeshaw PJ [26] 21 0.86 21 0.93a 21 0.93a 21 0.47
Francis A [24] 22 0.87 16 0.79 20 0.56 19 0.89
Boetes C [19] 36 0.81 36 0.34 36 0.24
Kepple J [25] 33 0.88 9 0.71
MMG = mammography, US = ultrasound, CE = clinical examination,
N= number o f lesions visible on the appropriate modality,
PCC= Pearson's Correlation Coefficient, K = Kappa Value.
a Kneeshaw et al. did not provide a correlation coefficient for either MMG or US, but only one for the 
combined modalities.
Boetes et al. [19] applied a correctness measure of 1.0 cm to their data and found that MRI 
underestimated disease extent in five of 36 tumors and overestimated extent in four cases 
by more than 1.0 cm. The data provided by Francis et al. [24] allow a similar calculation. 
Underestimation occurred in six of 22 cases and overestimation occurred in one.
Additional lesions
Five studies focused on the detection of concurrent additional lesions in the affected breast 
apart from the index lesion only visible by MRI [22,23,31,33,36]. In 44 of 146 patients, additional 
malignant lesions were found (Q 7.20 (p = 0.13), I2 = 44 %). Additional malignant findings only 
visible on MRI were present in 32% of cases (95% CI 22 -  44%). The results of the individual studies 
are presented in table 6.
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Table 6: Additional malignant findings in the ipsilateral breast by MRI
Author Number of Patients Number of additional findings
Weinstein SP [36] 18 7
Quan ML [31] 51 11
Schelfout K [33] 26 9
Diekmann F [22] 17 9
Fabre Demard N [23] 34 8
Total 146 44
Meta-analysis 100% 32%
Eight studies, presented in table 7, reported on findings in the contralateral breast [19,22­
25,28,31,40]. In 12 of 206 patients, unexpected contralateral cancer was discovered exclusively 
by MRI (Q 2.28 (p = 0.94), I2 = 0%). Cases where contralateral cancer was also visible on 
mammography and/or ultrasound are excluded. Contralateral carcinoma only visible by MRI 
was present in 7% of patients. (95% CI 4 - 12%)
Table 7: Additional findings in the contralateral breast by MRI
Author Number of Patients Number of contralateral findings
Francis A [24] 22 0
Munot K [28] 20 2
Quan ML [31] 53 5
Diekmann F [22] 17 1
Boetes C [19] 34 2
Berg WA [40] 15 0
Kepple J [25] 14 0
Fabre Demard N [23] 34 2
Total 206 12
Meta-analysis 100% 7%
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Effect on surgical treatment
Six studies explicitly stated the effect of MRI on the surgical treatment of their patients 
[23,26,28,31,32,39]. In 160 patients with ILC, a total of 44 changes in surgical management 
occurred (Q 7.90 (p = 0.16), I2 = 37%). Overall, MRI changed the surgical management in 28.3% 
of cases (95% CI 20 - 39%). In 24 cases breast-conserving therapy was changed to mastectomy. 
In nine cases a wider local excision was performed. In the remaining 11 cases the type of change 
was not further described. Forty-one of 44 changes in surgical management were retrospectively 
judged necessary based on pathologic findings (Q 1.24 (p = 0.94), I2 = 0%). Therefore, 88 %  of 
all changes were correct (95% CI 75 - 95%). In three cases the change in management was 
retrospectively judged unnecessary based on pathology. The data of the individual studies are 
presented in table 8.
Table 8: Changes in surgical management based solely on MRI findings
Number of 
Changes
Correct
Changes
incorrect
Changes
Correct Incorrect Correct Incorrect
Author
Number of 
patients
wider
excision
Wider
excision
Mastecto
my
Mastecto
my
Rodenko GN [32] 20 8 7 1 7 1
Munot K [28] 20 3 3 3
Kneeshaw PJ [26] 21 5 5 1 4
Quan ML [31] 51 11 11 5 6
Bedrosian I [39] 24 11 9 2 NA NA NA NA
Fabre Demard N [23] 24 6 6 3 3
Total 160 44 41 3 9 23 1
Number of changes 100% 28.3%
Correct changes 100% 88%
NA = not available. Number of changes and Correct changes show the result of meta-analyses.
Rodenko et al. [32] and Kneeshaw et al. [26] both reported one further unnecessary mastectomy 
based on MRI outcomes. However, these mastectomies would also have been performed based 
on the mammography findings and are therefore not only due to the MRI. Berg et al. [40] also 
reported that findings on MRI in 12 patients with ILC would have resulted in two unnecessary 
mastectomies. However, mastectomies were also indicated according to the ultrasound 
report. Nonetheless they based their treatment on the mammograms only and therefore these 
mastectomies were not performed.
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Discussion 
Studies and quality analysis
We included 18 studies, but the highest number of studies that could be used to answer a 
specific endpoint was 8 (sensitivity and contra-lateral findings). Strong evidence is therefore 
lacking and this review is thus a clear call for more substantial research in this area. The overall 
study quality of all studies is, according to the QUADAS score, reasonably high (lowest score = 
9/14). However, this tool does not include the study size in the analysis, which was generally low. 
The tool places a strong emphasis on the relation of the test to the reference standard (typical 
for observational studies). In all studies, the reference standard was pathology and therefore 
always acceptable as gold standard. However, the test results (in this case the MRI reports), 
were never shielded from the pathologist who performed the pathologic evaluation. In studies 
that were performed to evaluate the visual characteristics of ILC on MRI a thorough description 
of the pathological examination was, deservedly so, not included [23,30,32,33,36,38,41]. These 
studies thus scored a little lower. There are some other drawbacks that must be considered 
and that are not included in the QUADAS score. Firstly, all but 2 of the included 18 studies were 
retrospective in nature, and secondly, the applied MRI protocols were largely heterogeneous 
(see table 1). However, the presented data were extracted from studies that made use of the 
various standards in MRI of the breast of the last decade and therefore give a reasonable 
overview of the overall capability of MRI in ILC imaging in this period.
Sensitivity
The sensitivity of physical examination and conventional imaging for ILC of the breast is not optimal. 
The sensitivity of physical examination for ILC ranges between 65% and 98% [10,45-47], with usually 
over 50% of patients presenting with palpable abnormalities.
The sensitivity of mammography for ILC (BIRADS 3 or higher) ranges between 81% and 92% in 
literature [10,45-51]. In a recent study that evaluated intra- and interobserver variability, sensitivity 
even ranged from 88% to 98% [52], which could be regarded as sufficient. However, ILC often do not 
appear as a malignant lesion on mammography; approximately 30% is classified as equivocal and 
sensitivity is then approximately 57-59% [51].
The overall sensitivity of mammography in the current analysis appears lower than findings in 
the literature on mammography in ILC. However, equivocal findings may have been classified 
as undetected lesions in some studies resulting in the overall lower results. Nevertheless, the 
sensitivities of only 34% found by Berg et al [40], and 50% found by Munot et al. [28] are on the lower 
end of the spectrum. Munot et al. [28] did not state which views constituted their mammograms, 
while Berg et al. [40] made craniocaudal, mediolateral and spot-compression views on a standard 
mammography machine, which we regard as common practice. A possible explanation for the poor 
results in the study by Berg et al. [40] may be that they defined an ILC as a focus of tumor, thereby 
allowing more tumors to be present in one breast, whereas other authors defined this as multifocal 
or multicentric tumors and thus as detected when at least one lesion was visible on mammography. 
In literature, the reported sensitivity of ultrasound for ILC ranges between 68% and 98% [47,53-58].
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As this range is comparable to the range found in the present evaluation, we are of the opinion that 
an overall sensitivity of 83% is accurate. However, application of newer high frequency ultrasound 
transducers may improve sensitivity. Initial series using 7.5 MHz transducers show sensitivities of 
68% [47] and 78% [56], whereas series that used 10-13 MHz transducers report sensitivities up to 
98% [57,59].
Contrast-enhanced MRI is nowadays widely accepted as the most sensitive modality for detection 
of malignancy of the breast. Early reports on overall sensitivity of MRI for breast lesions range from 
93% to 100% [13,60-63]. Thus, the sensitivity of MRI found for ILC in the studies presented herein and 
the overall sensitivity of 93.3% calculated from these studies are not different from those known for 
malignancy in the breast in general. The relatively low heterogeneity of all studies describing lesion 
detection as well as detection of additional lesions in the ipsi- and contralateral breast show that the 
applied MRI technique only has a minor impact on the ability of MRI to detect lesions.
The overall sensitivity could even be increased to 96% (95% CI 92 - 98%) if an early study is 
excluded from the analysis [34]. This study reported a sensitivity for ILC of only 83%, a 
discrepancy that may well be explained by the fact that the slice thickness in this study was 
4.2 mm, thicker than in any of the other presented studies, which could have had a negative 
impact on sensitivity. Moreover, 15 of 23 patients in their series were scanned with a FLASH 3D 
sequence with TR 8.4/TE 3.0, resulting in image acquisition with a phase-shift of water and fat, 
which might have further decreased their sensitivity, although this was not apparent from their 
data.
It must be taken into account that the acquired sensitivity in all studies was achieved in cases 
where prior knowledge of the existence of ILC was present. Mostly because of the retrospective 
nature of the presented studies, but also because the two prospective studies both included 
their patients on the basis of histological proof of invasive (lobular) carcinoma by core biopsy. It 
is therefore not possible to formulate conclusions on the sensitivity of MRI for ILC prior to biopsy. 
In a large multicenter trial by Bluemke et al. [64] overall sensitivity for invasive cancer prior to 
biopsy was 91%, thus it might be expected that sensitivity for ILC prior to biopsy is also slightly 
lower. However, in most cases the indication for MRI is assessment of disease extent because of 
inconclusive findings at mammography or ultrasound. In conclusion, the sensitivity of MRI for 
ILC is higher than that achieved by any other modality, in direct comparison and validated by 
literature, and is equal to the overall sensitivity of MRI for malignant lesions of the breast. Only 
modern ultrasound examinations seem to have the ability to approach the performance of MRI 
in the detection of ILC [57].
Morphology
The morphologic appearance of ILC on MRI ranged from 69% non-mass-like lesions to 95% 
mass like lesions, thereby raising questions concerning the amount of heterogeneity in the 
description of morphology of lesions by radiologists. In fact, the general agreement on the 
description of lesion type according to the BI-RADS lexicon is only moderate [14,65]. In the 
current analysis, this is even further complicated because most authors did not specifically use 
the BI-RADS lexicon. Additionally, differences in scan techniques may have further affected the
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appearance of the lesion. However, in keeping with the above, the classification of lesion type 
is also highly variable on mammography, where the incidence of mass lesions ranges from 32% 
to 78% [10,45,46,48,50,51,55].
The vast majority of the mass-like lesions described on MRI are irregular or spicular lesions. The 
eight patients with a dominant mass surrounded by multiple enhancing foci, as described by 
Schelfout et al., may present noncontiguous foci of disease without visible spiculae due to the 
absence of desmoplastic reaction, which is a well-known histopathological presentation [8]. In 
all series only one round mass was described [38], suggesting this to be a very rare presentation 
for ILC. This is consistent with findings in mammography by Le Gal et al. [10], who described a 
round mass in only 2% of all patients where a mass was present (4/174) while the remainder was 
either classified as a spicular mass (54%) or poorly defined mass (44%).
Mammographic findings would therefore appear to correlate well with MRI findings. 
However, only one study allows direct comparison [33]: of all lesions visible in this study on 
both mammography and MRI, 78% (18/23) were classified as mass-like by MRI, while only 
48% (11/23) were classified as mass-like by mammography. Six masses on MRI were visible as 
architectural distortion on mammography and two as asymmetric density. In one case a lesion 
described as spicular mass on mammography was visible on MRI as multiple enhancing foci 
with interconnecting enhancing strands.
Non-mass-like ILC in mammography are typically described as architectural distortion or 
asymmetric density. In some cases microcalcifications are present, although these are often 
related to concurrent surrounding DCIS, sclerosing adenosis or fibrotic changes and might 
thus not be related to the presence of ILC [45,51,55]. The descriptors currently used for non­
mass-like lesions on MRI are diverse and include various types of abnormal enhancement, such 
as regional, ductal, segmental and diffuse enhancement. According to Qayyum et al. [30] the 
morphologic description of ILC on MRI has a good correlation to histopathologic findings. The 
non-mass-like presentation might specifically occur in cases where ILC grows in the classic 
pattern with cells arranged in a linear fashion along the ductuli.
It may thus be concluded that the appearance of most ILC on MRI and mammography is similar: 
most ILC are mass-lesions that have clear malignant properties. However, the more diffuse 
growing tumors are characterized by areas of unexpected enhancement and are more difficult 
to recognize. In a number of cases where no clear mass is visible on mammography, a mass-like 
lesion may be found on MRI [33].
Kinetics
The relatively late contrast enhancement of ILC apparent in all studies presented here and 
mirrored by the relatively low values of K21 and EFP in the studies by Qayyum et al. [30] and 
Yeh et al. [38] must be taken into account when evaluating ILC. Standard subtraction images, 
generated from the pre-contrast and the first or second post-contrast acquisitions may be 
inconclusive as maximum enhancement is not achieved at this point in time and the lesion is 
thus not yet clearly visible. In fact, false negative MRI in cases of ILC is usually contributed to 
inadequate enhancement of the tumor [26,35,66]. The diffuse and often slow tumor growth,
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not requiring extensive neovascularization, may partly cause this difficult visualization 
[1,67,68]. This is also clear from the relatively lower amount of vascular endothelial growth 
factor (VEGF) found in tumors with a lobular histology, which might also indicate a different 
signaling pathway in the formation of neovascular vessels in ILC, resulting in more mature and 
thus less leaky capillaries [69], with consequently diminished or absent contrast enhancement.
Correlation
In the herein presented studies overestimation of lesion extent by mammography is rare, yet 
underestimation is more rule than exception. This is also confirmed by studies that specifically 
deal with mammography in cases of ILC. Yeatman et al. [5] showed that mammography 
underestimated ILC by a mean of 12 mm. Uchiyama et al. [51] reported 56% of all visible ILC 
on mammography to be underestimated and Veltman et al. [52] showed 35-37% of all ILC to 
be mammographically understaged. Ultrasound also tends to underestimate tumor size in the 
studies presented here.
This finding is underlined by Tressara et al. [70] and more recently by Watermann et al. [71], who 
documented a structural underestimation of 5.4 ± 12.2 mm in cases of ILC versus 1.4 ± 12.0 mm 
for cases of IDC. This might be partly due to the observation that US tends to underestimate 
larger tumors more than smaller tumors and low grade tumors more than high grade [70], 
consistent with the finding that ILC usually presents with slightly larger and less aggressive 
tumors [1,5,67,72]. The current analysis shows that there is good correlation of tumor size 
measured on MRI compared to pathology. The various studies presented only moderately 
heterogeneous results.
In most cases MRI outperforms mammography and ultrasound in the assessment of disease 
extent. Most tumors are correctly classified as uni- or multifocal and multicentric disease is only 
seldom overestimated [19,32].
Additional lesions and effect on surgical treatment
Especially important in this analysis is the detection of additional lesions apart from the index 
lesion in patients with ILC. The co-existence of other invasive malignant lesions apart from the 
index lesion in the ipsilateral breast in 32% of patients only visualized by MRI is high. Moreover, 
the detection of contralateral cancer in another 7% of patients by MRI only, seems to make MRI 
indispensable. These findings are confirmed by the rate of change in treatment of the ipsilateral 
breast based on MRI. The fact that change in treatment was considered correct, as verified by 
pathologic findings in the specimen, in 88% of cases shows that ILC is often more extensive 
than appreciated on conventional imaging.
However, various authors have shown that there is no significant difference in disease free 
survival (DFS) or overall survival (OS) after breast conserving therapy (BCT) or mastectomy in 
patients with breast cancer. Although some authors report more local recurrence in patients 
with ILC after BCT [2,73], most authors showed that there is no difference in DFS or OS after 
BCT in ILC versus IDC [74,75]. On the other hand, Yeatman et al. [5] reported a higher rate of 
conversion from lumpectomy to mastectomy in ILC compared to IDC (17.5% vs. 6.9%). More
66
MRI compared to conventional work-up in ILC - a review
recently, Molland et al. [68] reported similar findings (37.2% vs. 22.4%). Hussien et al. [2] even 
reported failure of BCT in patients with ILC in 63% (34/54) of patients, resulting in conversion 
to mastectomy in 76% of failures (26/34). However, a very recent study by Morrow et al. [76] 
showed that BCT did not fail more often in patients with ILC when corrected for age and tumor 
size, although they still observed a trend of more excisions in patients with ILC (OR 1.58 (0.89­
2.79), p = 0.12).
To date, there is no evidence suggesting increase in survival for patients with ILC due to the 
performance of MRI. What is then the added value of MRI? The rate of recurrence 10 years after 
BCT followed by radiotherapy is between 7 and 18% and is not significantly different from 
the rate of recurrence in case of IDC [77,78]. However, in view of the MRI-findings (additional 
malignant lesions in 32% of patients), we can only conclude that in a large number of patients 
with ILC, surgery is not curative but merely debulking. As recurrence rates are fortunately 
much lower, we must assume that curative treatment is to be expected from adjuvant therapy. 
Unfortunately, because there is no possibility to determine which additional findings will 
respond to adjuvant therapy, the detection of additional lesions on MRI currently still requires 
a change of treatment when malignancy has been proven by core biopsy. This may further 
reduce the rate of recurrence in patients with ILC and may even improve survival. However, this 
requires confirmation in future studies.
Conclusion
MRI has a high sensitivity for ILC, not achieved by other imaging modalities. Therefore MRI is 
helpful in cases where conventional imaging is inconclusive. Morphology is often mass-like and 
a typical ILC presents as an irregular or spiculated mass. However, asymmetric enhancement 
that can be ductal, segmental, regional or diffuse in nature may be the only sign of tumor. MRI 
measures disease extent with a high reliability. Although underestimation and overestimation 
of lesion size by MRI still occurs, it is more accurate than size determination by other modalities, 
indicating often more extensive tumor burden than expected.
The underestimation by other imaging modalities results in more failure of BCT, more re­
excisions and more conversion to mastectomy in series where MRI is not used. Magnetic 
resonance imaging has an effect on surgical management in that when used to assess disease 
extent, surgical management was changed in 28.3% of which 88% were judged necessary 
based on pathology. Larger series of patients are required to confirm the findings of this review; 
especially evaluation of tumor morphology and dynamic profile seems feasible.
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Chapter 5
Pathophysiological basis of contrast enhancement
Contrast enhanced magnetic resonance of tumors is entirely dependent on the fact that 
malignant growth of more than 1-2 mm cannot occur without vascular supply of metabolites and 
oxygen [1]. In response to hypoxia tumors thus generate their own vessels in order to be able to 
grow. This is achieved by releasing various angiogenic factors that promote neovascularisation. 
Vascular endothelial growth factor (VEGF) is the most well-known of these angiogenic factors 
but others contribute as well[2]. The vessels thus produced are different from those in normal 
tissue. They are extremely heterogenous with many distorted and twisting capillaries with fragile 
walls, there are many arteriovenous shunts and areas of high vascular density are interspaced 
with hypoxic areas with high angiogenic activity. [3,4] The walls of these capillaries are 'leaky' 
due to widened inter-endothelial fenestrae and the (partial) absence of a basement membrane. 
Furthermore, under influence of VEGF vesiculo-vascular organelles, which provide a pathway 
for macromolecules trough the endothelium, are upregulated in hypoxic situations [4,5].
Typical contrast agents for dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) 
are gadolinium chelates. They are injected intravenously, usually as a bolus and are cleared by 
renal excretion. These contrast agents are usually administered in a dose of at least 0.1 mmol/ 
kg, although some reports claim better results with higher doses [6]. Gadolinium based contrast 
agent shorten the T1 relaxation time of the surrounding tissue and therefore increase the signal 
that is received from the tissue[7]. These contrast agents have a low molecular weight and 
'leaky' vessels allow easy passage into the extravascular space of tumors. They are however 
unable to enter the cell and remain therefore in the extracellular space. However, due to the 
motion of protons that pass the cellular membrane, the intracellular compartment is affected 
by the presence of the contrast agent.
As long as the concentration of the contrast within the vessels is higher than the concentration 
in the extravascular extracellular space (EES), also known as leakage space, contrast agent will 
accumulate here and the signal intensity on T1 weighted images will increase [8].
When the intravascular concentration of the gadolinium agent drops due to leakage and renal 
excretion the contrast agent flows from the extravascular space back into the intravascular 
space and out of the tumor area, the signal from the tissue therefore decreases.
The enhancing areas that are used for evaluation of the morphology of a lesion are thus the 
result of the accumulated contrast in the EES. For the assessment of morphology a high spatial 
resolution is of the utmost importance. This can only be achieved with a low temporal resolution. 
Slow dynamic acquisitions, usually made with a spoiled gradient echo sequence, every 90 
seconds can achieve a high enough spatial resolution to observe morphology and can be used 
to evaluate contrast influx and wash-out of the contrast. Rapid initial enhancement, especially 
when larger than 100% and early wash-out of the contrast agent, visible as a downward slope 
in the signal versus time curve, are suspicious for malignancy [9,10]. Especially the presence of 
wash out has been shown to be highly specific for malignant lesions.
Several semi-quantitative measures can be derived from this signal versus time curve. Especially
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amplitude of the signal peak and time to peak (ttp) have been used to evaluate tumors and to 
characterize them further. However, correct assessment of these values demands a more rapid 
acquisition of images than the standard 90 seconds [11].
Ultrafast sequences
Ultrafast sequences in oncologic imaging are designed to document the arrival of contrast 
within the lesion and the gradual shift of the contrast agent from intravascular to extravascular. 
They are typically not designed to document the later phase of contrast behaviour and are thus 
not used for assessment of morphology nor for the detection of wash out [12].
However, ultrafast sequences may be used to document changes that are caused by the 
pathologic changes in tumor tissue. First of all, the total number of vessels in a tumor may be 
increased. Furthermore the vessels are usually larger, therefore vascular resistance is less and 
the contrast may reach tumor tissue earlier than normal tissue, hence start of enhancement (t0) 
can be assessed [13]. Second, the easier exchange of contrast agent from the vascular to the 
extravascular space and vice versa can be documented. Third, due to the increased permeability 
and often diminished vascular and lymphatic drainage of the EES, enlargement of the EES can 
be assessed [14].
These sequences can be inserted in standard scanning protocols directly after the injection 
of the contrast bolus. Typical maximum enhancement in breast lesions is not achieved before 
90 seconds after injection, thereby allowing a time-frame for evaluation of initial contrast 
behaviour by ultrafast sequences without compromising the integrity of the scanning protocol.
Typical sequences are rapid spoiled gradient echo sequences (e.g. TurboFLASH) that document 
the changes in T1 relaxivity and thus signal increase, so called T1 weighted DCE-MRI (T1w DCE- 
MRI). The sequence we use consists of 22 TurboFLASH acquisitions with a temporal resolution 
of 3.6 seconds at 1.5 T and of 2.5 seconds at 3T. Sequences that document the susceptibility 
changes caused by the passing contrast are T2* weighted acquisitions. They demand an 
even higher temporal resolution because they are used for so-called 'bolus-tracking', i.e. they 
document the first pass of the contrast agent through the capillary bed within the tumor, as 
this causes signal voids in T2* maps. This is called T2* weighted DCE-MRI (T2*w DCE-MRI) [15].
Post-processing
The raw images produced by T1w DCE-MRI can be used to determine ttp and amplitude of 
the signal peak with greater accuracy than slow dynamic acquisitions. The produced data are 
however highly dependent on the used equipment and patient specific characteristics. This can 
be overcome by quantitative pharmaco-kinetic analysis, but complex post-processing of the 
acquired data is then needed. Several additional measurements must be undertaken.
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As the changes in T1 relaxivity are non-linearly related to the contrast concentration, knowledge 
of the native T1 is needed. Furthermore, measurement of contrast enhancement needs to be 
calibrated against changes in a reference tissue. Usually changes in blood plasma are used for 
this calibration, the so-called arterial input function (AIF) [16,17]. However, this demands the 
inclusion of a large vessel in the imaging plane, not typically present in the imaging of the 
breast. Therefore signal changes in healthy tissue, like the pectoral muscle, may be used as 
surrogate reference [18].
The distribution of the contrast agent is regulated by the regional blood flow, the blood 
volume, the vessel shape and size, the permeability of the endothelium, the endothelial surface 
area and the size of the leakage space. Correct pharmaco-kinetic analysis should take all these 
factors into account, which is extremely complex [19,20]. Therefore various simplified models 
have been produced. All these methods make use of curve fitting techniques, changing the 
parameters in the model to best match the observed intensity versus time curve. The more 
parameters included, the more the natural situation is approached. However, inclusion of more 
parameters increases the chance that good curve fitting can be achieved with several settings, 
thus decreasing the robustness of the model. The simplest of these pharmaco-kinetic models, 
known as the two compartment model by Tofts, makes use of only two compartments, namely 
a vascular compartment without volume and the extravascular extracellular space, which is a 
fraction of the total extravascular space. The contrast transfer constant (Ktrans), which describes 
the flow of the contrast agent from the vascular to the extravascular space is derived from this 
model as well as the relative fraction of the EES (ve). These two parameters are mathematically 
related trough the rate constant (kep), which is inversely related to the ttp but due to the 
calibration more robust [21].
Ktrans = k * vep e
More complex models will allow the vascular compartment a relative volume (vp), thereby 
decreasing the size of the EES [21,22].
It is common to think of Ktrans as a measure of vascular permeability and in cases where 
abundant contrast is present in the vasculature it is indeed limited by the permeability surface 
area product. However, when flow is limited or the applied contrast concentration is too low 
to saturate the complete permeability surface, Ktrans becomes essentially limited by blood flow 
and may not accurately represent vascular permeability [21].
Subtraction images generated from T2*w DCE-MRI techniques allow insight into the spatial 
distribution of perfusion in a tumor. Where the signal drops the most, the highest perfusion 
is present. Mathematic modelling of the data achieved with these sequences can provide 
quantitative measures of blood flow. This can be performed by fitting the acquired data to an 
idealised model (gamma-variate fitting) because in practice, due to extravasation of the contrast, 
the signal does not return to the baseline after the first pass of the contrast agent. Relative
76
Ultrafast sequences in MRI of the breast
blood volume (rBV), relative blood flow (rBF) and mean transit time (MTT)can be estimated 
from this model [23,24]. These are also mathematically related according to the central volume 
theorem equation.
rBV = rBF * MTT
Clinical applications
In the detection of lesions the role of these fast sequences is only limited. The sensitivity for 
breast lesions on T1 weighted contrast enhanced magnetic resonance images with a high 
spatial resolution is in the order of 95-100%. Only low grade ductal carcinoma in situ is more 
difficult to detect due to absence of enhancement, therefore little is to be expected of ultrafast 
sequences. However, the standard approach of breast MRI is not very specific. Many benign 
lesions like fibroadenomas enhance as well. Furthermore normal breast tissue may enhance 
to a certain limit and distinguishing enhancement based only on morphologic interpretation 
may be difficult.
Evaluation of the signal intensity versus time curve is in these cases essential. Pharmaco­
kinetic parameters may also be an easy way to increase specificity. We found that calculation of 
pharmaco-kinetic parameters of an enhancing lesion in a region of interest (ROI) indicated by 
inexperienced readers, was equal in predicting malignancy to morphologic analysis combined 
with analysis of the signal intensity versus time curve by a reader with over 20 years of experience 
(Veltman, unpublished data). Ktrans was the most specific of the pharmaco-kinetic parameters.
A signal intensity loss of over 20% in T2*w DCE-MRI also has been shown to have a very high 
specificity for malignancy and can also be applied in the differentiation between malignant 
and benign lesions [25,26]. It was even found to be the only significant factor differentiating 
benign from malignant lesions in breast tumors induced in rats [27]. As these techniques are 
both based on absolute values in an image, they can be easily integrated in computer assisted 
diagnosis and will be useful in the future. (Fig 1, fig 2)
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Fig 1: Subtraction image of both breasts (S). There is a suspicious enhancing lesion in the left breast. 
The signal intensity versus time: curve shows a plateau. Color-coded parametric maps of Ktrans (A), 
kep (B) and vn lC), projected ovev T1 -weighted images of theafSected breast, are not suspicious for 
malignancy. At pathology the lesion proved to be chronic inflammation.
Fig 2: Subtraction image of both breasts (Si). There is suspicious enhancement in the rig ht breast. 
The signal intensity versus time curve shows rapid initial enhancement followed by a plateau. 
Color-coded parametric maps o flC ^  (A), kep (B) and ve (C), projected over T1 weighled images of 
the affected Idteast are highly suspicious for malignancy. At pathology the Sesion proved to be an 
invasive ductal carcinoma.
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Another field where ultrafast sequences show promising results is the evaluation of malignant 
lesions that are treated with neoadjuvant chemotherapy (i.e. chemotherapy prior to surgical 
intervention). As this type of treatment is potentially harmful when the tumor does not respond, 
close evaluation of tumor response is needed. Furthermore, factors that predict the response 
prior to the start of treatment are needed.
The latter can be partly achieved by a close evaluation of tumor morphology. A circumscribed 
mass is usually the best responding tumour. Evaluation of the signal intensity versus time curve 
is also useful as a higher initial amplitude is associated with a better response. This is also clear 
in the pharmaco-kinetic analysis as higher Ktrans values are also closely linked to a better initial 
response [28,29].
During treatment, decrease in size, or, even better, in tumor volume are the most significant 
in response evaluation, but responders have a more marked decrease in the amplitude of the 
peak enhancement than non-responders [28,30]. The signal intensity curve tends to flatten in 
responders and the tumor becomes more homogenous in its curve distribution [28,31] and the 
wash-out profile also changes and can be accurately assessed, although the latter is so far not 
very helpful in the prediction of response [32]. Combination of changes in volume with changes 
in enhancement ratio increases the specificity of the detection of patients who will achieve a 
complete pathologic response [33].
Distribution analysis of Ktrans over a whole tumor decreases in responders and generally 
increases in non-responders [34,35], but although mean Ktrans and kep decrease in responders 
they generally also decrease in non-responders though not as strong, which hampers the 
differentiation [29,34,36,37]. In early follow-up MRIs, Ktrans and kep were however significant 
predictors of response and ve increased in eventual non-responders [29]. Changes in median 
rBF and rBV also correlated significantly with final clinical and pathological response [38].
Dynamic contrast enhanced derived parameters as prognostic factors
The pathophysiological basis of contrast enhancement implies that the process is linked to 
the biological nature of the tumor. Several authors have tried to correlate the enhancement 
characteristics and the pharmaco-kinetic parameters of DCE-MRI to known prognostic factors 
in breast cancer.
The slope of the enhancement curve is associated with microvessel density [39] and it was 
shown that nodal status of a breast tumor and histological grade were strongly associated with 
enhancement characteristics [40,41].
Pharmaco-kinetic parameters may therefore be used as non-invasive prognostic parameters, 
however their independent prognostic value still needs to be assessed.
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Conclusion
Ultrafast sequences are designed to document the influx of contrast agent in tumor vessels and 
the extravasation of the agent directly hereafter. The pharmaco-kinetic parameters that can be 
derived from these sequences are helpful in the differentiation between malignant and benign 
breast lesions and in the prediction and monitoring of reponse to neoadjuvant chemotherapy. 
However, their role in clinical practice still requires further evaluation.
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Abstract 
Purpose
Invasive lobular carcinoma (ILC) is suggested to enhance less than invasive ductal carcinoma 
(IDC) on contrast enhanced MRI of the breast. This may impair the diagnostic value of breast 
MRI in ILC. We compared enhancement characteristics between IDC and ILC to observe the 
magnitude of these differences.
Materials & Methods
We performed an analysis of enhancement characteristics on biphasic breast MRI in a series 
of 136 patients (103 IDC, 33 ILC) using an in-house developed application for pharmacokinetic 
modeling of contrast enhancement and a commercially available CAD-application that 
evaluated the contrast-enhancement versus time curve.
Results
Pharmacokinetic analysis showed that the most enhancing voxels in IDC had significantly higher 
Ktrans-values than in ILC ( p <0.01). However, no difference in ve-values was noted between 
groups. Visual assessment of contrast-enhancement versus time curves revealed wash-out 
curves to be less common in ILC (48% vs 84%). However, when using the CAD-application to 
assess the most malignant looking curve, the difference was blotted out (76% vs 86%).
Conclusions
ILC enhances slower than IDC, but peak enhancement is not significantly less. The use of a CAD- 
application may help to determine the most malignant looking contrast-enhancement versus 
time curve, and hence facilitates lesion classification.
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Introduction
Breast cancers are pathologically divided in several histologic types. The most common types 
are invasive ductal carcinoma (IDC) in approximately 85% and invasive lobular carcinoma (ILC) 
in 10-20% [1]. IDC is a diagnosis per exclusion, i.e. a tumor is an IDC if no specific subtype can be 
assigned. ILC on the other hand is a specific histological diagnosis [2,3]; it is a malignancy that 
is characterized by small, relatively uniform cells that grow in a loosely cohesive fashion due to 
the loss of the adhesion molecule E-cadherin, and may infiltrate the surrounding tissue in single 
cell file [4]. There are distinct and well documented differences between IDC and ILC; ILC are 
generally larger at detection, occur in older patients, show less surrounding fibrosis, are more 
often estrogen receptor (ER) and progesterone receptor (PR) positive and more often Her2/Neu 
negative.
The problem with ILC is the lower diagnostic performance of mammography [5-7] and 
ultrasound [8,9] compared to IDC. This is probably caused by the diffuse growth pattern of 
some ILC and the lack of sufficient surrounding fibrosis. The sensitivity of mammography for 
ILC ranges from 35 to 81% [10,11] and the sensitivity of ultrasound for ILC ranges from 68 to 
98% (overall approximately 83%, [10]). Moreover, on mammography, ILC presents much more 
regularly as an asymmetry in the glandular pattern or as architectural distortion than IDC [5,12]. 
Similarly, on ultrasound ILC are more often associated with hyper- or isoechoic patterns and/ 
or present as architectural distortion than tumors with an invasive ductal histology [9,13]. 
Consequently, adequate tumor size assessment is compromised, and it has been shown that 
mammography an ultrasound commonly understage the disease.
The diagnostic performance of breast MR for ILC is much better than the conventional imaging 
techniques. It is better in size assessment [14-20] and tumor staging and consequently changes 
the surgical management in 28% of ILC cases [21].
MRI also has become a screening modality for patients at high risk and for evaluation of the 
contralateral breast of women with proven unilateral breast cancer, hence tumor detection has 
become an important function of breast MRI. A recent meta-analysis showed that the sensitivity 
of breast MRI for ILC was 93% and as such not different from the overall sensitivity of MRI for 
breast cancer in general (90%) [21,22].
However, several studies suggest that ILC enhances later after contrast medium injection [23,24], 
does not reach similar peak enhancement and does not exhibit early wash-out of the contrast 
agent [23]. Furthermore, a non-mass like morphology appears to be more common [25,26]. 
Consequently, terms in the ACR BIRADS MRI lexicon, the standardized reporting tool for breast 
MRI [27], that have a high positive predictive value for malignancy, such as "irregular mass" and 
"spiculated margin" may be less commonly applicable [28]. Moreover computer aided diagnosis 
systems that use enhancement characteristics (all currently available commercial systems) may 
misdiagnose ILC as a benign lesion.
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The aim of this study is to quantify differences in the enhancement patterns of IDC and ILC on 
breast MRI, using an in-house developed application that has already been shown valuable 
in the differentiation between benign and malignant breast lesions [29] and a commercially 
available application dedicated to breast MRI.
Materials and methods 
Patients
We searched the clinical database and selected all women with invasive breast cancer who were 
treated at our hospital between January 2003 and December 2006. In total 327 women were 
eligible. From this group we selected all women that underwent contrast enhanced breast MRI, 
which yielded 150 patients. We excluded 13 patients that had a histologic diagnosis that was 
not pure IDC or pure ILC (with or without accompanying carcinoma in situ) and, furthermore, 
one patient with an incidentally detected low grade IDC of 7 millimeters because the tumor was, 
even in retrospect, not visible at breast MRI. The study was thus performed with the imaging 
data of 136 patients with pathologically assessed invasive breast cancer.
The indication for the performance of breast MRI was highly variable, some were performed 
as problem solving after inconclusive findings on conventional imaging, others were aimed 
at preoperative staging and screening of the contralateral breast. Moreover, many patients 
received a breast MRI due to participation in one of several prospective trials. However, the 
acquisition protocol in all patients was identical.
Scanning Protocol
In all patients, prior to the investigation, an intravenous canula was placed in the cubital vein for 
contrast administration. Patients were then placed in the prone position on the scanner table 
with both breasts hanging free in the coil loops of a dedicated bilateral four channel breast coil 
(Invivo, Germany). Patients were subsequently entered in the magnet (1.5T Avanto, Siemens, 
Erlangen, Germany), with the breasts carefully placed at the isocenter. During the investigation 
the contrast medium was administered at a dose of 0.2 mmol/kg (Dotarem, Guerbet, France), 
using a powerinjector at a speed of 2.5ml/sec (Medrad, Warrendale, USA).
The scanning protocol was bitemporal in nature, i.e. we performed both relatively high spatial, 
low temporal and low spatial, relatively high temporal acquisitions. Localizer images and 
proton density images at low and high temporal resolutions were acquired (used for calibration 
purposes, see below). This was followed by 1 pre- and 4 post contrast FLASH 3D acquisitions at a 
high spatial resolution and a relatively low temporal resolution (TR/TE 7.8/4, FA 20, rectangular 
FOV 340, matrix 256*256, slice thickness 1.3, orientation coronal, AT 90s), interleaved with a 
consecutive series of 22 turboFLASH acquisitions at a high temporal and low spatial resolution 
(TR/TE 72/1.54, FA 20, FOV 340, matrix 256 *82, slice thickness 4.5, orientation transversal, AT 
4.5s) that was started at the moment of contrast administration and lasted exactly 98 seconds.
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Post-processing
The MRI scans of all patients were collected and uploaded to two different dedicated breast MR 
working stations.
The first workstation was an in-house developed application (MRCAD) that performs 
pharmacokinetic analysis using the high temporal resolution acquisitions in a Tofts model. 
The exact mechanism of this modelling approach, which yields the parameters Ktrans (the 
volume transfer constant (min-1)), kep (the rate constant (min-1)), ve (the relative fraction of the 
extracellular, extravascular space (%)), t0 (start of enhancement (sec)), and latewash (final slope 
of the curve (%)), is described in detail elsewhere [29,30], but in short: the observed changes 
in signal are fitted to a general signal enhancement model. This reduces the acquired data 
to a standardized exponential curve based on the following five parameters; baseline signal 
(s0), start of enhancement (t0), time to peak enhancement (ttp), peak enhancement (sp), and 
wash. Subsequently this reduced signal intensity versus time curve is converted to a tracer 
concentration (mmol/ml) versus time curve, using the high temporal resolution proton density 
acquisition and one of the turboFLASH acquisitions to calculate the native T1 of the tissue, and 
the signal from the peripheral fat to calculate machine gain. This, effectively, converts the signal 
peak (sp) to a concentration peak (cp).
A standardized model of the plasma profile is used to calculate pharmacokinetic parameters 
for each voxel as: v =  cp / cp . , t0 = t0 - t0 . , k = 1 / (ttp - ttp. ), latewash =e 'tumor 'plasma' tumor plasma' ep v ■rumor 'plasma7'
wash - wash, , and Ktrans = v *  k , were the subscript tumor refers to the observed valuestumor plasma e ep
in the tumor voxels and the subscript plasma refers to the standardized plasma profile.
This allows the creation of color coded pharmacokinetic maps that can be used as overlays on 
images with a high spatial resolution on this workstation, but in this study we only used the 
numerical values per voxel for inter tumor comparison.
All lesions were scored on the MRCAD by a single reader (R.M.). Numerical values per tumor 
were obtained by drawing a region of interest (ROI) around the whole area where, according 
to the pathology report, the tumor was located (fig 1). All voxels within this ROI that showed 
at least 10% change in signal intensity over the observed period, were regarded as part of 
the tumor. The system automatically produced 10th-percentile and quartile scores for the 
parameters mentioned above. We analyzed only the distribution of Ktrans and ve , which were 
chosen because of the physiological conditions that are represented by these parameters. Ktrans 
is, in situations with sufficient blood flow, proportional to the permeability surface area of the 
blood vessels within the lesion and hence governs the speed of enhancement, whereas ve is the 
relative fraction of the extracellular extravascular space and as such determines the maximum 
relative enhancement at a given concentration of the contrast medium [31].
89
Chapter 6
V  1 '■ /
(
**
Fig 1: A wide ROL consisting of a combination of multiple sphere shaped region s, is drawn around a 
multifocal and highly irregular tumor using MRCAD.
The second application is a commercially available package (CADstream v3.1, Confirma, USA). 
This workstation was only used for the analysis of the high spatial resolution acquisitions.
With the settings used in our hospital, this system generates coronal and sagital subtraction 
images of the pre-contrast and first post-contrast sequence (early subtraction) which are 
automatically shown. Furthermore, a coronal pre-contrast T1 acquisition and a maximum 
intensity projection generated from the early subtraction are shown. CADstream produces 
a color-coded "angiomap" of the changes in signal intensity over time, using a relative 
enhancement of 50% as threshold. The applied colors correspond to the enhancement versus 
time curves as described by Kuhl et al [32]. By choosing the "volumes" option and clicking on 
a colorized voxel in the tumor, CADstream automatically segments a 3D volume of continuous 
enhancing voxels. Subsequently, it displays the most malignant looking relative enhancement 
versus time curve in a 3*3*1 voxel area within the selected volume, and the quantified 
distribution of kinetic parameters throughout the selected volume (e.g. 10% of voxels in the 
volume show rapid initial enhancement and wash-out) (fig 2).
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Fig 2: Auto-segmentation o fth e dominant focus using CADStream. No te the irregular margin of this 
mass-like lesion and the presence of rim-enhancement. Under the data-tab CADOtream shows the 
distribution of the relative enhancement curves within the segmented volume.
All images were evaluated at the CADstream workstation by a different independent reader 
(C.B.). The reader was aware of the fact that an invasive carcinoma was present and also knew in 
which breast the lesion was located, but was unaware of the exact location of the tumor within 
the breast and the final histology of the tumor . The morphologic appearance of all lesions 
was described according to the BIRADS lexicon. The most malignant looking curve that was 
representative for the lesion was first obtained by visual assessment.
Subsequently, the lesion, or in case of multifocality, the most dominant focus, was segmented 
using the "volumes" function. The most malignant curve as detected by the system was noted. 
The distribution of the enhancement parameters in the volume was also noted.
Pathology
Histopathological characteristics of each tumor were extracted from the pathology report 
created at the time of treatment.
Statistics
The differences in the desrri pti on oOtumor c ha racteristics bet ween I DC and ILC with a binomial 
or categorical distribution were evaluated using the chi-square test or Fisher exact test 
whenever appropriate. Differences in continuous variables were analyzed, using the T-test for 
unrelated samples.
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Results 
Pathology
We included 136 patients, 103 with IDC (76%) and 33 with ILC (24%). The mean patient age was
53.5 in the IDC group and 55.8 in the ILC group. In the IDC group 29 patients were treated with 
a lumpectomy and 74 with a mastectomy, these figures were respectively 11 and 22 in the ILC 
group. Table 1 shows the overall distribution of the pathologically evaluated parameters. We did 
not observe differences in the distribution of tumor stages according to the TNM classification 
between the IDC and the ILC group. Nevertheless, lobular cancers were overall slightly larger 
than ductal carcinomas, were more often multifocal and/or multicentric, had a different 
distribution of tumor grade and had an overall lower mitotic activity index (MAI). Typically, IDC 
were associated with concurrent DCIS. Some DCIS was seen in 60 of 103 cases, and in 39 cases 
an extensive DCIS component (that is, DCIS more than focal outside the tumor) was present. 
Only 9 of 33 ILC were associated with some concurrent DCIS and 3 of cases showed extensive 
DCIS. ILC were, however, usually accompanied by LCIS, which was present in 31 of 33 cases 
and was extensive in 22. In IDC, LCIS was rare, 21 cases had a small LCIS component and only 2 
showed extensive LCIS.
Table 1: Distribution of the pathologically evaluated parameters
Characteristic IDC ILC p-value
N 103 (76) 33 (24)
Mean patient age 53.5 55.7 0.4
Unifocal 63 (61) 13 (39) 0.03
Multifocal/Multicentric 40 (39) 20 (61)
Size of largest focus (mean (cm)) 2.2 3.0 0.05
ER- 16 (15) 1 (3) 0.07
ER+ 87 (85) 32 (97)
PR- 32 (31) 6 (18) 0.15
PR+ 71 (69) 27 (82)
Her2/Neu-a 53 (88) 22 (92) 0.70
Her2/Neu+a 7 (12) 2 (8)
Grade Ib 19 (19) 6 (20) 0.02
Grade IIb 35 (35) 20 (67)
Grade IIIb 45 (45) 4 (13)
MAI (mean) 22.9 7.7 0.03
amissing in 52 cases, 43 IDC and 9 ILC, bmissing in 7 cases, 4 IDC and 3 ILC
ER = Estrogen Receptor expression, PR = Progesteron Receptor expression
MAI = Mitotic Activity Index, Numbers between parenthesis represent percentages
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Pharmacokinetic analysis
We did not observe any difference in the distribution of ve, hence the relative fraction of the 
extravascular extracellular space does not differ between IDC and ILC. However, the distribution 
of Ktrans (~permeability surface area) was significantly different between the IDC and ILC groups. 
The mean Ktrans was higher in the IDC group than in the ILC group (1.2 vs 0.9 min-1, p=0.01), 
which was mainly caused by focal areas of much higher Ktrans in IDC than in ILC. Median Ktrans 
values were not significantly different between groups. Increasing percentile scores showed, 
however, increasing differences between the IDC and ILC groups, as shown in table 2.
In short, the most enhancing voxels per tumor in the IDC group showed a significantly higher 
permeability surface area than the most enhancing voxels per tumor in the ILC group.
Table 2: Differences in distribution of the pharmacodynamic parameters between IDC and ILC.
Parameter Percentile IDC ILC p-value
Ktrans (min-1) 50 0.97 0.74 0.11
75 1.86 1.3 0.01
90 2.8 1.9 <0.001
Ve (%) 50 29 29 0.99
75 43 42 0.84
90 56 54 0.74
Kinetic appearance
Visual assessment of the relative enhancement versus time curve revealed that wash-out was 
more common in the IDC group than the ILC group (87/103 vs 16/33, p<0.01), but this difference 
was no longer present when evaluating the most malignant curve that was automatically 
selected by CADstream's "volumes" option (table 3). In other words, in most tumors at least one 
small area can be detected with a type 3 enhancement curve, regardless of the histological 
origin.
Maximum relative enhancement was not different between IDC and ILC, nor was the fraction 
of voxels that showed rapid initial enhancement (at least 100% at the first post-contrast high 
spatial resolution acquisition) (56 vs 58%, p=0.6).
The distribution of relative enhancement versus time curves in the segmented volumes differed 
between tumors in the IDC and ILC groups. A type III curve (wash-out) was seen in less than 10% 
of all segmented voxels in 31/103 IDC and 21/33 ILC (p<0.01). Moreover the fraction of voxels 
that showed continuous enhancement was also lower in the IDC group than in the ILC group 
(51% vs 61%, p=0.03).
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Table 3: Results of the evaluation of the most malignant looking curve per tumor by visual assess­
ment and as selected by CADstream. Numbers between parenthesis represent percentages.
Visual assessed curve Automatically detected 
Method curve
IDC ILC IDC ILC
Curve Type I) Continuous
enhancing
1 (1) 1 (3) 1 (1) 1 (3)
II) Plateau 15 (15) 16 (48) 13 (13) 7 (21)
p-value
III) Wash-out 87
<0.01
(84) 16 (48) 89 (86)
0.45
25 (76)
Maximum
(mean (%)) x x 382 360
Amplitude
p-value 0.76
Morphologic appearance
Table 4 shows the distribution of all BIRADS lexicon descriptors for morphology in the evaluated 
population. We did not observe typical differences in the distribution of morphologic descriptors 
between IDC and ILC. Most tumors were accompanied by surrounding foci of enhancement 
and mass-like enhancement was the most common form of presentation for both IDC and ILC. 
The relative fraction of non-masslike enhancement was higher in the ILC group, but this did not 
reach statistical significance. Although we allowed the assignment of a tumor to both mass-like 
and non-mass-like enhancement in case of substantial contribution of both lesion types, only 
two tumors in the IDC group and two tumors in the ILC group were scored likewise.
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Table 4: Distribution of morphological descriptors according to the BIRADS lexicon. Numbers 
between parenthesis represent percentages.
Sub-descriptor IDC ILC p-value
95 (92) 31 (94) 0.75
86 (83) 25 (76) 0.32
Circular 11 (13) 4 (16)
Oval 10 (12) 3 (12)
Lobular 8 (9) 2 (8)
Irregular 57 (66) 16 (64)
Smooth 9 (10) 2 (8)
Irregular 23 (27) 7 (28)
Spiculated 54 (63) 16 (64)
Homogeneous 6 (7) 3 (12)
Heterogeneous NOS 69 (80) 20 (80)
Rim Enhancement 10 (12) 2 (8)
Enhancing septations 1 (1) 0 (0)
Dark septations 0 (0) 0 (0)
19 (18) 10 (30) 0.15
Linear 1 (5) 1 (10)
Ductal 0 (0) 0 (0)
Segmental 10 (53) 6 (60)
Regional 4 (21) 1 (10)
Diffuse, Patchy 3 (16) 1 (10)
Diffuse, Nonspecific 1 (5) 1 (10)
Homogeneous 0 (0) 2 (20)
Heterogeneous NOS 18 (95) 6 (60)
Stippled / Punctate 0 (0) 1 (10)
Clumped 0 (0) 0 (0)
Descriptor
Foci of Enhancement 
Mass-like enhancement 
Shape
Margin
Internal Enhancement
Non-mass like enhancement 
Type
Internal Enhancementa
aIn 11DC and 11LC internal enhancement could not be assessed
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Discussion
To our knowledge, this is the first study to directly compare the enhancement characteristics 
and morphological features of IDC and ILC. However, several other small studies evaluated the 
appearance of ILC on MRI by itself [14,20,23-26,33-35].
We observed that Ktrans values were lower in the ILC group than in the IDC group.
Two small studies that performed quantitative pharmacokinetic analysis in ILC did not compare 
their data to parameter values obtained from IDC and did not include enough patients to 
produce otherwise statistically meaningful results [33,35]. However, both studies (which 
respectively evaluated the extraction flow product (EF) and k21, both comparable to Ktrans in 
our study) stated that blood vessel permeability in ILC can, in large areas of the tumor, be very 
similar to blood vessel permeability in normal breast tissue and appeared lower than in IDC, 
which corresponds well with our data.
The lower Ktrans values in the ILC group imply that enhancement (especially in the most rapidly 
enhancing voxels) in the IDC group is faster than in the ILC group (because the permeability of 
the blood vessels is higher). However, as we did not observe differences in ve (which governs the 
maximum possible enhancement), peak enhancement does not differ between groups (which 
is in accordance with our results from the analysis of the high spatial resolution acquisitions) 
thus the peak is only reached earlier. There is also some histopathological evidence for these 
differences in the microvasculature between IDC and ILC. Lee et al. showed that the expression of 
vascular endothelial growth factor (VEGF), a messenger protein that is very important for tumor 
angiogenesis and increases vascular permeability (it is also known as vascular permeability 
factor) is higher in IDC than in ILC. Nevertheless, the microvessel density did not differ between 
these tumor types [36].
We did detect a difference in the appearance of the relative enhancement curves between IDC 
and ILC when evaluated by visual assessment. This is the most common procedure to assess 
curve shape in literature [28,32], and is widely used in clinical practice. However, adequate use 
of the BIRADS lexicon implies the use of the most malignant looking curve in a 3*3*1 voxel area 
within the tumor for lesion classification [27], therefore, the machine detected most malignant 
looking curve is probably the most suited to classify lesions as benign or malignant.
The higher permeability in IDC should theoretically lead to steeper wash-out slopes of the 
relative enhancement versus time curves as contrast also leaves the extravascular extracellular 
space more easily. However, apart from the 10% signal decrease cut-off point for wash-out, 
the standard curve classification does not take the slope of the wash-out curve into account. 
Consequently, the most malignant looking relative enhancement versus time curves of ILC are 
hardly different from those of IDC when the delay between contrast administration and the post­
contrast acquisition is long enough. So far, little research has been undertaken investigating the 
shape of enhancement curves in ILC [23,24]. Trecate et al. noted in a series of 18 patients with 
ILC that a type III curve was commonly present, but that this was preceded by a delay before
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actual enhancement started in eight patients [24]. Maximum enhancement was consequently 
reached earlier in IDC than in ILC. Sittek et al. also noted in a series of 23 patients with ILC 
that a peak contrast enhancement was only reached after approximately 3 minutes [23]. More 
recently Caramella et al. found a wash-out curve in only 6 of 35 patients, but they did not state 
how the curve was assessed [14].
Similar to our observations, the most common morphologic pattern of ILC on breast MRI 
described in literature is an irregular spiculated mass, but the fraction of non-mass like 
enhancement patterns is highly variable and ranges from 5-69% [20,25,26,33-35]. So far, only 
one study by Yeh et al., made consistent use of the BIRADS lexicon for the description of lesion 
morphology [35]. They described an irregular mass-like lesion in 8/19 cases and non mass-like 
enhancement with a segmental distribution in 5/19 cases, other patterns were less frequently 
observed. It thus appears that NMLE is indeed (slightly) more common in ILC and may reach 
statistical significance in larger series. Nevertheless, morphological analysis, even using the 
rigorous approach of the BI-RADS lexicon is subject to significant interreader variability. For 
analysis using CADstream an overall kappa-value of 0.41 has been reported, which was similar for 
ILC (k =0.40) and IDC (k =0.42) and is well in-line with earlier reported values in literature[37-39]. 
Hence, differences between various tumor types can only be appreciated in relation to each 
other.
This study does not show the potential of breast MRI to detect ILC. It is still retrospective in 
nature and most tumors were detected by other means. To observe whether MRI is capable of 
showing ILC undetected by conventional imaging modalities at an earlier stage, a prospective 
screening trial in a normal population is needed.
In conclusion, ILC enhance slower than IDC but do reach equal peak enhancement. The delay 
between contrast administration and the post-contrast acquisition should be sufficient to 
prevent ILC from being misclassified as benign lesions on the basis of continuous enhancement. 
We recommend a delay of approximately 90 seconds, because in our series this has been shown 
useful, whereas longer delays may allow more enhancement of normal breast tissue and hence 
lesions may become obscured. The use of a dedicated workstation that allows automatic 
detection of the most malignant looking curve may help to assess the most malignant looking 
curve.
The morphologic features of ILC are only slightly different to those of IDC and can thus be used 
to describe and classify these lesions. Naturally, the detection of NMLE should initiate work-up. 
Using these precautions it appears that MRI, as opposed to mammography and ultrasound, is 
able to detect ILC as well as IDC.
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Abstract 
Aims
Invasive lobular carcinoma of the breast (ILC) is known to be substantially underestimated by 
mammography, which makes correct planning of treatment difficult. MRI has been proposed as 
a valuable adjunct to mammography. The purpose of the current study is to evaluate its value, 
compare it to mammography and assess the possible causes of over- and underestimation of 
lesion size on MRI.
Method
The mammograms and MRI scans of 67 consecutive patients with ILC were retrieved and re­
evaluated. Size measurements were correlated to the sizes extracted from the pathology report.
Results
MRI measurements correlated better to pathologic size (r=0.85) than mammographic 
measurements (r=0.27). Underestimation of tumour size was more common on mammography 
(p<0.001); overestimation occurred with equal frequency (p=0.69). Overestimation on MRI, 
caused by non-malignant findings, was attributed to enhancing lobular carcinoma in situ.
Conclusion
MRI is a more accurate modality to determine tumour size in patients with ILC than 
mammography. The typical underestimation of lesion size by mammography can be prevented 
with the aid of MRI, without increasing the risk of lesion overestimation.
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Introduction 
Preoperative extent estimation of breast cancer
In the treatment of breast cancer, there is an increased importance of adequate tumour extent 
estimation prior to surgery. The main reason is that breast conserving treatment (BCT) has replaced 
mastectomy as the principal therapy of choice. Local recurrence after BCT and radiotherapy occurs 
in 3 - 19% of patients and is usually caused by (unrecognized) incomplete resection or multifocality. 
Theoretically, this can thus be prevented by correct pre-operative assessment of tumour extent [1]. 
Another reason is the increasing use of neoadjuvant chemotherapy [2]. The decision to treat a 
patient with neoadjuvant chemotherapy is entirely based on pre-operative tumour size assessment 
and is advocated for all T3 and T4 tumours [3]. In many studies, however, large resectable T2 breast 
cancers are also treated with neoadjuvant chemotherapy [1,3]. Additionally, initial tumour size is a 
strong predictor of subsequent response to chemotherapy (the smaller, the better the response) 
and the eventual prognosis [4].
A third reason is the upcoming use of non-surgical treatment modalities in the local treatment of 
breast cancer, such as radiofrequency ablation [5], cryoablation [6] and high-focused ultrasound [7]. 
These techniques cannot be controlled by pathological examination as no tissue is excised. Their 
success is, therefore, dependent on perfect size measurement by imaging. This requires imaging 
modalities that allow robust size measurement of breast cancer.
Extent estimation in invasive lobular carcinoma
Invasive lobular carcinoma of the breast (ILC), the second most common type of invasive breast 
cancer (present in 10-15%) after invasive ductal carcinoma (IDC), is a diagnostic problem. It 
is characterized by an insidious growth fashion (present in 33-70% of cases); the stroma is 
infiltrated in single cell file. Therefore, it is not only more difficult to detect ILC, but also much 
more difficult to accurately determine the extent of ILC.
Several studies have shown that size measurements in ILC on mammography and ultrasound 
correlate only moderately with pathological tumour size [8-10]. MRI on the other hand has 
been more successfully used in adequate tumour size estimation [11-13]. However, the risk of 
overestimation of lesion size on MRI (and consequently, unnecessary, more invasive treatment) 
hampers the general acceptance and implementation of this technique in clinical practice [14].
Study objectives
The sample size of the published studies to date is low and does therefore not allow an 
evaluation of the reasons for under- or overestimation of lesion extent by MRI. The purpose of 
this study is to evaluate whether size estimation on MRI is indeed superior to mammography 
in a larger cohort of ILC. Moreover, we elaborate on the causes of under- and overestimation of 
tumour size and their consequences in patient treatment.
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Patients and Methods
We retrospectively searched the pathology and database of all patients surgically treated 
for breast cancer at our hospital between 1993 and 2005 and reviewed their surgical record. 
All patients with ILC who were surgically treated and where a MRI was performed in the pre­
operative work-up were selected. Patients with other histologic types of invasive cancer and 
patients with tumours with a mixed histology were excluded. Concurrent ductal carcinoma in 
situ (DCIS) or lobular carcinoma in situ (LCIS) were accepted.
Mammography
All collected mammograms up until 1999 were acquired with a Mammomat 3000 (Siemens, 
Erlangen, Germany). After 1999, the Radiology department converted to digital mammography 
and all mammograms were made using a Senograph 2000 D or a Senograph DS (GE Healthcare, 
Wisconsin, USA). In each patient medio-lateral oblique and cranio-caudal views were obtained. 
An experienced breast radiologist reviewed all mammograms. The radiologist was aware of the 
patient's condition but unaware of the clinical findings, location of the tumour or size measured 
at pathology. All lesions were scored from 1 to 5 according to the Breast Imaging Reporting and 
Data System (BI-RADS) classification. The position of any finding on mammography that would 
have prompted further evaluation (i.e. BI-RADS 3 or higher) was compared to the location of 
the tumour at pathology. When the actual tumour was present in the same quadrant of the 
same breast, the lesion was classified as detected by mammography. The size of the tumour was 
measured as the largest diameter of the whole tumour in any direction. In case of multifocal 
disease, besides the size of the whole tumour area, the maximum diameter of the largest focus 
was also recorded. Spiculae were regarded as desmoplastic stromal reaction, according to the 
findings by Flanagan et al. [15], and were not included in size measurement.
Ultrasound
We did not review the ultrasound reports, nor the ultrasound images, as we regard ultrasound 
to be an operator dependent imaging modality that is poorly represented by evaluation of the 
incidental screenshots taken at the time of evaluation.
MRI
The MRI investigations of all patients were retrieved. Indications for the performance of MRI 
were clarification of uncertain findings, assessment of tumour extent or participation in one 
of several prospective studies that were performed at our hospital in the above-mentioned 
period of time. All MRI were made using a Magnetom Vision or Magnetom Avanto MRI scanner 
(Siemens, Erlangen, Germany), both at 1.5T. Prior to examination a canula was placed in the 
cubital vein for contrast administration. The patient was placed in the prone position, with both 
breast hanging free in a bilateral open breast coil (Machnet, the Netherlands or InVivo, Germany). 
Localizer images were created, followed by six FLASH 3D acquisitions that were positioned 
on the localizer (TR/TE 7.8/4 ms, flip angle 200, matrix 256*128, rectangular field of view 340
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mm, coronal orientation, slice thickness 1.3 mm, acquisition time 98 sec). The contrast agent 
(Magnevist, Schering, Germany or Dotarem, Guerbet, France) was administered between the 
first and the second FLASH 3D acquisition (dose of 0.2 mmol/kg) by a power injector (Medrad, 
Pittsburgh, USA) at a speed of 2.5 ml/sec and flushed with 20 ml of saline. The collected MRI 
were presented on a DynaCAD (InVivo, Germany) workstation to the same breast radiologist 
that re-evaluated the mammograms, but separately from mammography. Again, all lesions 
were located and scored according to the BI-RADS classification.[17] The maximum diameter 
of the lesion in any plane was recorded as the tumour size on MRI. In case of multifocal disease, 
both the size of the entire lesion area and the size of the largest focus were measured.
Pathology
Pathologic findings were extracted from the pathology report created at the time of treatment. 
The location and maximum size of the lesion area were noted, as well as the maximum size of 
the largest focus in case of multifocal disease.
Statistical methods
Pearson's correlation coefficients were calculated for both mammographic size and MRI size 
versus pathologic size. In case of multifocal disease, the size of the whole tumour area was used 
whenever available. When the size of the whole tumour was unavailable or not measurable in 
any of the three evaluations, the size of the largest focus was used for correlation.
Because the cohort has been acquired over a long period of time, we split the cohort into two 
sub-cohorts based on date of surgery (1993-1999 and 2000-2005) and also evaluated these 
sub-cohorts separately. Fisher's Z-test was used to compare correlation coefficients of these 
sub-cohorts.
Measurements of lesion size on mammography or MRI were considered correct when lesion size 
was within 1 cm from the pathologic measurement. Lesions were considered underestimated 
when the measured size was more than 1 cm smaller than pathologic size and overestimated 
when they were more than 1 cm larger. McNemar's test for related samples was used to test 
for differences in the amount of cases with overestimation and underestimation between 
mammography and MRI.
P values smaller than 0.05 were considered significant in all cases.
Specific cut-off sizes
As 3 cm is the cut-off size to initiate treatment with neoadjuvant chemotherapy in our 
hospital, as is the case in many trials reported in literature, we assessed the accuracy of both 
mammography and MRI to discriminate between tumours both larger and smaller than 3 cm 
by receiver operating characteristic (ROC) curve analysis. The area under the curve (AUC) was 
used as a measure of accuracy. Logistic regression was used to test whether the combination 
of mammography and MRI findings would be beneficial in this assessment. We also performed 
this analysis for lesions larger and smaller than 5 cm as there is a wide consensus that lesions 
larger than 5 cm should be treated by mastectomy with or without neoadjuvant chemotherapy
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and these patients are no longer candidate for BCT.
Subsequently, we analyzed the amount of lesions on both MRI and mammography that 
appeared smaller than 5 cm but were larger at pathology because this may have clinical 
implications, whereas underestimation of lesions larger than 5 cm resulting in a size still larger 
than 5 cm results in the same treatment and has no clinical value.
Results 
Patients and lesions
In the investigated period 148 women with ILC were treated. As 78 did not undergo pre­
operative MRI, they were excluded. Furthermore, three patients were treated with neoadjuvant 
chemotherapy and were excluded because the pathological assessment is affected by this 
therapy. The remaining 67 women were included (age mean/median 55/55 years, range 35­
78). In 66 of these patients, an ILC was detected by conventional triple assessment (physical 
examination, mammography and ultrasound). In the last patient, triple assessment detected 
an IDC in the left breast, subsequently MRI detected an ILC in the contralateral breast. Only the 
latter tumour was entered in the study. Two patients had a second, contralateral ILC, in both 
cases also detected by MRI only. We thus included 69 ILC. Tumour characteristics are presented 
in table 1.
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Table 1: Tumour (n = 69) characteristics
Characteristic N
Palpable
Yes 55
No 14
Detected on Mammography
Yes 55
No 13
Detected on MRI
Yes 69
No 0
Tumour Stage
T1 17
T2 28
T3 22
T4 2
DCIS present 15
LCIS present 61
Lymph node Stage
N0 36
N+ 33
Final Treatment
Lumpectomy 20
Mastectomy 49
In one patient no mammography was performed; she had complained of pain during an earlier 
mammography and refused to undergo this examination. Furthermore, 13 tumours were 
mammographically occult and 1 was not measurable. The remaining lesions (n = 55) could be 
measured. On MRI no lesions were occult, and all lesions were measurable (n = 69).
Correlation to pathology
We observed no significant correlation between size measured on mammography and the actual 
tumour size on pathology. Tumour size measured on MRI was significantly correlated to pathologic 
size. Figure 1A and 1B show scatter plots of mammographic and MRI lesion size versus pathologic 
lesion size, respectively. Table 2 gives an overview of the measurements compared to pathology. 
After division of our cohort in two sub-cohorts (operated prior to, or after January 2000), no 
significant differences in performance over time for both mammography and MRI were 
detected (mammography r = 0.27 versus r = 0.31 (p = 0.86), and MRI r = 0.81 versus r = 0.89 
(p = 0.22)). Further sub-division of our cohort did not yield any significant results.
107
Chapter 7
A  Mammographie vs. Pathologic tumor size B  MRI vs. Pathologic tumor size
10,0
8,0
S  6,0
01
® 4,0 . ;aï ■
N
in . ’ r
. ■. I' ■
' : ,:.V . '  ■
2.0
0,0
10,00
Êo 8,00
Q .
6,00
-
Ecc
5 4,00TO
ili
N
05 2,00
0,00
0,0 3,0 6.0 9,0 12,0 15,0 0,0 3,0 6,0 9,0 12,0 15,0
Size at Pathology (cm) Size at Pathology (cm)
Fig 1: Scatter plots of tumour sizes as measured on mammography (A) and MRI (B) versus pathologic 
tumour size.
Table 2: Measurement of tumour size on the respective imaging modalities, MRI and MMG 
(MMG = mammography) compared to pathology (PA). In case of mammography, 
only detected and measurable lesions are included. NA = Not Applicable
MMG MRI PA
Mean tumour size (cm) 2.9 4.1 4.3
Median tumour size (cm) 2.4 3.0 2.8
Range (cm) 0.1 - 10 0.7 - 10 0.1 -15
Under-estimated (> 1cm) 29 11 NA
Correct Measurement 20 51 NA
Over-estimated (>1 cm) 5 7 NA
Pearson's Correlation 
Coefficient 0.27 (p=0.46) 0.85 (p<0.01) NA
Under- and overestimation of lesion extent
The maximum underestimation on mammography was 13 cm, while maximum overestimation 
was 4.8 cm. On MRI, maximum underestimation was 6 cm, while maximum overestimation was
5.5 cm.
Underestimation of lesion size occurred significantly more often on mammography (p < 0.001) 
(fig 2, fig3), overestimation, on the other hand, occurred with equal frequency on mammography 
and MRI (p = 0.69). In the five cases where mammography led to overestimation of tumour size, 
two were attributed to concurrent extensive ductal carcinoma in situ (DCIS) (+3.0 and +2.7 cm, 
respectively), one case was attributed to sclerosing adenosis (+2.4 cm) and in two cases only
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lobular carcinoma in situ (LCIS) was detected at pathologic examination of the specimen (+1.7 
and +2.0 cm, respectively).
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Fig 2: A and B show the mammogram of a fa tty left breast in medio-lateral oblique (MLO) and 
cranio-caudal (CC) orientation, respectively. Retroareolair, an irregular spiculated mass is observed 
with a maximum diameter of 26 cm. C and D show subtracted MRI imaget of the same breast in axial 
and coronal orientation. The irregular, spiculated enhancing lesion measures 4.4 cm. Pathologic 
examination revealed an unifocal ILC wfth a maximum diamefer of 4.6 cm.
109
Chapter 7
L MLO
* «
' V
5,5 cm
f *  - - j e
S R I lí
Fig 3: A and B show the mammogram of a dense left breast in medio-lateral oblique (MLO) and 
cranio-caudal (CC) orientation, respectively. There is a clip from prior surgery of a benign lesion. 
Lateral, an irregular mass is observed with a maximum diameter of 2.3 cm. C and D show a 
subtracted MRI image in axial orientation and a maxim um intensity projection (MIP) of the same 
breast, respectiuely. MRI reveals multifile enhancingi highly suspicious lesione over an area of 6.8 
cm. Histological proof of malignancy was obtained prior to sutgery by core biopsy. Pathology after 
surgery revealed a multifocal ILC over an area of 7.3 cm.
In seven patients where MRI overestimated the invasive tumour size, two were attributed to 
concurrent DCIS in and around the tumour (+3.0 and +5.5 cm respectively). In these cases the 
amount of overestimation correlated well with the extent of DCIS. In one patient the tumour 
had infiltrated the skin and nipple and overestimation of lesion size (+2.0 cm) was attributed 
to inflammatory changes. In the remaining four patients, overestimation of tumour size could 
only be explained by extensive LCIS detected in the specimen (+1.9, +2.1, +2.1 and +3.0 cm, 
respectively).
110
MRI compared to mammography in the assessment of tumor extent in ILC
In one of these latter patients, the invasive tumour was 2.7 cm and therefore a breast conserving 
approach would have been possible according to the standards valid at the time of treatment, 
but a mastectomy was performed. This might have been due to the performance of MRI.
Specific cut-off sizes
MRI was significantly better able to discriminate between tumours larger and smaller than 
3 cm (AUC 0.94) than mammography (AUC 0.81) (p = 0.04). Figure 4A shows the ROC curves 
of mammography, MRI and the combination, respectively. Adding mammography to MRI 
measurements did not significantly increase the AUC (AUC=0.96, p = 0.42). Similar results, 
shown in figure 4B, were observed for the discrimination between tumours larger and smaller 
than 5 cm (MRI: AUC 0.94, mammography: AUC 0.77) (p = 0.02). We observed in total 23 ILC with 
a pathological size larger than 5 cm, mammographically 19 of these ILC appeared smaller than 
5 cm (mean underestimation 5.76 cm), whereas only one appeared smaller than 5 cm on MRI (7 
cm tumour, underestimated by 6 cm).
Fig 4: A : ROC curves for the prediction of pathologic tumour size > 3cm by mammography (MMG) 
and MRI and the combination of both. B: ROC curves for the prediction of pathologic tumour size > 
5 cm.
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Discussion
All ILC evaluated in this study were visible on the MRI. Therefore, MRI has an advantage over 
mammography, by which only 55 of the tumours were visible. However, false negative results 
of breast MRI in cases of ILC are reported by other authors. Wurdinger et al. described 5 false 
negative MRI examinations due to delayed or absent contrast enhancement in a series of 193 
invasive carcinomas [17]. Four of these had a lobular histology and the fifth was of tubular origin. 
The insidious growth fashion of ILC requires less extensive neovascular proliferation. As 
a consequence, vessels may be more mature and leakage of contrast from the vessels to 
the extravascular extracellular space, the very reason for enhancement on MRI, can be less 
pronounced than in other types of breast carcinoma [18], but this does not decrease the value 
of MRI. Our results clearly show that MRI is by far superior to mammography in the estimation of 
tumour size. These results are constant over time, we did not observe any statistical differences 
over the long period of inclusion in this analysis.
Importance of adequate extent estimation in ILC
The importance of adequate tumour size estimation in case of ILC is stressed by the observation 
that margin status after BCT is more often compromised in ILC than in IDC. As a consequence, re­
excision and conversion of BCT to mastectomy are more common for ILC than for IDC [19,20]. The 
risk is especially increased in ILC larger than 1.5 cm at mammography, and in younger patients 
[19]. Unfortunately ILC are generally larger than IDC and a size of more than 1.5 cm is common. 
A further complication is that ILC tend to be more often multifocal and/or multicentric than IDC 
(14-31%) [21], which is in many cases not observed on mammography or ultrasound [22]. MRI, 
on the other hand, has been shown to document up to 100% of all cases of multifocality [22]. 
However, we did not address multifocality as a separate item in this analysis. Instead, we 
measured, whenever possible, the size of the whole tumour area because this has the most 
important implications for patient treatment.
Mammography
Our results indicate that size measurement on mammography in cases of ILC is of no value. 
More than half of all visible lesions are underestimated by more than 1 cm. Furthermore, 
overestimation of tumour size occurred in another 5 cases. Fortunately, other authors report 
more positive results of tumour size estimation on mammography in ILC. In a recent study by 
Heusinger et al. an overall correlation coefficient of 0.70 was reported for ILC. They noted that 
the accuracy of tumour size estimation on mammography was, apart from histologic type, 
largely dependent on tumour size itself [23]. Accuracy decreased with increasing tumour size, 
the size of larger tumours tended to be underestimated, and more so with increasing size. 
Therefore, it was more difficult to predict mammographically whether or not a tumour was 
larger than 3 cm than whether a tumour was larger than 2 cm. This finding was even more 
prominent in ILC than in IDC. Similar results were presented by Dummin et al., who reported 
a R2 of 0.73 for size measurements of ILC on mammography compared to pathologic size [24].
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This value, however, dropped to 0.21 when only T2 tumours were included in the analysis and 
eight lobular carcinomas over 3 cm in size were underestimated by a mean of 60%. The lower 
value of our measurements with mammography can thus be explained by the overall large size 
of the tumours in this study. This is also apparent from the enormous underestimation in the 
subgroup of tumours larger than 5 cm. However, we were unable to produce better results with 
only the (small) subset of T1 tumours in our study.
Another possible explanation for the structural underestimation of tumour size on 
mammography might be the exclusion of spicules from the tumour size measurement. This 
method is commonly used in literature [15,24], but some studies indicate that although 
spicules are usually only a desmoplastic reaction, some may contain tumour cells [25]. 
Mammographically, these spicules cannot be separated from each other, therefore it has been 
argued that the spicules should be included in the measurement [25].
MRI
Reported correlation coefficients for tumour size and MRI measurements are, in contrast to 
mammography and ultrasound, reasonably constant and substantially better. The presented 
correlation coefficients in literature range from 0.86 to 0.97 and our observation (r = 0.85) is thus 
on the lower edge of this range [12,13,26,27]. Adequate tumour size estimation in case of ILC is 
therefore achievable with MRI.
Unfortunately, underestimation of tumour size with MRI is still impossible to exclude. We 
observed 11 cases where the actual tumour size was more than one cm larger than predicted on 
MRI. In these cases, an attempt for BCT would probably have led to compromised margins and 
subsequent re-excision. This observation also prohibits the use of non-surgical treatment for ILC. 
Although not diminishing the significance of MRI underestimation, these cases were in general 
large lesions (mean 7.57 cm) with a diffuse growth pattern that would not have been eligible to 
any non-surgical treatment protocol. In all cases, suspicious enhancement was only present in 
part of the lesion. Furthermore, small satellite lesions surrounding the index lesion may have been 
excluded from the tumour area, even though these foci are often found in lobular breast cancer 
[22] and are usually malignant in origin and thus need to be included in tumour sizing [28]. 
However, the main reason that MRI is not yet widely accepted for tumour extent estimation prior 
to therapy is not the possibility that MRI may underestimate lesion size but exactly the opposite. 
MRI may overestimate the actual lesion size and thus result in unnecessary more radical treatment 
[29,30]. In our study overestimation of lesion size on MRI by more than 1 cm was present in seven 
cases. In four cases this was probably caused by enhancing LCIS, as this was the only additional 
histologic finding present in these patients. Although, we can not provide a direct histological 
correlation for the enhancing area, other authors have also shown that LCIS may enhance on MRI 
[31].
However, the recent acknowledgement that LCIS still may be a precursor lesion rather than a high­
risk lesion for subsequent development of invasive breast cancer may even justify more extensive 
treatment based on MRI findings [32]. Additional research in this area should be conducted as 
scientific evidence is lacking.
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We could not confirm that MRI measurements led to a more structural overestimation of lesion 
size than mammography. Therefore, MRI seems a safe way to increase knowledge of tumour 
extent prior to treatment. Nevertheless, pathological confirmation of additional findings on MRI 
that might change the intended treatment, prior to surgery, is mandatory because false positive 
results do occur [28,29].
MRI provides a high accuracy in the discrimination between ILC larger or smaller than 3 and/or 5 
cm. Therefore, it can be confidently used to assign patients to adequate surgical treatment and 
neoadjuvant chemotherapy. Adding mammographic measurements to the MRI measurements 
did not further increase this accuracy and is thus not useful.
With respect to the above, we believe that MRI should be the imaging modality of choice in case 
of pathological proof of ILC. Nevertheless, apart from tumour size, size of the breast, expected 
cosmetic outcome, physical state of the patient, patient history and patient preference should 
be taken into account with every treatment decision. Any of these factors, alone or combined, 
may in time be more heavily weighted than tumour size itself.
Conclusion
MRI is the most accurate modality for tumour size estimation in patients with ILC currently widely 
available. Lesion size is not more often overestimated than with mammography. However, when 
overestimation occurs due to non-malignant findings, it can usually be attributed to extensive 
LCIS in and around the tumour. The typical underestimation of lesion size by mammography 
can be prevented with the aid of MRI. This may be helpful in the reduction of tumour positive 
margins after BCT and the rightful assignment to neoadjuvant chemotherapy treatment 
protocols.
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Abstract 
Purpose
Re-excision rates after breast conserving surgery (BCS) of invasive lobular carcinoma (ILC) are 
high. Preoperative breast MRI has the potential to reduce re-excision rates, but may lead to an 
increased rate of mastectomies. Hence, we assessed the influence of preoperative breast MRI on 
the re-excision rate and the rate of mastectomies.
Methods
We performed a retrospective cohort study of a consecutive series of patients with ILC who 
presented in one of two dedicated tertiary cancer centers between 1993 and 2005. We assessed 
the initial type of surgery (BCS or mastectomy), the re-excision rate and the final type of surgery. 
Patients were stratified into two groups: those who received preoperative MRI (MR+ group) and 
those who did not (MR- group).
Results
In the MR- group, 27% of the patients underwent a re-excision after initial BCS. In the MR+ 
group, this rate was significantly lower at 9%. The odds ratio was 3.64 (95% CI: 1.30 - 10.20, 
p=0.010). There was a trend towards a lower final mastectomy rate in the MR+ group compared 
to the MR- group (48% vs 59%, p=0.098).
Conclusions
Preoperative MRI in patients with ILC can reduce re-excision rates without increasing the rate 
of mastectomies.
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Introduction
Invasive lobular carcinoma of the breast (ILC) is more prone to incomplete surgical excision 
and subsequent re-excision than other histological types of breast cancer. Reported re-excision 
rates in ILC after breast conserving surgery (BCS) range from 29 to 67% [1-5]. In 16-48% of 
patients with ILC local surgical therapy is still converted to mastectomy after failure of BCS [1,5­
10].
Contrast-enhanced magnetic resonance imaging (MRI) of the breast has often been proposed 
as the solution to failure of obtaining tumor free margins in BCS and subsequent re-excision 
or conversion to mastectomy. The technique is superior to conventional imaging methods in 
staging ILC [11-18], which is mainly achieved by improving tumor delineation and detection of 
additional tumor foci.
Conversely, many studies have shown that preoperative breast MRI changes therapy in 12-33% 
of patients from BCS to mastectomy [11,13,16,19-22]. Although the changes may be appropriate 
in 88% of cases according to pathology [23], this percentage is still relatively high compared to 
local recurrence rates [24]. Nonetheless, large trials have demonstrated that incomplete tumor 
excision is a risk factor for local recurrence [25]. Hence, the question remains whether MRI is 
capable of reducing the frequency of incomplete surgery and subsequent need for re-excisions 
without adverse side effects, such as dramatically increasing the rate of mastectomies [26-28]. 
This information is essential if MRI is to be implemented in the standard preoperative staging 
of all patients with ILC.
The aim of this study, therefore, was to assess whether preoperative breast MRI influences the 
rate of re-excisions and the rate of mastectomies in a large consecutive series of patients with 
ILC.
Materials and Methods 
Ethics
This cohort study was performed according to good clinical practice and the Dutch legal 
regulations. No approval of the local ethical committees or informed consent was needed for 
this study. However, patients who participated in earlier prospective clinical trials (approved 
by the local ethical committees) tailored to different research questions provided informed 
consent for those studies.
Patients
The pathological and oncological databases of the Radboud University Nijmegen Medical 
Centre (RUNMC) and the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital 
(NKI-AVL) were searched and all patients who presented with ILC between January 1993 and
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December 2005 at the RUNMC and between January 1999 and December 2005 at the NKI-AVL 
were included. Both hospitals perform preoperative breast MRI in nearly all patients with ILC 
since early 2006. Consequently, no patients were included after 2005.
We excluded all patients who: (1) had a history of cancer of any type (n = 32), (2) had prior 
surgery to the affected breast except for excisional biopsy to establish the diagnosis (n = 15), 
(3) were initially treated with neoadjuvant chemotherapy or other non-surgical techniques (n = 
41), (4) were initially treated in another hospital (n = 378).
Data acquisition
We reviewed the medical, radiological, and pathological records of all patients who met the 
inclusion criteria. We registered patient characteristics, when the diagnosis was established, 
time to initial surgery, and type of initial surgery (BCS or mastectomy) [29]. Furthermore, the 
number and type of repeat operations after initial surgery (due to the detection of involved 
resection margins at pathological examination in more than two low power fields (10x objective) 
at microscopy) were recorded. When tumor margins were clear or were only focally involved at 
microscopy (less than two low power fields) and no re-excision was deemed necessary, the 
surgical procedure was recorded as being radical (final pathology).
The radiological databases were searched for imaging studies to establish: (1) the type 
of conventional imaging performed to detect and stage the tumor, (2) whether contrast 
enhanced breast MRI was performed within 3 months prior to initial surgery, (3) the number 
of days between tumor detection (either at mammography or clinically), the breast MRI, and 
final pathology. All patients in whom breast MRI was performed were assumed to have been 
preoperatively staged with breast MRI.
The pathology databases were reviewed to obtain tumor size and pathological characteristics 
from the surgical specimens at final pathology. In the case of multifocal lesions the largest 
diameter of the total area with tumor foci was recorded. If this information was not available, 
the size of the largest focus was recorded.
Breast MRI
Due to the extensive study period and data acquisition in two cancer centers, the patients were 
scanned using various MRI systems, various field strengths ranging from 1.0 to 3.0 T and various 
scan protocols. The spatial resolution of these protocols generally improved over time. However, 
all patients were scanned in the prone position with the use of a dedicated bilateral breast coil. 
All protocols included a series of T1 weighted sequences that was repeated at least four times, 
first prior to the administration of a Gd-containing contrast agent and then several times after 
intravenous contrast administration at a dose of 0.1 mmol/kg. In all patients, subtraction images 
were created from the pre and post contrast scans to evaluate tumor morphology and tumor 
kinetics (internal enhancement and enhancement curve type) according to the BIRADS lexicon 
[30]. The size of the tumor was measured and reported in three perpendicular planes (coronal, 
axial, and sagital). The indications for the performance of MRI were diverse and included 
accepted clinical indications, patient wish and participation in clinical studies that assessed: (1)
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the radiologic pathologic correlation of MR-visible tumors, (2) screening of women at high life­
time risk of breast cancer, (3) preoperative staging, and (4) new MRI sequences.
Therapeutic approach
Prior to surgery, the available information for each patient (including clinical examination, 
mammography in two directions, ultrasound of the affected breast, and breast MRI when 
available) was discussed in a multidisciplinary meeting of breast cancer specialists (radiologists, 
pathologists, surgeons, radiation oncologists, and medical oncologists). This team devised the 
treatment plan in consensus.
Both hospitals applied the policy that MRI findings required pathologic proof of malignancy 
prior to adaptation of the surgical plan, except if such adaptation was a small extension of a 
local excision. Proof of malignancy was typically acquired by second look ultrasound or MRI 
guided (excision) biopsy [29,31].
Statistics
Our primary endpoint was to compare the rate of re-excisions in all patients who underwent 
preoperative MRI compared with the rate of re-excisions in those who did not undergo preoperative 
MRI. The rate of initial mastectomies in both groups, the final rate of mastectomies and the time 
between tumor detection and final pathology were regarded as secondary endpoints.
In addition, we analyzed the rate of re-excisions and the final mastectomy rate in the subset of 
patients that underwent initial BCS.
All means are expressed as mean ± 1 SD. Binomial comparisons were performed using the chi- 
square test to check for statistical significance, or a Fisher's exact test whenever appropriate. 
Continuous variables were compared with the T-test for independent samples. Correlations 
were assessed with Pearson's correlation coefficient. We calculated odds ratios and 95% 
confidence intervals for the chance of re-excision with and without preoperative breast MRI for 
the whole population and for the subset of patients that initially underwent BCS. Calculations 
were performed using SPSS version 16.0 (SPSS Inc. Chicago, USA). P values smaller than 0.05 
were considered significant.
Results
Patient and tumor characteristics
In total, 267 patients met the inclusion criteria. Ninety-nine of these women underwent pre­
operative MRI (MR+ group), 168 did not (MR- group). Patient groups were comparable, although 
the mean age of patients in the MR+ group was less. Patient characteristics are described in 
Table 1.
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Table 1: Characteristics of the patients included in the study.
MR - 
(N = 168)
MR+
(N = 99)
p-value
Age (years)
Mean
Median
Range
61
60
37-89
± 13 
57
36-86
56 ± 10 0.001
Menopausal State
Premenopausal 51 (30) 30 (30) 0.880
Postmenopausal 106 (63) 64 (65)
HRTa 11 (7) 5 (5)
Family History
Blank 137 (82) 80 (81) 0.578
Positive 31 (18) 18 (18)
BRCA mutation carier 0 (0) 1 (1)
aHRT = complete hormone replacement therapy
The tumors in both groups were equally distributed in size and although the rate of multifocal 
lesions in the MR+ group was slightly higher, this did not reach statistical significance. 
Concurrent DCIS was incidentally present in both groups, whereas concurrent LCIS was very 
common and often extensive. We did not observe any significant difference in hormone 
receptor expression. Although the Her2/Neu receptor was more often over-expressed in the 
MR- group, the expression was only assessed in 155 patients and the difference did not reach 
statistical significance. In Table 2 tumor characteristics are shown.
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Table 2: Pathological characteristics o f  the included malignancies.
MR -  
(N = 168)
MR+
(N = 99)
p-value
Size (cm)
Mean
Median
Range
3.4 
2.3 
0.1 -
± 2.8 
14.0
3.4
2.4
± 2.6 
0.2 -11.0
0.985
Focality
Unifocal 80 (48) 44 (44) 0.615
Multifocal 88 (52) 55 (56)
DCISa present
No 128 (76) 74 (75) 0.849
Limited 28 (17) 17 (17)
Extensive 9 (5) 7 (7)
LCISb present
No 31 (18) 19 (19) 0.994
Limited 57 (34) 34 (34)
Extensive 78 (46) 46 (46)
Estrogen receptor expression
Negative 5 (3) 2 (2) 0.720
Positive 144 (86) 83 (84)
Missing 19 (11) 14 (14)
Progesterone receptor expression
Negative 36 (21) 17 (17) 0.460
Positive 111 (66) 67 (68)
Missing 21 (13) 15 (15)
Her2/Neu Expression
Normal 88 (52) 55 (56) 0.057
Over expressed 11 (7) 1 (1)
Missing 69 (41) 43 (43)
aDCIS = ductal carcinoma in situ 
bLCIS = lobular carcinoma in situ
Surgery
Initial surgery was radical in 237 of 267 (89%) patients. In total, 30 patients underwent re-excision 
because of involved margins. Only one of these patients underwent initial mastectomy. This 
patient underwent an additional resection of residual tumor in the axillary tail. In 4 patients, 
the re-excision consisted of an extended local excision, in 25 cases the surgical procedure was 
secondary mastectomy.
The rate of re-excisions was significantly higher in the MR- group (15%) than in the MR+ group
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(5%) (P = 0.014), as is shown in Table 3. The odds ratio for re-excision was 3.29 (95% CI 1.22-8.85). 
In other words, patients in the MR- group were 3.3 times more likely to undergo re-excision 
than patients in the MR+ group.
Table 3: Rate o f re-excisions and mastectomies in the entire study population.
MR - MR+ p-value
(N = 168) (N = 99)
Re-excisions 25 (15) 5 (5) 0.014
Intial mastectomies 78 (46) 44 (45) 0.753
Final mastectomies 99 (59) 48 (48) 0.098
Numbers between parenthesis represent percentages.
Initial mastectomy was performed in 122 of 267 patients (46%). We did not observe a higher rate 
of mastectomies in the MR+ group. The final rate of mastectomies was even lower in the MR+ 
group, though this did not reach statistical significance. Overall, the rate of initial mastectomies 
declined over the years. We observed a negative correlation coefficient of -0.19 (P = 0.002) 
between the year of treatment and the rate of initial mastectomies (fig. 1).
Rate of initial mastectomies
1 0 0 ­
9 0 ­
8 0 ­
7 0 ­
6 0 ­
%  5 0 ­
4 0 ­
3 0 ­
2 0 ­
1 0 ­
0 -
Fig1: Rate o f patients in itia lly  treated w ith mastectomy by year o f inclusion
□ Observed 
_  Linear
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Year of treatment
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Patients in itia lly  treated w ith  breast conserving surgery
In the subset of patients who initially underwent BCS after preoperative staging, mean tumor 
size was lower and multifocality was less common. We did not observe differences in tumor 
size or rate of multifocality between the MR- and MR+ groups (Table 4). However, the rate of 
re-excisions was significantly higher in patients in the MR- group, than in patients in the MR+ 
group (odds ratio 3.64 (95% CI 1.30-10.20)). Consequently, mastectomy as final therapy was 
much more common in patients who initially underwent BCS but did not undergo preoperative 
breast MRI (P = 0.010).
Table 4: Results in the subset o f patients tha t in itia lly  underwent BCS.
MR - MR+ p-value
N 90 55
Mean tumor size (cm) 2.1 ± 1.4 2.0 ± 1.4 0.724
Multifocal 37 (41) 19 (34) 0.431
Re-excisions 24 (27) 5 (9) 0.010
Final mastectomies 21 (23) 4 (7) 0.013
Numbers between parenthesis represent percentages.
We did not observe differences in tumor characteristics of initially incompletely excised tumors 
in the two groups. Mean tumor size was 3 cm in both groups, ranging from 0.8 to 7.0 cm in the 
MR- group, and from 1.0 to 7.6 cm in the MR+ group (P = 0.959). In the MR- group 17 of 25 tumors 
(68%) were multifocal, while 3 of 5 tumors (60%) in the MR+ group were multifocal (P = 1.000).
Time
The mean time from diagnosis to breast MRI in the MR+ group was 14 (±11) days, ranging from 0 
(tumor detected at MRI) to  53 days. The mean time from diagnosis to  final pathology in patients 
in whom initial surgery was successful for 40 (±22) days in the MR- group and 38 (±18) days in 
the MR+ group (P = 0.436). Hence, no evidence could be found that the time to final pathology 
was increased by the preoperative MRI.
However, failure to perform radical surgery increased the time to final pathology to 67 (±48) 
days in the MR- group (P = 0.010) and 81 (±42) in the MR+ group (P = 0.078), respectively. 
Overall this led to a slightly longer time to final pathology in the MR- group of 44 (±29) days 
compared to 40 (±21) days in the MR+ group, although this did not reach statistical significance 
(P = 0.238).
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Discussion
The most essential finding o f our study is that preoperative breast MRI in patients w ith ILC who 
undergo BCS reduced the rate of surgical re-excision after BCS.
Furthermore, preoperative MRI was not associated with an increased rate of initial mastectomies, 
the most common objection to preoperative staging o f breast cancer with breast MRI. In fact, 
the final rate of mastectomies was higher in patients who did not have a preoperative breast 
MRI. Hence, this is the first study that, in terms o f outcome, shows benefit of preoperative breast 
MRI in patients with ILC.
With conventional methods (mammography and ultrasound) adequate staging of ILC is difficult 
[10,32-34]. The sensitivity is limited and although most lobular carcinomas do eventually 
present as a mass, ILC is often much larger than anticipated and is often multifocal [10,35].
MRI has proved to tackle many of the difficulties in detection and staging that occur with 
conventional modalities. With a stable sensitivity of approximately 93%, an accuracy in lesion 
size estimation of 80% (with an accompanying 10% underestimation of lesion size and 10% 
overestimation of lesion size) and a good correlation with tumor size at pathology, breast MRI 
aids in lesion appreciation [11,14,20,23]. Consequently, MRI has been shown to change the 
therapeutic approach in approximately one-third of patients w ith ILC [11,16,19,21-23].
Nevertheless, even in ILC, preoperative breast MRI is still disputed, because breast cancer staging 
with MRI is thought to delay treatment and to result in more aggressive surgery [9,28,29]. 
Additional lesions detected by breast MRI raise the need for additional work-up.
Since we did not observe a difference in time to final pathology between the MR- group and the 
MR+ group, it is apparently feasible to perform additional work-up w ithin 40 days on average 
(the mean time between diagnosis and final pathology in the present study). As long as the 
waiting time for surgery is longer, preoperative breast MRI will not delay therapy. Re-excision 
does, however, delay therapy.
The reduction in the re-excision rate is considered to be emotionally important to patients, as 
it prevents the anxiety that is caused by a second surgical procedure and the increased time 
to full excision. Moreover, it has been shown that a good cosmetic outcome is reduced by re­
excision [36,37]. Finally, re-excision is associated with significant financial costs, which may be 
reduced by preoperative MRI. However, this requires further study.
In a recent study by Pengel et al. [38], a similar reduced rate of re-excisions due to preoperative 
breast MRI was shown in a subgroup of patients w ith IDC. A reduction in the re-excision rate in 
ILC was not observed but far fewer patients with ILC were included and both focal and extensive 
involvement of resection margins were regarded as unsuccessful surgery. Moreover, they did 
not analyse the impact of pre-operative breast MRI on the initial mastectomy rate.
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Because studies have shown that the rate of local recurrences is higher in patients who undergo 
re-excisions than in patients who are initially successfully treated [39,40], our study suggests 
that preoperative MRI in patients w ith ILC has the potential to improve local control and 
therefore survival. However, this negative effect from re-excisions was not evident from other 
studies [2], and is therefore uncertain.
So far, only two studies have evaluated the impact of preoperative breast MRI on recurrence and 
survival, none of which evaluated specifically ILC. Unfortunately these studies had contradictory 
results.
Fischer et al. [41] showed a reduced rate of local recurrences after preoperative MRI, but this 
study is largely biased due to  very different tumor stages between groups. More recently Solin 
et al. [42] did not observe any differences in local control between patients that did or did not 
undergo pre-operative MRI. However, they had only a short follow-up period and included 
many patients in the MR+ group that underwent MRI only after initial surgery.
We agree that the most valid proof of improved outcome is a clear reduction in breast 
cancer mortality, following a reduction of local recurrence. Such evidence in patients with 
ILC is still lacking, we neither assessed local recurrence nor survival in this study. However, 
due to improving overall diagnosis and treatment current recurrence rates have dropped to 
approximately 0.6-1% per year [43]. Furthermore, ILC is a relatively infrequent breast cancer, 
so large studies to evaluate the impact of preoperative MRI on recurrence and survival will be 
acquired over a very long time span. Consequently, surgical approaches and adjuvant therapies 
will have continued to develop and an effect on outcome using these terms may be difficult to 
interpret as they are prone to bias.
There are several limitations to our study.
First, the non-randomized and retrospective nature of this study must be taken into account. 
However, since both the American College of Radiology (ACR) and the European society of 
breast imaging (Eusobi) currently recommend pre-operative breast MRI for evaluation of the 
contralateral breast in all women with proven breast cancer [44,45], prospective randomized 
studies on patients with breast cancer can no longer be deemed ethical.
Second, although mastectomy is more commonly performed for ILC than for IDC due to the 
typically larger extension o f ILC and preference of surgeons and patients, we still observed 
relatively high rates of initial mastectomies in both groups. This is probably mainly explained 
by the long time span o f the study, since we observed a clear decline of the rate of initial 
mastectomies over time. The initial mastectomy rate o f 35% observed in 2005 is comparable to 
reported values in literature [6,9].
Third, from the observed similarity in the rates of initial mastectomy between groups it is likely 
that a selection bias has occurred. Many studies have shown that preoperative MRI changes the 
surgical approach in 22-44% of patients [11-18], and as mentioned before, in 12-33% of patients
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this change is a conversion from BCS to mastectomy [11,13,16,19-22]. Based on few reported 
findings, this rate of therapy change is balanced by a conversion rate in the opposite direction 
of approximately 5% [11]. Consequently, a 15-20% higher initial mastectomy rate in the MR+ 
group would be expected. Since tumor sizes were not different between groups, nor was the 
rate of multifocality, patients who were unlikely to  undergo BCS based on psychological factors, 
were apparently also less likely to undergo preoperative MRI. We believe this also explains the 
slight age difference between groups that is also observed in other studies [38,42].
Fourth, all patients were treated in tertiary dedicated cancer centers, generally treating larger 
and more technically challenging carcinomas. Both centers also had a wide experience in the 
use of breast MRI which may have improved the outcomes o f this study. Since breast MRI is 
subject to a learning curve for both radiologists and surgeons, our results cannot be directly 
extrapolated to centers w ithout extensive experience.
Last, breast MRI has also evolved over time. Consequently, the MRI protocols were non-uniform 
in the study period. Moreover, nowadays spatial resolutions are achievable that were impossible 
only 5 years ago. Furthermore, the addition of other sequences, such as T2 and diffusion 
weighted imaging, may further improve pre-operative staging. Our study only evaluated the 
use of contrast enhanced breast MRI. It is therefore impossible to tell whether or not such 
advantages may result in further benefit for patients [46,47].
Since we only evaluated ILC, it is not possible to extrapolate our findings to other types of breast 
cancer. However, we need to  discuss the role of preoperative breast MRI in patients who do 
not qualify for BCS. The main objection that preoperative breast MRI will increase the chance 
of mastectomy obviously does not hold. Conversely, there is a small chance that preoperative 
breast MRI will result in BCS due to  better delineation of the tumor [11]. Moreover, the indication 
for screening of the contralateral breast remains valid regardless of the size o f the ipsilateral 
tumor [44,45]. Thus, for optimal therapy and optimal performance o f preoperative MRI, it is 
recommended in all patients w ith ILC, not only the subset that is eligible for BCS.
In summary, preoperative breast MRI in patients with ILC leads to  a reduction o f the re-excision 
rate w ithout increasing the rate of initial mastectomies and is thus directly beneficial for patients 
with ILC.
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Abstract
The aim of breast MRI is to obtain a reliable evaluation of any lesion within the breast. It is 
currently always used as an adjunct to  the standard diagnostic procedures of the breast, i.e., 
clinical examination, mammography and ultrasound. Whereas the sensitivity of breast MRI is 
usually very high, specificity —as in all breast imaging modalities— depends on many factors 
such as reader expertise, use o f adequate techniques and composition of the patient cohorts. 
Since breast MRI will always yield MR-only visible questionable lesions that require an Mrguided 
intervention for clarification, MRI should only be offered by institutions that can also offer a 
MRIguided breast biopsy or that are in close contact with a site that can perform this type 
of biopsy for them. Radiologists involved in breast imaging should ensure that they have a 
thorough knowledge of the MRI techniques that are necessary for breast imaging, that they 
know how to evaluate a breast MRI using the ACR BI-RADS MRI lexicon, and most important, 
when to perform breast MRI. This manuscript provides guidelines on the current best practice 
for the use of breast MRI, and the methods to be used, from the European Society of Breast 
Imaging (EUSOBI).
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In troduction
The overall aim of breast imaging can be summarized under several general headings. First, it 
is performed in symptomatic women to exclude breast cancer or other disease that requires 
immediate treatment. In this respect, it should provide a definitive diagnosis or exclude the 
presence of a harmful abnormality. Second, in patients w ith known malignancies, imaging 
helps in the preoperative staging and subsequent choice o f appropriate therapy, either surgical 
or medical. Third, in patients with known malignancies that are initially treated medically with 
neoadjuvant chemotherapy, imaging is helpful in the assessment of response to treatment and 
the evaluation of residual disease afterwards. Fourth, imaging is performed in asymptomatic 
women to detect breast cancer in its early stages, when it can be better treated, and in this 
respect imaging increases the prognosis and survival of breast cancer patients. Last, imaging 
may be used to evaluate foreign bodies w ithin the breast, such as the location o f clips and 
markers or whether breast prostheses are intact. Magnetic resonance imaging of the breast 
can be used to pursue any o f the above-mentioned goals. The aim of this paper is to  provide 
guidelines for the performance and use of breast MRI, w ith respect to both the technical aspects 
of this procedure and the current indications.
Technical aspects 
Patient handling
MRI o f the breast is a study that requires the administration o f a gadolinium-containing contrast 
agent during the study [1, 2]. Early studies have shown that breast MRI w ithout contrast agent is 
not of diagnostic value [3, 4]. The uptake o f contrast medium in breast tissue in premenopausal 
women is also dependent on the phase of the menstrual cycle. It is essential to perform 
breast MRI in the correct phase of the cycle as enhancing normal breast tissue may otherwise 
complicate the interpretation o f the study. The optimal time in pre-menopausal women to 
perform a breast MRI is between the 5th and 12th day after 
the start o f the menstrual cycle [5-7].
Placement o f an intravenous cathether should be done before positioning the patient on the 
MR table. A long IV line avoids table and patient movement before the injection. The contrast 
agent should preferably be given by a power injector. It is important to position the patient as 
comfortably as possible in order to avoid motion artifacts. A dedicated bilateral breast coil is 
mandatory for this investigation, and the patient should be placed in the prone position with 
both breasts hanging in the coil loops. The breasts may be supported to further reduce motion 
artifacts, but should not be compressed.
The position of the breast should be checked before the start o f the examination, both breasts 
must be placed as deeply as possible in the coils w ith the nipples pointing down. A larger breast 
coverage is usually obtained by placing both arms at the side o f the body and not above the 
patient's head.
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Virtually any MRI scanner can be used to perform contrast-enhanced breast MRI, as long as 
the system allows image acquisition at a sufficient spatial and temporal resolution (see below). 
However, scanning protocols need to be adapted to the scanners used, also because the 
relaxivity of the most commonly used contrast agents decreases at higher field strengths [8, 
9]. Breast MRI at low and midfield strength (0.2 T, 0.5 T) depends heavily on parallel imaging 
to obtain a sufficient resolution. As this further decreases the signal-to-noise ratio (SNR), this is 
not optimal. In practice, most studies that employed low or midfield scanners did not obtain 
a sufficient spatial resolution [10, 11]. An increasing field strength (1.5 T, 3 T) allows a higher 
spatial resolution at a similar temporal resolution and consequently may increase diagnostic 
confidence [12]. A disadvantage is that, at higher field strengths (e.g. 3 T), inhomogeneity in the 
B1 field may cause reduced signal in parts o f the image and thus less contrast enhancement, 
which in turn may cause falsenegative image interpretation. Two-dimensional acquisitions are 
particularly sensitive to this effect and are therefore discouraged at 3 T [13].
Sequences
The conventional breast MRI investigation begins precontrast w ith either T2- or T1-weighted 
images. The signal from the body coil can be used to evaluate the position and anatomy of 
the breasts. Furthermore, both axillae, the supraclavicular fossae, the chest wall and anterior 
mediastinum can be checked (e.g., for enlarged lymph nodes). However, this is not the purpose 
of a breast MRI, and this evaluation may also be omitted as there is no evidence of its diagnostic 
value. Afterwards the signal from the dedicated double breast coil should be used. T2-weighted 
fast spin echo images can be performed as a start. In the T2-weighted images water-containing 
lesions or edematous lesions have an intense signal, and in this sequence small cysts and myxoid 
fibroadenomas are very well identified. In most cases cancer does not yield a high signal on T2- 
weighted images; thus, these sequences can be useful in the differentiation between benign 
and malignant lesions. However, as most of these lesions can also be identified on T1-weighted 
images, there is no evidence as yet of added value of T2-weighted sequences in breast MRI [14, 
15].
The most commonly used sequence in breast MRI is a T1-weighted, dynamic contrast enhanced 
acquisition. The sequence is called 'dynamic' because it is first performed before contrast 
administration and is repeated multiple times after contrast administration. A T1-weighted 3D 
or 2D (multi-slice) spoiled gradient echo pulse sequence is obtained before contrast injection 
and then repeated as rapidly as possible for 5 to 7 min after a rapid intravenous bolus of a 
Gd-containing contrast agent. A 3D pulse sequence offers a stronger T1 contrast and enables 
thinner slices than 2D; in turn, a 2D sequence suffers less from motion and pulsation artifacts. 
Both sequences can be performed with and w ithout fatsuppresion [16, 17].
The choice of the image orientation is important. For bilateral dynamic breast MRI, axial or 
coronal orientations are most frequently used. Coronal imaging has advantages in that it can 
reduce heart pulsation artifacts, but it is more susceptible to respirational motion and also 
to flow artifacts because vessels tend to travel perpendicular to the slice encoding direction.
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Although bilateral sagittal imaging is possible today, it requires about double the number of 
slices required for the other orientations. As this hampers the spatio-temporal resolution, such 
an orientation is currently not feasible.
The optimal dose o f the contrast medium is unknown and also depends on the contrast agent 
used. In literature, applied doses range roughly from 0.05 to 0.2 mmol/kg. One study showed 
some benefit o f 0.16 mmol/kg gadopentetate dimeglumine over 0.1 mmol/kg [18]. However, a 
more recent evaluation did not find any improvement in diagnostic accuracy using 0.2 mmol/ 
kg gadobenate dimeglumine over 0.1 mmol/kg of the same agent [19]. Consequently, a dose of 
0.1 mmol/kg is probably sufficient.
Peak enhancement in the case of breast cancer occurs w ithin the first 2 min after the injection 
of contrast medium. Therefore, relatively short data acquisition times, in the order of 60-120 
s per volume acquisition, are necessary. This allows sampling of the time course of signal 
enhancement after contrast injection, which is useful because the highly vascularized tumor 
of the breast shows a faster contrast uptake than the surrounding tissue. More importantly, it 
enables a detailed analysis of morphologic details, because only in the very early postcontrast 
phase, the contrast between the cancer and the adjacent fibroglandular tissue is optimal. 
Tumors may lose signal (a phenomenon referred to as "wash out") as early as 2-3 min after 
contrast material injection, whereas the adjacent fibroglandular tissue can still exhibit 
substantial enhancement, resulting in little contrast between the cancer and the fibroglandular 
tissue. Long acquisition times will be associated with the risk of not resolving fine details of 
margins and internal architecture; this could have key importance for the differential diagnosis, 
and may even run the risk of missing cancers altogether because they are masked by adjacent 
breast tissue.
A dynamic sequence demands at least three time points to be measured, that is, one before the 
administration of contrast medium, one approximately 2 min later to capture the peak and one 
in the late phase to evaluate whether a lesion continues to enhance, shows a plateau or shows 
early wash-out of the contrast agent (decrease of signal intensity) [20]. It is thus recommended 
to perform at least two measurements after the contrast medium has been given, but the 
optimal number of repetitions is unknown. However, the temporal resolution should not 
compromise the spatial resolution. It was shown that an increase in spatial resolution results 
in higher diagnostic confidence even when the temporal resolution is slightly sacrificed. [21]. 
The final spatial resolution of the images depends on different factors, especially the size of the 
imaging volume, defined by the field of view (FOV), the slice thickness and the acquisition matrix. 
Breast MRI should be capable of detecting all lesions larger than or equal to 5 mm. Therefore, the 
voxel size should be under 2.5 mm in any direction. Preferably, the in-plane resolution should be 
substantially higher as morphologic features needed for lesion characterization, such as margin 
appearance, can only be evaluated when the resolution is sufficiently high. Therefore, the in­
plane resolution should be at least 1 mm-1 , in other words: pixel size (FOV/matrix) should not 
be greater than 1x1 mm, which requires a matrix of at least 300x300 in a 300-mm FOV.
137
Chapter 9
Assessment of lesion morphology can be performed directly on the enhanced fat-suppressed 
images. However, as residual fat-signal (hyperintense at T1-weighted images) may cause 
difficulties in interpretation, the calculation of subtraction images from the pre- and post­
contrast series is recommended [22, 23]. Subtraction suppresses the signal from bright fat 
because fatty tissue hardly enhances. When subtraction is performed, fat suppression in the 
acquisition is not needed and is even discouraged, because in the large fields of view that 
are usually required for axial and coronal imaging, homogenous fat suppression is difficult to 
obtain. This can be problematic since fat and water resonance frequencies are relatively close 
at 1.5 T—which implies that with less-than-optimal B0 homogeneity across the field o f view, 
water (rather than fat) suppression can occur. Moreover, fat-suppression increases the noise in 
the image and usually also compromises spatio-temoral resolution.
Evaluation
Use of both detailed morphological information provided by high spatial resolution images and 
kinetic information (curve type) provided by at least two repetitions of the high spatial resolution 
sequence represents the latest trend in acquisition protocols and image interpretation to take 
into account the increasing importance of detailed morphological information w ithout losing 
identification of washout enhancement curve types [24].
For the diagnostic interpretation the ACR breast imaging reporting and data system (BIRADS) 
for breast MRI illustrates many of the morphological findings seen on contrast-enhanced breast 
MRI. It also includes a lexicon that should be used for uniform reporting of the features seen on 
MRI [25].
Indications fo r breast MRI 
Inconclusive findings in conventional imaging
Patients referred by their general practitioner or through a nationwide screening program to 
secondary are told that there is a chance that they might have breast cancer. In this situation 
imaging, with or w ithout biopsy, should exclude the presence of a malignancy sufficiently. The 
sensitivity of breast MRI for the detection of cancer is the greatest of all imaging techniques [26­
28], and when the findings of conventional imaging are inconclusive (i.e., BI-RADS 0), MRI can 
be used as a problem-solving modality. In general, a negative breast MRI excludes malignancy. 
Only in case of mammographic microcalcifications, MRI is unable to exclude cancer sufficiently, 
and the decision to perform biopsy should be based on mammographic findings in this specific 
situation [29].
Preoperative staging
Breast tumors may be solitary, well-circumscribed masses that are well recognized at 
mammography and/or sonography. However, tumor size may be underestimated severely by 
mammography and ultrasound, especially in tumors larger than 2 cm [30, 31]. Tumor size of
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invasive carcinomas on MRI correspond in general well to pathologic sizes [32, 33]. Unfortunately, 
MRI has a tendency to overestimate the size of pure DCIS lesions [34]. Furthermore, in about 
25% o f the cases, the tumor is multifocal; in other words, there are more invasive tumors in one 
quadrant. Moreover, multicentricity, which means one or more invasive foci more than 4 cm 
from the primary tumor, is present in about 20% of all invasive malignancies.
Inadequate size estimation or failure to detect additional foci of disease may thus result in 
positive resection margins after surgery or early recurrent disease. The sensitivity of breast MRI 
is, in the setting of preoperative evaluation, close to 100% [26]. MRI is the most reliable imaging 
technique to measure the tumor size [35, 36], and it detects additional foci o f the tumor in the 
ipsilateral breast in 10-30% of patients [37-45]. Also the presence o f an intraductal component 
(EIC+) can be better evaluated by MRI than w ith mammography [36, 46-48].
On MRI this may be seen as an area of contrast enhancement with a dendritic configuration 
close to the primary tumor. However, approximately 20% of the additional foci detected by MRI 
are benign [43, 49]. Consequently, before large adjustments to  the surgical management are 
effectuated, histological analysis o f MR detected additional foci should be performed. Several 
studies have shown a change in surgical management in about 20% to 30% of all patients 
undergoing preoperative MRI [26, 37, 39, 49]. Changes were greatest in patients w ith tumor size 
greater than 4 cm [50], lobular carcinoma [37] or breast density 4 [49].
However, it is so far unclear whether breast MRI contributes to better control of the disease 
or survival of all patients with diagnosed breast cancer. Only one study has evaluated such 
outcomes, and although MRI appears to reduce the incidence of local recurrence (1.2% vs. 6.8%), 
confounding differences in tumor characteristics between patients treated w ith and w ithout 
MRI did occur [51]. The British COMICE trial is a large multicenter trial that randomizes patients 
between MRI and no-MRI and evaluates the quality of preoperative staging, the differences in 
outcome, differences in quality of life and costeffectiveness [52]; the first results are expected 
in 2008. This study and similar ongoing studies may provide better evaluation of staging in the 
near future.
Synchronous bilateral breast cancer is reported in about 2-3% of all breast cancer patients 
[53-55], but it is probably more common. Synchronous contralateral lesions are occult on 
mammography in about 75% of cases. MRI detects otherwise occult lesions in 3-5% of patients 
that undergo preoperative MRI [56-58]. Some studies show even more alarming results and 
report MRI-only detected contralateral breast cancer in 19% [59] and 24% [60].
These lesions would probably have presented as metachronous contralateral carcinomas 
w ithout MRI, as is also clear from the above-mentioned outcome study. The rate of contralateral 
carcinomas detected at follow-up decreased from 4% without MRI to 1.7% with MRI [51]. 
Screening of the contralateral breast in patients with proven unilateral breast cancer is thus 
a valid indication for the performance of preoperative breast MRI. In practice this means that 
preoperative MRI is recommended in all patients w ith histologically proven breast cancer, even 
though the indication for ipsilateral staging of the cancer is still under investigation. Especially 
in the case of dense breasts, MRI is recommended preoperatively. Furthermore, in patients with 
histologic evidence of invasive lobular carcinoma, a preoperative MRI is strongly recommended
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as these tumors show a more permeative growth pattern and, consequently, are more difficult 
to measure [32, 61], are more often multifocal or multicentric (additional foci in 32%) [62,63] and 
are more often complicated by concurrent contralateral carcinomas (occult tumors detected in 
7%) [62, 64, 65].
Unknown prim ary
In the case of a carcinoma of unknown primary, metastases are diagnosed, but a primary tumor 
site cannot be identified. These metastases may either present in the axillary lymph nodes, the 
supraclavicular lymph nodes, the bones, the liver, the brain or the lungs. When the mammogram 
does not show any abnormality, reports in the literature show, in about 50% of the cases, an 
abnormal MRI [66]. In case of metastatic axillary lymph nodes, MRI is even able to detect a 
primary breast tumor in 75-85% o f patients [67, 68]. MRI thus can subsequently be used to plan 
the most appropriate treatment as the size of these lesions on MRI is usually concordant with 
the size at pathology, thus MRI may prevent unnecessary mastectomies or assign patients with 
large tumors to neoadjuvant protocols.
The evaluation o f therapy response in the  neoadjuvant chem otherapy setting
Neoadjuvant chemotherapy is the administration of chemotherapy prior to surgical treatment 
of cancer. Its principal indication is the treatment of unresectable breast cancers, and its goal in 
this setting is to reduce the tumor to a size that allows resection. However, many studies have 
shown that the prognosis of breast cancer is equal when chemotherapy precedes or follows 
after surgery. Because there are some theoretical benefits in the neoadjuvant setting, and 
tumor response can be closely evaluated with the tumor in situ, neoadjuvant chemotherapy 
is also the standard o f care in large T2 and T3 tumors. MRI has been shown to  be superior to 
evaluate tumor response to  neoadjuvant chemotherapy compared to clinical examination, 
mammography or ultrasound and is thus the imaging investigation of choice.
If neoadjuvant chemotherapy is given to a patient, the first breast MRI should be performed 
before the start o f chemotherapy. A second MRI, for the evaluation of the effect of chemotherapy 
on the tumor, should be performed when approximately half o f the course of chemotherapy 
has been administered. A third MRI investigation should be performed after the final course 
of chemotherapy to evaluate the residual disease. In most hospitals four to six cycles of 
chemotherapy are given in the neoadjuvantsetting.
Response is normally measured using the RECIST criteria [69]. Using these, complete response 
(CR) is defined as complete vanishing of the tumor, partial response (PR) is defined as decrease of 
the sum of the longest axes o f all individual lesions by more than 30%, progressive disease (PD) 
is defined as an increase of this sum by more than 25% and the remainder is classified as stable 
disease (SD). Response to chemotherapy is especially well evaluated in the non-responders 
(SD, PD) and the good-responder group (CR). The effect of the chemotherapy in partial 
responders is less well established. Several studies compared the ability o f clinical examination, 
mammography, ultrasound and MRI in the assessment of final response [70-80]. They showed 
that MRI measurement after therapy correlated best w ith the pathological findings and was
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the best technique for assessing response. Nevertheless, MRI is unable to detect small residual 
tumor foci that may persist after neoadjuvant chemotherapy. Radiological complete response 
is thus no proof for pathological complete response (pCR); therefore, resection of the initial 
tumor bed is still essential in the treatment of these patients [77, 79].
Observation o f response during treatment is important as this is the only measure that justifies 
the applied chemotherapeutic regimen and is the only response evaluation that allows a 
change in this regime before its completion.
Currently, the performance of MRI halfway during treatment may only change the treatment in 
clear nonresponders and those with progressive disease as there are no other criteria for early 
response evaluation. This is due to the fact that size of the tumor often does not immediately 
decrease. Therefore, the performance of MRI earlier in the treatment (e.g., after the first cycle) 
as is under investigation in several large trials (such as the ACRIN 6657 trial) is currently not 
recommended, although in one study complete responders had a change in diameter of at 
least 45% after the first course o f chemotherapy [72]. In another study early change in volume 
was the most predictive of final response [75]. The value of these MRI investigations first should 
be established, and criteria for early response need to be defined.
Several other techniques, such as MR spectroscopy [81], diffusion imaging [82] and FDG-PET 
[83-85] show promise in the (early) evaluation of tumor response to therapy. However, none 
of these techniques have been tested in large-scale prospective studies and can thus not (yet) 
be recommended for clinical practice. For a more detailed description of the studies so far 
performed in the evaluation of response to neoadjuvant chemotherapy, we refer to the review 
by Tardivon et al. [86].
Imaging o f the breast a fte r conservative therapy
MRI may be considered after breast-conserving therapy (BCT) in three instances: first as 
an evaluation tool for residual disease after positive tumor margins, second as a method of 
evaluating suspected recurrence by either clinical examination, mammography or ultrasound 
and third as a screening tool in all patients who undergo BCT.
Unfortunately, early postoperative MRI is hampered by strongly enhancing resection margins 
in response to the surgical intervention. Therefore, MRI is unable to exclude residual tumor at 
the biopsy cavity sufficiently, and hence does not change the surgical approach consisting in 
a larger resection of the tumor bed in the direction where pathological analysis of the surgical 
specimen showed positive margins [87-89].
Although preoperative staging MRI is to be preferred over MRI after initial surgery, it can be 
performed when surgical margins are badly involved. In such cases, the first acceptable MRI 
results are not to be expected sooner than a month after surgery [90]. However, as MRI may 
reveal more widespread disease throughout the breast remote from the lumpectomy site, it 
can provide valuable information concerning the decision o f wider excision versus mastectomy 
[91-93]. Morakkabati et al. have shown that postradiation changes occur during and up to 3 
months after radiation therapy, but do not reduce the accuracy of MRI to identify residual or 
recurrent tumor compared to patients w ithout radiation therapy [94].
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Most local recurrences after BCT and radiotherapy occur w ithin 5 years after the initial surgery, 
and the annual risk is estimated at 1-2% per year [95-98]. Early detection and treatment of 
recurrent disease are important as it may still present w ithout distant metastases. Second 
primary ipsilateral carcinomas in the treated breast can occur at every site and develop on 
average 7 years after the first primary tumor [99]. The sensitivity of mammography for recurrent 
disease in the treated breast is limited, but breast MRI can be a valuable complementary tool 
as explained earlier. A local recurrence on MRI has the same appearance as a new primary 
malignancy w ith strong early enhancement, while a fibrous scar shows either no enhancement 
or very slow enhancement. In a treated breast, the specificity of breast MRI is higher than in 
an untreated breast. Different studies have shown that MRI is the most sensitive technique in 
detecting a local recurrence o f the disease [36, 100-104]. When a local recurrence is suspected 
upon clinical findings or abnormalities on mammography or ultrasound, MRI can be used to 
exclude local recurrence with a high negative predictive value and thus prevent unnecessary 
biopsies [93, 103, 104].
Analogous to the situation in preoperative staging, MRI is able to detect multifocality and 
multicentricity unnoticed by conventional imaging. Naturally, in these cases, the evaluation 
of the contralateral breast is also important. There is currently not sufficient evidence to 
recommend or not the screening of patients treated by BCT with MRI.
So far, only one small trial has been performed [101], which showed no difference in sensitivity 
for recurrence between clinical examination combined w ith mammography and MRI alone. 
However, the specificity of MRI was much higher (93% vs. 67%), confirming its value as 
additional investigation. Moreover, in some patients, it can be impossible to image the primary 
tumor region by mammography after conservative therapy [105]. In these cases breast MRI is 
mandatory.
The risk of local recurrence is strongly dependent on the age of the patient at the time of 
diagnosis [106-109]. Patients over 50 have a risk of approximately 4% after 5 years, but this risk 
is estimated at 12% after 5 years for patients who were under 45 years of age [108] and at 20% 
after 5 years for patients under 40 [106]. Although additional boost radiotherapy to the tumor 
bed can reduce this risk to 10% at 5 years, these patients have a lifetime risk that is probably still 
greater than 20%, which is equal to the lifetime risk demanded for MRI screening in the general 
population, as described below.
Therefore, annual MRI screening is an option for all patients under 50 at the time of diagnosis of 
the first primary carcinoma, but this should first be investigated in larger trials.
MRI screening
The high sensitivity for cancer makes breast MRI a desirable technique for screening purposes. 
Therefore, many countries have performed screening studies in highrisk populations. The 
American Cancer Society (ACS) has recently issued guidelines for the performance of MR 
screening based upon the analysis of six of these studies [110]. As the most important of these 
studies were all performed in Europe (e.g. the Dutch MRISC study [111], The UK-based MARIBS 
study [112], the German singlecenter study [113] and the Italian HIBCRIT study [114]), the ACS
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recommendations apply mostly to the European situation. The overall sensitivity for breast 
cancer in these high-risk populations is between 71 and 100% for MRI compared to 16-40% for 
mammography. The specificity ranges from 81 to 99% for MRI and 93 to  99% for mammography, 
which is illustrative for the higher detection rate o f MR and the (almost two times) higher recall 
rate that unfortunately complicates MR screening.
There is evidence for the value of annual MR screening in BRCA gene mutation carriers, their 
first degree, untested relatives and all women with a lifetime risk o f 20-25% according to 
models that depend largely upon family history. Furthermore, MRI screening is advised in 
patients who received radiation to the chest in their 2nd or 3rd decade (mostly patients with a 
history of lymphoma) and patients w ith inherited syndromes, such as LiFraumeni and Cowden 
syndrome, and their first-degree relatives, although there is no direct evidence for these latter 
recommendations.
Currently there is not sufficient evidence to recommend MRI or not in women with a lifetimerisk 
of 15-20%, those with high-risk lesions (LCIS, ALH, ADH) and those with heterogeneously or 
extremely dense breasts on mammography.
Women with a lifetime risk of less than 15% should currently not be enrolled in MR screening 
programs. It is still unclear when to start screening. In most highrisk patients, starting at the 
age of 30 will probably be sufficient. However, in families where the first carcinomas presented 
at younger ages, the screening needs to start earlier as well. It seems advisable to  follow the 
guidelines for mammography in this aspect and start screening at an age 5 years younger than 
the youngest relative that presented with cancer. It is also unclear for how long screening with 
MR should be continued; in older women the breast density decreases significantly, and the 
added value of MR might thus decrease. However, at every age, the sensitivity for breast cancer 
of MRI is higher than that of mammography.
Prosthesis imaging
The evaluation o f breast implants, which are either placed for breast augmentation or for breast 
reconstruction after surgery for breast cancer, can be done with MR. This demands specific 
sequences that are aimed at the visualization of silicone and provide concurrent suppression 
of the water signal [115-117]. By using these sequences and specific evaluation criteria [116, 
117], MRI is the most accurate modality in the evaluation o f implant integrity. Its sensitivity for 
rupture is between 80 and 90%, and its specificity is approximately 90% [117-119], whereas 
the sensitivity o f mammography is approximately 25% [120, 121]. Nevertheless, the indication 
for breast MRI is less clear than might be expected. Ten years after insertion, approximately 
50% of all breast implants are ruptured [117, 118]. It seems therefore advisable to use breast 
MR only when there are specific complaints that might be caused by leaking prostheses (e.g., 
local inflammation or the formation o f silicone granulomas). MRI may then be used to  exclude a 
ruptured prosthesis as the underlying cause of the complaints, and it may also aid explantation 
surgery as it documents the presence and extent of silicone leakage better than any other 
imaging modality.
In patients with prosthesis and prior breast cancer, MRI may be used to evaluate suspected
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recurrent disease or as a postoperative screening modality. The presence o f the implant does 
not seem to decrease the sensitivity of breast MR [122, 123].
MR-guided biopsy and lesion localization
It is clear that the increasing list of indications for the performance of breast MR leads to 
the detection of many lesions that are neither palpable nor visible on conventional imaging 
techniques. Although most MR-detected lesions can be found (and biopsied) at second-look 
ultrasound, many can not. This stresses the importance of the possibility of performing MR- 
guided biopsies and localizations. Any site that performs breast MR examinations should either 
be able to  perform MR-guided interventions in the breast or should be in close contact with 
a site that can perform these investigations for them. However, the exact description of the 
involved techniques and the minimal requirements that need to be met when performing these 
interventions are quite extensive and cannot be described in this paper. A separate guideline 
describing these interventions will be published soon by Heywang-Kobrunner et al.
Conclusion
Breast MRI is no longer an experimental modality, but has attained a solid position in the 
diagnosis and workup of (suspected) breast lesions. For adequate performance, some important 
points should be kept in mind.
• A dedicated bilateral breast coil is mandatory.
• The spatial and temporal resolution must be sufficient.
• ATI-weighted sequence should be obtained for at least three time points, 
one prior to and two after contrast administration.
• Reporting should be performed by a radiologist w ith experience in breast MRI, 
using the ACR BI-RADS MRI Lexicon.
• MRI-guided breast biopsy must be available.
The most important indications currently present are listed below.
• Problem solving in case o f inconclusive findings on conventional imaging.
• Screening of the contralateral breast in women with histological evidence of 
unilateral breast cancer.
• Evaluation of the breasts in case of metastases of an unknown primary carcinoma.
• Evaluation of therapy response in patients treated with neoadjuvant chemotherapy.
• Exclusion of local recurrence after breast-conserving therapy.
• Screening o f women with a lifetime risk o f 20% or more to  develop breast cancer, 
including mutation carriers.
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Conventional imaging methods in ILC
In the first evaluation o f interval cancers after the initiation of breast cancer screening with 
mammography in the Netherlands, it became clear that ILC was a common pathologic diagnosis 
in the missed carcinoma group [1]. This was attributed to the diffuse infiltrative pattern of the 
tumors and the poor desmoplastic reaction of the surrounding tissue [2]. In a later, larger study 
about a third of the interval carcinomas were of lobular origin. In a recent evaluation that 
differentiated between 'true' interval carcinomas (fast growing tumors not present at the time 
of screening) and false-negative screening mammography, 47% of the latter category were 
tumors with lobular features [3,4]. This may be due to the fact that ILC is more often better 
visualized on craniocaudal (CC) mammographic images, than mediolateraloblique (MLO) 
images, while the former are not routinely performed in all screening programs [5,6]. However, 
even in retrospect 10-20% of ILC is not visible at mammography [6-9].
The hallmark of malignancy on mammography, a spiculated mass, is reported in 28-63% of ILC 
cases [6,9-13] (fig 1,2). Mammographic findings in the remainder of ILC cases are often subtle. 
There is no association o f ILC with microcalcifications, and the tumors are often isodense to 
fibroglandular tissue [5,8,10,14,15].
Fig 1: /Mammogram o f a 60 year o ld woman (A: Left breast, CC view, B: Left breast, MLO view ) who 
presented with a palpable mass in the upper outer quadrant o f the le ft breast. There is a hyperdense 
mass in the upper outer quadrant with an irregular spiculated margin and a maximum diameter o f 
3.6 cm, which was shown to b ra  m ultifocal ILC ove r an area o f  4.2 cm, the largest focus was 2.5 cm.
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Fig 2: Mammogram o f a 71 year o ld woman (A: Left breast, CC view, B: Left breast, MLO view ) who 
presen ted w ith a palpable lump with skin retraction o f the le ft breast. There is a large architectural 
distortion in the le ft breast (at least 5 cm), isointense to the fibroglandular tissue, retracting the 
whole breast. Histology showed a T4a ILC.
Common descriptors include: ill-defined mass (7-33%) [6,9,12] architectural distortion (10- 24%) [6,9­
12], and asymmetry (4-14%) [6,9]. Th e wide rang es reported probably reflect interreader variability 
of the descriptive terminology.
Not surprisingly tumor size estimation with mammography is difficult in ILC. Reported correlation 
coefficients range widely from 0.2 to 0.8. Small tumors in fatty breasts are quite accurately assessed, 
but accuracy decreases rapidly with increasing tumor size and increasing density [16-18], resulting 
in structural underestimation of larger tumors. The vague borders commonly seen in ILC makes 
assessment of these tumors particularly difficult. This results in measurements with a stronger 
negative deviation from pathological tumor size when compared with those seen in IDC [6,18]. 
Consequently, it has been shown that mammography understages over one third of ILCs [19]. 
Sonography is hardly ever used as a screening modality, hence studies that report on sensitivity
155
Chapter 10
of ultrasound in ILC, report on lesions that have already been detected by other means (either 
physical examination or mammography).
Nevertheless most ILC are visible at sonography, and reported sensitivities range from 78 to 
98% [20-26]. In a recent meta-analysis comparing the sensitivity of ultrasound directly with MRI, 
the sensitivity o f ultrasound was 83%, with a 95% confidence interval ranging from 71-91% [27]. 
Although one initial study reported difficulties w ith ultrasound for the detection o f ILC under 1 
cm in size (only one out of four) [28], later studies using more sophisticated equipment reported 
sensitivities in the normal range [29,30]. Important to note is that ultrasound sensitivity 
is also high in lesions that are hardly visible or occult at mammography. Hence there is a 
complementary value of ultrasound in the detection o f ILC in the symptomatic patient [20]. 
Approximately 60% of ILC lesions exhibit the typical features o f malignancy at ultrasound and 
present as a hypoechoic heterogeneous mass with ill-defined margins and posterior acoustic 
shadowing [20,21,24] (fig 3). Internal hyperechoic patterns are more commonly seen in ILC than 
in IDC [21,26] (fig 3D), and some ILC present as areas of focal shadowing w ithout a discrete mass 
[20,24]. This latter ultrasound pattern may suggest the classic type ILC histology [20].
Regarding tumor size estimation of ILC, ultrasound performs equally to mammography though 
the spread of reported correlation coefficients is a bit lower, ranging from 0.5 to 0.8 [25,31-33]. 
Similar to mammography, the quality o f the tumor size assessment decreases with increasing 
size of tumor. This holds particularly true for ILC tumors over 3 cm in size which cannot be 
accurately assessed with ultrasound [26,32].
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Fig 3: Ultrasound images o f 4 different ILC. The tumors in image A, B and C exhibit typical m alignant 
features, showing hypoechoic irregular spiculated lesions with posterior acoustic shadowing. The 
tum or in image D was almost isoechoic to norm al fibroglandular breast tissue but showed multiple 
pathologic Doppler signals, due to extensive neovascularisation. The tum or in figure A was over 5 
cm a t pathology, in B over 8 cm, inC14 mm and tn ID 3.'2 cm, showing that ultrasound measusements 
especially in larger tumors a re far from accurate.
Featutes o f ILC on b^reast MRI
The retrospective sensitivity of breast MRI for ILC is high. In a meta-analysis evaluating studies 
published until April 2006 describing in total 209 patients, the sensitivity was 93.3% with a 95% 
confidence interval ranging from 88 to 96%. Leaving out the results of one very early study 
that scanned patients with an inadequate scan protocol, the sensitivity was even higher at 96% 
(95% CI 92-98%) [27,34-41]. Since the publication of this meta-analysis, three new studies have 
appeared in the literature that allowed evaluation of sensitivity [42-44]. The two largest studies 
both reported a retrospective sensitivity of 100% (in respectively 57 and 69 patients) [43,44]. 
The third study, that was actually aimed at the evaluation o f breast specific gamma imaging for 
the detection of ILC, reported two false negatives in a series of only 12 patients, resulting in a 
sensitivity of 83% [42], which can only be explained by bad luck and the low number of patients, 
as it is far below the earlier reported confidence intervals [27].
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Almost all available studies are retrospective in design. Only two studies completely report 
prospective data and one study is partly prospective [34,37,43]. Francis et al. reported a 
sensitivity of 95% in 22 ILC, Berg et al. reported a sensitivity of 97% in 29 ILC and Caramella et al. 
reported a sensitivity o f 100% in 35 ILC. Hence, prospective data are well in-line with the results 
from the retrospective studies.
Nevertheless, all studies evaluated patients that were known to have a carcinoma. Although 
various authors report ILC that were incidentally detected in MRI examinations performed for 
other indications, few data are available that report the sensitivity of breast MRI for ILC in a 
screening situation. In general the sensitivity o f breast MRI for breast cancer in screening is 
lower than in pre-operative staging, though much better than mammography; reported 
sensitivities range from 77-100% [45]. In the large screening studies too few ILC were detected 
to produce conclusive results, however, Kriege et al. reported a sensitivity of 100% for MRI in the 
detection of four ILC, compared to 25% for mammography [46], suggesting an additional value 
over mammography of screening for ILC with MRI.
For optimal detection of ILC in a screening setting it is essential to know the MR-features of 
ILC. It is commonly stated that ILC appears more often as non mass-like enhancement and in 
general enhances less than IDC. At the same time good scientific evidence for these statements 
is lacking. This is partly due to the fact that the interpretation of breast MRI, even using the 
rigorous approach of the BI-RADS lexicon, is subject to considerable interreader variability [47­
49]. As a direct consequence, the principal distinction between mass-like and non mass-like 
lesions is a very difficult one to  make. Different studies report the incidence of non mass-like 
enhancement to  be between 5 and 69%. Pooling of this data is not possible due to the large 
heterogeneity in the studies [27].
In the large group of mass-like lesions, about 85% are described as irregular and spiculated. 
Therefore, an irregular spiculated mass is in fact the most common appearance of ILC on MRI 
[27,43,50] (fig 4). However, round masses w ith sharp margins have also been described, that 
subsequently turned out to be ILC [43,50,51]. Non-mass like enhancement can be either ductal, 
segmental, regional or diffuse (fig 5).
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Fig 4: Three examples (Row A, B and C) o f mass-like ILC in the right breast o f three different patients 
at respectively mammography (first column), subtraction MRI (second column) and maximum  
intensity projection o f the MRI (uhird no lumn). Thase masses are a ll irregular and especially the macs 
in A is heavily spiculated. Note tha t a ll masses were also visible a t mammography (straight arrows), 
tine additional tum or focus in pao 'ient C, more a ^ e r  'iorly located and in these imagnu onsy  visible on 
the MIP (curved arrow), was only detected a t MRS.
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Fig 5: Three examples (Row A, B and C) o f non-mass-like ILC in the left breast o f three different 
patients a t respectively mammography (first column), subtraction MRI (second column) and 
maximum intensity projection o f the MIRI (third column). The enhancement was respectively 
regional (A), segmental (B) and diffuse (C). The tumors in A and C were palpable but no t seen at 
memmography, while the tum or in B was mammographically detacted, but its m ultifocal nature 
was only depictpd a t MRI.
Evaluation of the enhancement pattern has lets often been dercribed. Sittek et al. and Treiate 
et al. both noted that peak enhancement was reached relatively late, and wash-out in the 
late phcse oy enhancement was uncommon [41,52]. Caramella et al even rioted continuous 
enhancement in the late phase of enhancement (commonly referred to as a type 1 curve) in 37 
% of ILC [43]. Two studies that evaluated quantitative enhancement parameters also noted that 
these values appeared much lower for ILC than in other studies evaluating the same parameters 
for IDC [51,53].
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In the absence of studies that directly compare morphological and kinetic descriptors between 
IDC and ILC, the magnitude o f the differences between the appearances of ILC and IDC cannot 
be adequately assessed. Such direct comparison studies have been performed and reported 
upon, but are so far unpublished.
Newstead et al. presented a comparison of 22 ILC to 257 IDC and 83 DCIS lesions at RSNA 2005 
[54]. They reported that 55% o f ILC presented as a mass, compared to 76% o f the IDC and only 
16% of DCIS lesions. Time to peak enhancement was twice as long for ILC as for IDC (270 ± 112 
s vs. 131 ± 90 s) and enhancement after 68 seconds was consequently lower in ILC than in IDC. 
Mann et al. reported at ISMRM 2008 in a comparison of 33 ILC to 103 IDC that 75% o f ILC 
presented as a mass, compared to 84% o f IDC [55]. Interreader variability was moderate (k 
= 0.41), comparable to literature values, and similar for ILC and IDC. Peak enhancement was 
not different between ILC and IDC (360 vs 382%), but at visual assessment wash-out was less 
common in ILC (48 vs 84%). Using a CAD application, this difference was blotted out, wash-out 
was detected in 88% of ILC and 94% of IDC, suggesting that CAD applications may be especially 
helpful in the assessment of ILC (fig 6). This is explained by the observation that the fraction of 
the lesion that shows wash-out is generally smaller in ILC ( <10% of the dominant focus in 64% 
of ILC vs. 30% of IDC). The results o f pharmacokinetic analysis also showed that ILC in general 
enhance slower than IDC, but not less.
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Fig 6: 40 year old woman with strong fam ily history for breast cancer, who presented with nipple 
discharge. The mammogram showed dense breast tissue w ith multiple benign calcifications and 
was thus negative (not shown). Microdochectomy revealed LCIS. MRI was performed, showing a 
multifocal ILC over an area o f 4.7 cm. Although most o f the tum or showed continuous enhancement 
a small area was detected tha t showed earl)/ wash out o f the contrast a gent. (A: T1w FLASH 3D 
acquisition with color coded overlay o f enhancement, the csosshair is placed a t the machine detected 
spot with most suspicious enhancement curve, B: subtraction image o f pre- and postcontrast 
MRI, C: maximum intensity p/ojection, note the tum or area (double headed arrow), an ipsilateral 
intram ammary lymph node (arrow hea d) and the biopsy proven fibroadenoma ,n the contralateral 
breast (curved a rro w lD : machine detected most m aiignant enhancement curve (corresponding to 
the crosshair in A)).
Lastly, Dietzel et eil. reported at ECR 2009 on a comparison of 108 ILC to 3-47 IDC [56]. In their 
series ILC were more oiten irregular lesions than I DCS (62 vs 55%), though this did not reach 
statistical significance. An essential finding was, however, that internal necrosis (and hence ring 
enhancement) was less common in ILC than in IDC (3 vs. 15%) and that perifocal edema was 
less often observed (30 vs 45%). Moreover they also noted that wash-out was less frequent in 
ILC than IDC (57 vs. 73%). Both tumor types were nearly always iso- to hypointense compared 
to glandular breast tissue on T2 weighted imaging.
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In summary:
• Almost all ILC are retrospectively visible.
• Most ILC still present as an irregular spiculated mass, but the frequency of non­
mass-like enhancement (between 20 and 40%, approximately) is slightly higher 
than in IDC.
• Ring-enhancement and surrounding edema are less frequently observed.
• Contrast enhancement is slower than in IDC, but not necessarily less, which results 
in a higher proportion o f lesions that do not show a typical wash-out curve.
• CAD applications may help to adequately assess the most malignant curve shape, 
however, the morphologic appearance is usually that of a suspicious lesion and should 
not be misinterpreted in the absence o f a wash-out curve.
Agreement o f MRI findings w ith  pathologic assessment o f ILC
Since both mammography and ultrasound findings do not correlate very well with the 
pathologic assessment of ILC, many studies have focused on the correlation of MR findings 
with pathology [35,37-40,43,44,57-59]. In general, multifocal disease can be correctly predicted 
in approximately 80 - 90% of patients. Caramella et al. showed a kappa coefficient of .87 for 
the detection of multifocal disease compared to pathology [43], which can be translated as 
excellent inter-reader agreement. This is in comparison to .22 for both mammography and 
ultrasound, which translates into poor to  fair agreement. Nevertheless, both overestimation 
and underestimation of the number of tumor foci occurs. Overestimation has been attributed 
to enhancing LCIS [44]. Rodenko et al. noted in a series of 20 patients two cases of single 
quadrant disease that were interpreted as multicentric disease on MRI. These two cases stress 
the importance of obtaining histology prior to radical changes to the surgical treatment [59] 
(fig 7).
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Fig 7: MRI guided breast biopsy o f a multifocal ILC in the le ft breast, after negative mammography 
and negative second look ultrasound. A computer program (DynaCAD, Invivo, Orlando, USA) is 
used to accurately position the needle. In A a native sagital T1 image o f the left breast: is shown, 
the needle is currently aimed a t the crosshair. In B a subtraction image in the coronal plane o f both 
breasts is shown, which is used to locate the lesion1 The ley ion is in the center o f the crosshair In C 
the biopsy grid is shown, it  shows where to position the biopsy block (purple block with holes) and  
in which o f the holes to insert the needle (yellow dot) to come closest to the optim al position (red 
circle). The necessary depth can be read a t the bottom o f the screen. Using vacuum assisted biopsy, 
the diagnostic yield is approximately 95%.
More recently Onesti et al. reported in a series of 10 ILC that 5 tumors were in size overestimated 
by, an average of 1.2 cm [58]. Noneteeless, most studi es report actually yood correlation 
between MRI findings and pathology (table 1, fig 8). Unfortunately, in April 2006 it was not
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yet feasible to perform a meta-analysis due to the large variability among the studies [27]. 
Nowadays, with the publication o f the studies by Caramella and Mann, 7 studies have been 
published that either calculate Pearson's correlation coefficients for tumor size on MRI versus 
pathology, or present sufficient data to  calculate this correlation coefficient [43,44]. Since one of 
the latter studies is an extension to an earlier published study, there are now six studies, totaling 
220 patients, that can be entered in a meta-analysis as listed in table 1.
Table 1: Reported correlation coefficients o f MRI measured sizes with sizes o f ILC a t pathology.
Study N Pearson's correlation coefficient
Munot et al. 20 0.97
Kneeshaw et al. 21 0.86
Francis et al. 22 0.87
Kepple et al. 33 0.88
Caramella et al 57 0.88
Mann et al. 67 0.85
Applying simple meta-analytical principles to this data yields no longer significant variability (Q 
= 9.75, (p = 0.084), I2 = 49 %) and consequently data-pooling can be performed. The estimated 
correlation coefficient for MRI compared to pathology is 0.89 (95% CI 0.84 -  0.93), which is 
much better than what can be achieved by mammography or ultrasound, even in the hands of 
experienced practitioners.
The bad performance of conventional imaging methods is partly explained because MRI 
detects in many patients tumor foci separate from the index lesion in the ipsilateral breast that 
were mammographically and sonographically occult. Such additional tumor foci are present 
in approximately 32% of patients (95% CI 22-44%) and can be both multifocal as well as 
multicentric [27,36,40,60-62].
In summary:
• In patients with ILC, correlation of MRI findings w ith pathology is good, 
yielding a correlation coefficient o f 0.89.
• Additional tumor foci, only detected by MRI, are present in 32% of patients with ILC.
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Fig 8: Images o f a 37 year o ld women, known to be a BRCA2 mutation carier. A t mammography (A) 
an isointense spiculated mass was observed w ith a maximum diameter o f 2.3 cm. A t sonography 
(B) a hypoechoic mass with m in im al posterior acoustic shadowing was observed. The maximum  
diameter o f the tum or appeared to be 2.0 cm (B2). The MRI, shown in C (C l: native T1 post contrast 
acquisition, C2: subtraction image, C3: maximum intensity projection, C4: enhancement versus time 
curve corresponding w ith the crosshair in the other images) reveals a m ultifocal tum or over an area 
o f 6.9 cm. Consequently mastectomy was performed. A t pathology, a multicentric ILC was seen over 
an area o f 7.3 cm.
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Consequences fo r the  therapeutic approach o f ILC
The good correlation of MRI findings with pathology and the frequent detection o f additional 
tumor foci has a huge impact on the therapeutic approach in patients with ILC. Since the primary 
treatment for breast cancer, ILC and IDC alike, is usually surgery, the performance of preoperative 
breast MRI and visualization of additional sites in many patients initiates more extensive surgery. 
The surgical plan changes in approximately 28% of cases (95% CI 20-39%) [27,36,38,39,59,61]. 
In 12-33% o f patients breast conserving surgery (BCS) followed by radiotherapy is replaced 
by mastectomy [36,38,39,43,59,61]. Change of therapy in the other direction due to  better 
delineation o f the tumor has been reported, but in a substantial smaller percentage of patients 
(approximately 5%) [43]. Consequently, it has been estimated that overall the primary therapy 
shifts from breast conserving therapy to mastectomy in 15 to 20% of patients [63]. Furthermore, 
preoperative MRI is able to stratify some patients to neoadjuvant chemotherapy or vice versa, 
from chemotherapy to direct surgery, due to better tumor evaluation. Moreover, MRI can also 
be used to evaluate the effect of neoadjuvant chemotherapy (fig 9).
About 88% (95% CI 75-95%) of changes based on MRI are subsequently deemed correct by 
pathological con firmation of tumor in the specimen [27].
Fig 9: Two subtraction images o f a 47 year old woman, who presented with a T4 ILC in the left 
breast. In itia l assessment w ith MRI (A) shows a large diffuse growing tum or w ithin the left breast 
with involvement o f the skin (arrowhead). She was in itia lly treated with neoadjuvant chemotherapy. 
The control MRI (B) unfortunately shows that the tum or d id not respond well, but in fact had grown, 
while the patient became much thinner. Moreover tine skin involvement wotrened (curved arrow). 
Consequently salvage mastectomy iwas perfofmed.
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In summary:
• Preoperative MRI in patients with ILC changes the surgical plan in 28% of cases.
• The primary therapy shifts from breast conserving therapy to mastectomy in 
approximately 15-20% of patients.
• Based on pathological evaluation o f the specimen 88% of changes is correct.
Effect o f preoperative breast MRI on outcome in patients w ith  ILC
So far, there is no evidence that suggests an increase in survival for patients with ILC due to the 
performance o f pre-operative MRI. The two studies that have evaluated recurrence and survival 
as a function o f performing pre-operative breast MRI so far have not specifically addressed ILC, 
nor have they convincingly shown an increased survival for all women with breast cancer [64,65]. 
The rate of recurrence after BCS followed by radiotherapy is at approximately 0.6-1% per year. 
This is acceptably low and one can hardly expect this to decrease much further by the addition 
of MRI in all patients. This implies that at least some of the additional lesions detected by MRI 
and not surgically excised are adequately treated by radiotherapy and adjuvant chemotherapy. 
However, reported re-excision rates for ILC in the literature due to failure to radically excise the 
tumor at the first attempt are unacceptably high, ranging from 29 to  67% [66-70]. Moreover, 16­
48% of BCS attempts are still converted to mastectomy after initial unsuccessful surgery [70-75]. 
These facts are devastating to  the mental state o f the patient who already has to  deal w ith the 
fact that she has breast cancer. Moreover, re-excision is detrimental to the cosmetic outcome 
[76].
It is clear that MRI is the best diagnostic imaging modality currently available for ILC. The question 
is no longer whether the tumor is correctly depicted, but whether surgeons are able to use this 
information for the benefit of the patient. The high rate of changes induced by preoperative 
MRI should assign patients directly to the correct therapy (either BCS or mastectomy), w ithout 
unnecessarily assigning patients to mastectomy. The surgeon needs to be able to appreciate 
breast tumors in 3D images rather than on flattened mammography images, requiring training 
and skill. Moreover, it is necessary to transform the MR image mentally from the prone position 
in which the patient is scanned to the supine position in which the patient is operated, taking 
into account the movement of the breast tissue in all directions.
Only recently a retrospective study evaluated the re-excision rate in 267 patients with ILC of 
which 99 underwent preoperative MRI [63]. Initially,one-hundred-forty-five of these patients 
underwent BCS, 90 w ithout preoperative MRI and 55 with preoperative MRI. Re-excision was 
deemed necessary in 24 patients (27%) w ithout preoperative MRI and 5 patients (9%) with 
preoperative MRI. An odds- ratio for re-excision w ithout preoperative MRI o f 3.64 (95% CI 
1.30 -  10.20) was calculated. In other words, patients who did not undergo preoperative MRI 
had a more than 3.5 times higher chance to need a re-excision and, 23% chance of ending 
with a mastectomy. This is in comparison to  only 7% in the group of patients that underwent
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preoperative breast MRI and were surgically treated by surgeons used to working with breast 
MRI. The final rate of mastectomies appeared even lower in the group of patients that underwent 
MRI (48 vs 59%), though this did not reach statistical significance. Finally, the total treatment 
time (approximately 42 days) was not dependant on the performance of MRI, but was extended 
by the need for re-excision.
Currently, there are only two other studies published that evaluated the effect of preoperative 
MRI on margin status [77,78], none o f which specifically addressed ILC. Pengel et al. included 
52 patients w ith ILC of whom half underwent preoperative MRI [78]. Excision was extensively 
incomplete (and thus requiring re-excision) for 3 o f 26 patients (12%) with preoperative MRI and 
5 of 26 patients (19%) w ithout preoperative MRI. In this study, the overall reported re-excision 
rates (much lower than in the previous mentioned study due to the large fraction o f IDC) are 
more than twice as high in the group of patients that did not undergo preoperative MRI (10.6% 
vs. 5%), but the authors do not report on statistical significance concerning the re-excision rate. 
The study by Bleicher et al. does not provide sufficient data to extract numbers for ILC, but in 
general did not detect a reduction in the rate of positive margins, nor in the number of patients 
that finally underwent mastectomy [77]. Apparently, they were thus unable to use the increased 
knowledge from MRI for the benefit o f the patients, which underlines the need for training and 
experience, not only of radiologists, but of surgeons as well.
In summary:
• The performance o f preoperative MRI may reduce the rate of re-excisions in patients 
with ILC from 27% to  9%.
• Preoperative MRI in patients w ith ILC does not increase the final rate of mastectomies.
• Preoperative MRI in patients with ILC does not delay the time to final therapy.
• The success of preoperative MRI is highly dependent on the experience o f both 
radiologists and surgeons with breast MRI.
Evaluation o f the  contralateral breast w ith  MRI in patients w ith  ILC
Apart from staging of the known cancer, breast MRI in the preoperative setting serves a second 
purpose that may be even more important. According to Arpino et al. contralateral carcinoma 
is present in 20.9% o f patients with ILC compared to 11.2% of patients with IDC [79]. Overall MRI 
is estimated to detect in approximately 4% of patients a synchronous contralateral carcinoma 
that was not detected by any other imaging modality [80]. It may not be surprising that the rate 
of synchronously detected contralateral breast cancers by MRI in ILC is almost double that seen 
in IDC and is currently estimated at 7% (95% CI 4-12%) [27,34-37,39,57,60,61,80] (fig 10). This 
is independent o f tumor size and implies the need of preoperative evaluation with MRI in all 
patients w ith ILC, not only the subset that initially opts for BCS.
It is essential to realize that the specificity of breast MRI in the screening of the contralateral 
breast is only about 50% [80]. Histological verification of detected contralateral lesions is thus
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Fig 10: Subtraction MRI image o f both breasts o f a 48 year o ld woman who presented with a 
palpable lump in the left breast. A t mammography and ultrasound (not shown) an ILC o f 1.5 cm 
was detected in the left breast. MRI shows a m ultifocal tum or in the left breast over an area o f 3.4 
cm (arrowhead). A second ILC in the right breast is detected (curved arrow) (histologically validated 
using second look ultrasrund).
essential (as wel l as verification of any lesion in the ipsilateral breast that would largely change 
the surgical approach). Second look ultrasound may allow ultrasound guided breast biopsy in 
approximately 50% of detected lesions [81,82]. MRI guided breast biopsy is a safe, fast, easy and 
conclusive method to assess the remaining 50%, but easy availability is required [83,84] (fig 7). 
The strength, as well as the weakness of MRI in the detection of contralateral carcinomas is that 
most tumors are identified at an early stage. It is uncertain to what extent these carcinomas 
influence prognosis in the setting of an already detected ipsilateral carcinoma, and specific 
data regarding ILC are completely lacking. Contralateral tumors are different from ipsilateral 
additional detected tumor foci that receive radiotherapy anyway. Most importantly, contralateral 
tumors remain untreated if undetected. At the same time, adjuvant systemic therapy if given 
may prevent these tumors from becoming clinically significant. One would expect that 
the incidence of metachronous contralateral breast carcinoma decreases in patients who 
underwent preoperative MRI at the time o f ipsilateral tumor detection. Unfortunately, the two 
studies that evaluated this issue report conflicting results. Fischer et al. reported a reduction in 
the rate of metachronous contralateral carcinoma from 4% to 1.7% due to preoperative MRI, 
whereas Solin et al. reported an incidence of 6% contralateral carcinoma with and w ithout 
preoperative MRI [64,65].
Nonetheless, adjuvant therapy alone is generally not considered curative for breast cancer. Since 
a recent study has shown that early detection of asymptomatic second breast cancer in the 
ipsilateral breast or the contralateral breast in women with a history of breast cancer increases 
relative survival by 27 to  47% [85], we can assume that detection of additional contralateral 
carcinoma by MRI indeed increases survival. The magnitude of this effect remains uncertain.
170
General Discussion and Conclusions
In summary:
• Preoperative MRI in patients with ILC detects otherwise undetected contralateral 
carcinoma in 7%
• It is unsure whether preoperative MRI reduces the occurrence of metachronous 
contralateral carcinomas, there is no evidence available for patients with ILC.
• There is indirect evidence that early detection of contralateral carcinomas improves 
relative survival.
Current evidence fo r the performance o f breast MRI in ILC, shortcom ings and fu tu re  
perspectives
So far, many studies have shown that MRI is able to  depict ILC well. MRI has also been shown 
to correlate better w ith pathology in the assessment of ILC when compared with other 
commonly available imaging modalities. Moreover, it significantly affects diagnostic thinking 
and subsequent therapeutic management.
The notion that preoperative MRI in ILC affects therapeutic management of these tumors is 
known as level 4 evidence of its value [86]. This, however, does not automatically imply that 
the performance o f preoperative MRI is also good for the patient (known as level 5 evidence). 
At this level of evidence, the rate of re-excisions is the shortest term outcome parameter that 
can be evaluated, but also reductions in unwanted side effects of therapy, local recurrence and 
other metachronous carcinomas can be evaluated. Moreover, the ultimate gain for a patient is 
increase in survival or even better quality-adjusted life years, which is therefore the principal 
outcome parameter in many studies.
Only very recently the first studies evaluating outcome parameters after preoperative MRI have 
been published [63-65,77,78] w ith only one of these studies specifically addressing ILC [63]. 
The retrospective study discussed above shows that in experienced hands preoperative breast 
MRI can reduce the rate of re-excisions in patients with ILC. However, it does not show an effect 
on tumor recurrence, metachronous contralateral carcinoma or survival, nor does it evaluate 
cost-effectiveness. Regarding these issues, only indirect evidence is available. Evidence in favor 
of preoperative breast MRI in patients with ILC at the fifth  level is only moderate and further 
studies are essential. Moreover, the sixth (and highest) level of evidence, which questions 
whether or not the use of preoperative breast MRI in ILC is beneficial to society and hence is 
dependent on a cost-effectiveness analysis from a societal viewpoint, has not been addressed.
I am, on the other hand, of the opinion that the currently available evidence in favor of 
preoperative breast MRI in patients w ith ILC is substantial. The inherent benefits of breast MRI 
for patients are large: lowering the chance o f incomplete excision and subsequent need for 
re-excision, and possibly improving survival, while the detrimental effects of preoperative 
MRI, if adequately performed, are only minor with the possible additional need for biopsy. 
Consequently, based upon the currently available data, imaging w ith pre-operative MRI is 
strongly recommended in all patients w ith ILC prior to therapy.
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Future perspectives o f breast MRI, the  broader approach
Although the value of preoperative MRI in patients with ILC may be clear, this holds only partly 
true for other types of breast cancer. In IDC the reported re-excision rates are much lower, 
and though these can probably also be reduced by preoperative MRI in experienced hands, 
as shown by Pengel et al. [78], this gain (a reduction from 8 to 2% incomplete excisions) is of 
a much lesser magnitude than in patients with ILC. The same holds true for the detection of 
contralateral carcinoma in IDC, since the frequency of MRI detected unexpected contralateral 
lesions is at 4% only half of the frequency in ILC [80]. Consequently, the possible impact on 
survival is less. Nevertheless, these numbers are still not insignificant and it w ill be very difficult 
to refuse to  perform an MRI if a well informed patient requests the investigation.
Moreover, it has been clearly shown that screening with MRI and mammography in patients 
with a lifetime risk of 15% or more detects more cancers and reduces the frequency of interval 
carcinomas [45,87,88]. In a recent meta-analysis by Warner et al. it was shown that the addition 
of mammography in this setting is only very small [89]. Thus, if anything, screening with MRI 
should be preferred over screening with mammography. This holds particularly true, since it has 
been shown that MRI is at least as good in the detection o f DCIS as mammography and might 
be even better, which is discussed in more detail in Appendix 1 [90]. Based upon these results 
and the notion that the lifetime risk of developing breast cancer for the general woman in the 
Netherlands is at 12-13% only slightly lower than in the tested high risk populations [91], MRI 
will probably play a major role in breast screening in the near future [92,93].
One of the limiting factors has always been the difficulty of MRI guided breast biopsy. But 
recently this has become more widely available and nowadays should be accessible to every 
breast radiologist [83]. When screening is mainly performed by MRI, the discussions about 
preoperative staging will o ff course be obsolete, as most tumors will initially be detected and 
thus staged by MRI.
The most essential drawback to wide implementation of breast MRI in the current medical 
practice is the still high cost of the examination. It is therefore essential that the prices of MR 
machines decrease and imaging protocols become standardized and faster, which is still work 
in progress.
More experimental is the use of breast MRI to  assess breast cancer prognosis. The fact that breast 
MRI is an investigation that leans heavily on physiological principles allows the observation of 
physiological parameters in every tumor. Because there are many different methods to evaluate 
these tumors (e.g. contrast enhancement, diffusion, metabolic maps) many different aspects of 
tumor biology can be assessed. It should therefore be possible to predict tumor behavior and 
metastatic potential. The big advantage of this approach over standard pathological evaluation 
is that the entire tumor can be evaluated instead of a random sample. The recently reported
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correlation of contrast enhancement and necrosis with so called "triple negative" (i.e. estrogen 
and progesterone receptor negative and no over expression of Her2/neu) breast cancer is only a 
first step in this direction [94]. Studies to changes in enhancement pattern, water diffusion and 
choline spectrum in patients treated with neoadjuvant chemotherapy are a second, already 
more accepted, example of these possibilities [95-100]. A new dimension, however, is the use 
of contrast enhancement and diffusion weighted imaging prior to the start of chemotherapy 
to predict eventual tumor response [101,102], which might allow a more patient selective 
administration of therapy.
Last, the capability o f MRI to accurately assess tumor extension might be used to  optimize 
treatment protocols. Especially the use o f radiotherapy, essential to the current practice of 
breast conserving therapy but in itself a treatment w ith severe side effects, might be reduced 
or even abandoned in patients were MRI shows no additional tumor foci [103,104]. Moreover 
MRI might be used for the guidance of non-surgical treatment of breast cancer, either RFA, 
cryotherapy, focused ultrasound or vacuum assisted transcutaneous tumor excision [105]. 
Although it w ill probably be a long run before such treatment options are seriously considered 
competitors for surgical therapy.
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SAMENVATTING 
Introductie
Dit proefschrift is gericht op de evaluatie van MRI bij het in beeld brengen van het invasief 
lobulair carcinoom van de borst (ILC). Het primaire doel van d it proefschrift is het formuleren 
van een "state of the art" aanbeveling voor het gebruik van MRI bij patiënten met ILC. Deze 
aanbeveling moet gestoeld zijn op bewijs uit klinische studies en moet ook rekening houden 
met de gevolgen van het uitvoeren van een MRI voor de patiënten. Het verbeteren van de 
kwaliteit van het beschikbare bewijs, het aanvullen van het bewijs waar d it incompleet is 
en het evalueren van de gevolgen van een MRI voor patiënten met ILC werden dan ook als 
secundaire doelen aangemerkt. Deze samenvatting geeft een globaal beeld van de inhoud van 
d it proefschrift. Het is geen gedetailleerd overzicht van de gepresenteerde feiten.
Hoewel de samenvatting dus beperkt is in omvang, wordt deze gevolgd door een integrale 
vertaling van de algemene discussie en conclusies van dit proefschrift (hoofdstuk 10). Deze 
tekst presenteert de data die op d it gebied momenteel voor handen is, in relatie to t de huidige 
inzichten voor optimale behandeling van het ILC. De in d it proefschrift beschreven onderzoeken 
vormen een belangrijk deel van de huidige bewijslast en worden hier daarom uitvoeriger 
besproken, met name ook in relatie to t de recente bijdragen van andere onderzoekers. U treft 
hier dan ook vooral mijn overkoepelende conclusies aan. Ik hoop, (voor een ieder die de Engelse 
taal niet machtig is,) dat na het lezen van d it document de boodschap van het proefschrift toch 
volkomen duidelijk is.
Globale samenvatting
Hoewel de mortaliteit van borstkanker de laatste decennia licht is afgenomen, is borstkanker nog 
een van de belangrijkste oncologische doodsoorzaken bij vrouwen in Nederland. De diagnostiek 
en behandeling van het mammacarcinoom is derhalve nog voor verbetering vatbaar.
Aan de diagnostische kant biedt de mamma MRI mogelijkheden to t een aanzienlijke 
verbetering. Toch is de rol van mamma MRI in de evaluatie van borstkanker niet duidelijk. Dat 
mammacarcinomen met MRI goed afgebeeld kunnen worden is helder, maar MRI wordt (nog) niet 
op grote schaal ingezet voor het screenen van de vrouwelijke populatie. Dus worden de meeste 
carcinomen niet met MRI gedetecteerd. Het is daarom onzeker of een patiënte daadwerkelijk 
profiteert van eventuele toegenomen informatie over de grootte en plaats van een carcinoom, 
zoals MRI die levert.
Omdat de meer standaard beeldvormende technieken voor de analyse van mammacarcinomen, 
mammografie en echo, vooral bij het ILC niet goed in staat zijn de grootte en uitbreiding van de 
tumor accuraat vast te stellen lijkt dit een gebied waar mamma MRI bij uitstek een toegevoegde 
waarde kan hebben.
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In hoofdstuk 2 worden de verschillen tussen het ILC en het veel vaker voorkomende invasief 
ductale carcinoom (IDC) bekeken vanuit een radiologisch oogpunt. De belangrijkste bevinding 
is dat het ILC een meer diffuse groeiwijze heeft en daardoor minder makkelijk is te onderscheiden 
van normaal mammaweefsel dan het IDC. Hoofdstuk 3 beschrijft het gebruik van mamma 
MRI bij ILC op basis van de gegevens die beschikbaar waren bij aanvang van dit proefschrift. 
Enerzijds bleek dat MRI bij de evaluatie van lobulaire carcinomen een toegevoegde waarde 
kan hebben, anderzijds dat er veel gebieden zijn waar de beschikbare literatuur geen heldere 
antwoorden kan geven of waar de resultaten van verschillende studies ver uiteen lopen. Als 
direct gevolg hiervan is in hoofdstuk 4 getracht de kwaliteit en waarde van de in de literatuur 
beschikbare data te analyseren door middel van een systematische review van de literatuur 
en waar mogelijk de data van verschillende studies te combineren met meta-analytische 
technieken. Hierbij is getracht 4 vragen te beantwoorden, namelijk:
1) Hoeveel procent van de ILC is daadwerkelijk zichtbaar op MRI?
2) Hoe ziet een ILC er eigenlijk uit op MRI?
3) Is datgene wat er op MRI wordt gezien hetzelfde als wat er bij pathologisch onderzoek (PA) 
wordt gezien?
4) Wat is de invloed van de MRI op het chirurgisch beleid?
Hoewel duidelijk bleek dat verreweg de meeste ILC (93%) goed zichtbaar zijn op MRI, bleek uit 
deze analyse ook dat er op andere terreinen nog vraagtekens bestonden. Zo was absoluut niet 
duidelijk hoe een ILC er nu eigenlijk uitziet. In absolute zin doordat verschillende radiologen 
dezelfde verschijnselen nu eenmaal anders benoemen, maar wellicht belangrijker in relatieve 
zin omdat nooit vergelijkende studies zijn verricht waarbij de karakteristieken van ILC werden 
afgezet tegen die van andere typen carcinomen. Daarnaast bleek het niet mogelijk om een 
eenduidig antwoord te geven op de vraag of de tumorgrootte op MRI goed correspondeert 
met de grootte bij PA, omdat de resultaten van de studies onderling sterk verschilden. Hierdoor 
was het niet mogelijk om de resultaten van de verschillende studies te combineren. Wel was 
duidelijk dat MRI bij een groot aantal patiënten additionele tumor foci ontdekte in de ipsilaterale 
(32%) en de contralaterale (7%) mamma.
Tot slot bleek ook eenduidig dat MRI een grote impact had op het chirurgisch beleid, dit 
verandert in 28% van de patiënten. Het bleef echter onduidelijk o f de patiënten hier vervolgens 
ook baat bij hadden.
In hoofdstuk 5 zijn vervolgens een aantal technieken beschreven om de mate van aankleuring 
van tumoren op MRI te kwantificeren. Dit zou het vergelijken van verschillende onderzoeken, 
gemaakt op verschillende MRI systemen, mogelijk moeten maken. Bovendien reduceert het de 
invloed van de beoordelend radioloog op het uiteindelijk resultaat. Een van deze kwantificatie 
technieken is, samen met de meer conventionele technieken om aankleuring te evalueren, in 
hoofdstuk 6 ingezet om verschillen in aankleuringspatroon tussen ILC en IDC aan te tonen. 
Uit deze analyse bleek dat ILC trager aankleurt dan IDC, maar niet noodzakelijkerwijs minder. 
Daarnaast bleek de conventionele aankleuringsanalyse eenduidiger wanneer gebruik gemaakt
183
Chapter 11
werd van een computerprogramma om de meest verdachte regio binnen een afwijking te 
lokaliseren. Tot slot waren er geringe verschillen in de morfologische karakteristieken van de 
twee tumor typen, waarbij ILC zich iets vaker dan IDC presenteert zonder duidelijke massa. 
Niettemin bleken de verschillen zo gering dat dezelfde terminologie gebruikt kan worden om 
de kenmerken van beide tumor typen op MRI te beschrijven.
In hoofdstuk 7 is vervolgens ingegaan op de correlatie tussen metingen van de tumor 
grootte op mammografie, MRI en PA. Hieruit bleek dat er geen significante relatie kon worden 
vastgesteld tussen de grootte van de tumor op mammografie en de grootte van de tumor bij 
PA. De correlatie van de tumor grootte op MRI met de tumor grootte bij PA was echter heel 
goed (r=0.85). Desondanks werd ook op MRI ongeveer 10% van de carcinomen meer dan 1 cm 
te klein en 10% meer dan 1 cm te groot ingeschat. Een van de oorzaken van het overschatten 
van tumor grootte is waarschijnlijk de aanwezigheid van aankleurend lobulair carcinoom in 
situ.
In hoofdstuk 8 is vervolgens gekeken of de betere kennis over de exacte tumor grootte en 
lokalisatie, die MRI levert ook leidt to t minder operaties. Iedere patiënte moet natuurlijk 
eenmaal geopereerd worden. Aanvullende operaties zijn nodig als de tumor bij de eerste 
operatie niet volledig is verwijderd. Het percentage patiënten dat zo'n extra operatie nodig had 
was in de groep patiënten die geen MRI had gehad 27%. In de groep patiënten die wel een MRI 
had gehad was dit slechts 9%. Daarbij bleek dat het percentage mastectomieën (= volledige 
verwijdering van de borst) in de groep patiënten die een MRI hadden gehad niet hoger was dan 
in de groep patiënten die geen MRI had gehad. Bovendien resulteerde de MRI niet in vertraging 
van de behandeling. Met andere woorden, een grote groep patiënten had daadwerkelijk baat 
bij de MRI, zonder dat deze MRI negatieve bijeffecten had.
In hoofdstuk 9 is gepoogd op basis van de beschikbare literatuur en met toevoeging van de 
opinie van experts op het gebied van de mamma MRI, als de literatuur te kort schoot, te komen 
to t algemene aanbevelingen voor:
1) De minimale kwaliteitseisen waaraan mamma MRI moet voldoen
2) De indicaties voor het gebruik van mamma MRI
Als kwaliteitseisen zijn geduid:
- Het gebruik van een specifieke mammacoil (een speciale antenne, die de MR signalen uit 
de borsten opvangt)
- Voldoende hoge ruimtelijke en tijdsresolutie van de MR opname
- T1 gewogen beelden van beide mammae op tenminste 3 tijdspunten in relatie to t de 
contrast toediening. Eenmaal voor en tweemaal na toediening van intraveneus contrast
- Rapportage door een ervaren radioloog en met gebruik van het BI-RADS lexicon
- Beschikbaarheid van MRI geleide biopsie faciliteiten
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Als indicaties zijn geduid:
- Evaluatie van de mammae in geval van niet conclusieve conventionele beeldvorming
- Het screenen van de contralaterale mamma in patiënten met een bewezen carcinoom in 
een borst
- De evaluatie van de mammae bij patiënten met bewezen metastasen, maar geen bekend 
primair carcinoom
- De evaluatie van therapie respons in patiënten die initieel met chemotherapie worden 
behandeld
- Het uitsluiten van een lokaal recidief bij patiënten met in de voorgeschiedenis een borst 
sparende operatie voor een mammacarcinoom
- De screening van patiënten met een risico om gedurende hun leven een 
mammacarcinoom te ontwikkelen van 20% of meer
In hoofdstuk 10 tenslotte volgt de algemene discussie, waarvan u op de volgende pagina's een
volledige Nederlandse vertaling aantreft.
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ALGEMENE DISCUSSIE EN CONCLUSIES 
Conventionele beeldvorm ing b ij het invasief lobu la ir carcinoom
Na de initiatie van borstkankerscreening werd snel duidelijk dat invasieve lobulaire carcinomen 
(ILC) vaker werden gemist dan andere carcinomen en zich daarom vaker presenteerden als 
interval carcinomen [1]. Dit werd verklaard door het diffuse infiltratieve groeipatroon van 
deze tumoren en de slechts zeer beperkte desmoplastische reactie van het normale weefsel 
[2]. Ongeveer een derde van de interval carcinomen blijkt lobulair van origine en, indien 
gedifferentieerd wordt tussen werkelijke intervalcarcinomen en fout negatieve screenings 
mammogrammen, blijkt zelfs dat bij 47% van de fout negatieve mammogrammen, de tumoren 
een lobulaire groeiwijze hebben [3,4]. Dit kan deels worden verklaard doordat ILC vaak beter 
zichtbaar zijn op de cranio-caudale mammografie opnamen, terwijl deze in de screening niet 
standaard verricht worden [5,6]. Niettemin is zelfs retrospectief 10-20% van de ILC niet zichtbaar 
op een mammogram [6-9].
Het klassieke beeld van een maligniteit op mammografie, een gespiculeerde massa, wordt 
gerapporteerd in 28-63% van de patiënten met ILC [6,9-13] (fig 1,2). De mammografische 
bevindingen bij de overige patiënten zijn vaak erg subtiel. ILC zijn niet geassocieerd met 
microcalcificaties en de densiteit van de tumor is vaak gelijk aan, of zelfs lager dan, die van het 
omringende klierweefsel [5,8,10,14,15].
Fig 1: Mammogram van een 60-jarige vrouw (A: linker mamma, CC opname, B: linker mamma, 
MLO opname) die zich presenteerde met een palpabele zwelling in het laterale bovenkwadrant van 
de linker mamma. Er is een hyperdense massa zichtbaar in het laterale bovenkwadrant met een 
irregulaire gespiculeerde begrenzing en een maximale diameter van 3,6 cm. Bij PA bleek er sprake 
van een multifocaal ILC over een gebied van 4,2 cm. Het grootste focus was 2,5 cm.
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Fig 2: Mammogram van een 71-jarige vrouw (A: linker mamma, CC opname, B: linker mamma, 
MLO opname) die zich presenteerde met een palpabele massa en intrekking van de huid. Op het 
mammogram is een grote architectuurverstoring te zien (tenminste 5 cm), isointens ten opzichte van 
het normale fibroglandulaire weefsel. De hek mamma is vervormd. Histologie liet een T4a ILC zien.
Deze tumoren worden onder meer beschreven als: slecht gedefinieende massa (7-33%) [63,9,12], 
architectuor verstoring (10- 24%) [6,9-12] o f asymmetrie (4-14%) [6,9]. De opvallend wijde 
marges in het gebruik van de descriptieve terminologie zijn waarschijnlijk het gevolg van de 
slechts matige overeenstemming tussen verschillende experts.
Zoals verwacht is het slechts zeer beperkt mogelijk om in te schatten hoe groot een ILC is op 
mammografie. In de literatuur gerapporteerde Pearson's correlatie coëfficiënten variëren van 
0.2 to t 0.8. In de praktijk zijn met name kleine tumoren in 'lege' mammae redelijk op maat te 
schatten. De accuratesse decimeert echter naarmate de tumoren groter en de mammae denser 
worden. Dit resulteert in een structurele onderschatting van de grootte van grotere tumoren 
[16-18]. Hoewel ook de grootte van invasief ductale carcinomen (IDC) op mammografie wordt 
onderschat, resulteren de meestal vage begrenzingen van ILC in een sterkere onderschatting 
van de tumor grootte dan bij IDC [6,18]. Als gevolg hiervan wordt ongeveer een derde van de 
ILC op mammografie te laag gestadieerd [19].
Echografie wordt niet gebruikt voor screening, daarom is de sensitiviteit van echo voor ILC
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alleen bekend voor laesies, die reeds op een andere wijze zijn gedetecteerd (mammografie of 
lichamelijk onderzoek). De meeste ILC zijn zichtbaar met echo: de gerapporteerde sensitiviteit 
varieert tussen de 78 en 98%. [20-26]. In een recente meta-analyse, waarin de sensitiviteit van 
echografie direct werd vergeleken met de sensitiviteit van MRI, werd voor echo een sensitiviteit 
van 83% vastgesteld, met een 95% betrouwbaarheidsinterval (BI) van 71-91% [27].
Hoewel een vroege studie problemen rapporteerde met de detectie van kleine ILC (< 1 cm), 
(slechts een van de vier ILC gedetecteerd) [28], is d it in latere studies gerectificeerd. Deze 
latere studies rapporteren allen een sensitiviteit voor kleine laesies in de boven beschreven 
range (71-91%) [29,30]. Essentieel is dat de sensitiviteit van echo ook goed is voor laesies die 
mammografisch occult zijn, hierdoor kan echo een belangrijke rol spelen in de evaluatie van 
symptomatische (meestal palpabele) ILC [20]. Ongeveer 60% van de ILC hebben echografisch 
de klassieke kenmerken van een maligniteit en zien eruit als hypoechoische heterogene 
massa's met slecht gedefinieerde marges en met een akoestische slagschaduw [20,21,24] (fig 
3). Niettemin hebben ILC vaker een intern hyperechogeen patroon dan IDC [21,26] (fig 3D) 
en sommige ILC presenteren zich als een slagschaduw zonder discrete massa [20,24]. Van dit 
laatste echopatroon wordt gesteld dat het suggestief is voor een klassiek type ILC (een zeer 
diffuus groeiende tumor die in lange tumordraden het mammaweefsel infiltreert) [20].
Fig 3: Echo b eelden van 4 verschillende ILC. De tumoren in A,B en C hebben de typische karakteristieken 
van maligne laesies, d.w.z. een hypoechogene, gespiculeerde massa met posterieur akoestische 
beschaduwing. De tumor in D is vrijwel isoechogeen ten opzichte van normaal mammaweefsel, 
maar ter plaatse zijn multipele pathologische Doppler signalen zichtbaar als gevolg van uitgebreide 
neovasculasisatis (zie hoofdstuk 10 voor een afdruk van dit figuus in kseur). Bij pathologie was de
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tumor op A meer dan 5 cm groot, de tumor op B meer dan 8 cm, op C 14 mm en op D 3,2 cm, wat 
duidelijk aangeeft dat echografische metingen, vooral in grote tumoren ver van accuraat zijn.
Echo is ongeveer even goed in het schatten van de tumorgrootte als mammografie. De range 
van gerapporteerde correlatiecoëfficiënten is echter iets beperkter en varieert van 0.5 to t 0.8 
[25,31-33]. Net als bij mammografie is de accuratesse van de schatting slechter naarmate de 
tumor groter is, meer nog bij ILC dan bij IDC. De afmetingen van tumoren groter dan 3 cm 
kunnen niet adequaat worden geschat met behulp van echografie [26,32].
Karakteristieken van ILC op MRI
In een retrospectieve setting is de sensitiviteit van MRI voor ILC hoog. In een meta-analyse die 
de studies to t april 2006 analyseerde en de sensitiviteit in een totaal van 209 patiënten met 
ILC beschreef, was 93.3% zichtbaar. Het bijbehorende 95% BI liep van 88 to t 96%. Wanneer 
de resultaten van een zeer vroege studie, waarin een inadequaat scan protocol was gebruikt 
worden geschrapt, bleek de sensitiviteit 96% te zijn (95% BI 92-98%) [27,34-41]. Na de publicatie 
van deze meta-analyse zijn er, voor zover mij bekend, nog drie studies verschenen waarin de 
sensitiviteit van MRI voor ILC werd bepaald [42-44]. De twee grootste studies rapporteerden 
beiden een sensitiviteit van 100% (bij respectievelijk 57 en 69 patiënten) [43,44]. De derde 
studie, die eigenlijk gericht was op de evaluatie van mamaspecifieke gamma-imaging bij het 
detecteren van ILC, beschreef 2 fout negatieve MRI onderzoeken in een serie van slechts 12 
patiënten, resulterend in een sensitiviteit van 83% [42]. Aangezien deze resultaten ver beneden 
het eerder gemelde 95% BI vallen, kan dit alleen maar worden verklaard door het zeer lage 
aantal geïncludeerde patiënten [27].
Vrijwel alle studies zijn opgezet als retrospectieve cohortstudies. Slechts twee studies 
beschrijven prospectief verzamelde cohorten en een studie beschrijft een deels prospectief 
verzameld cohort [34,37,43]. Francis et al. melden een sensitiviteit van 95% in 22 ILC, Berg et 
al. melden een sensitiviteit van 97% in 29 ILC and Caramella et al. melden een sensitiviteit van 
100% in 35 ILC. De resultaten van de prospectief verzamelde cohorten sluiten dus nauw aan bij 
die van de retrospectieve cohortstudies.
Niettemin hebben alle studies, zowel de retrospectieve als de prospectieve, alleen patiënten 
geëvalueerd waarvan al bekend was dat ze een carcinoom hadden. Hoewel verscheidene 
auteurs gevallen rapporteren van bij toeval met MRI gedetecteerde ILC, zijn er vrijwel geen 
data beschikbaar over de waarde van MRI voor de detectie van ILC in een screeningssituatie. 
Globaal is de sensitiviteit van MRI voor carcinomen in een screeningssituatie slechter dan in 
pre-operatieve stadiering, hoewel MRI voor screening wel veel beter is dan mammografie. De 
gerapporteerde sensitiviteit varieert van 77% to t 100% [45]. In de grote screeningsstudies bij 
hoog risico patiënten zijn niet genoeg ILC beschreven om conclusieve uitspraken te doen. Toch 
rapporteerden Kriege et al. een sensitiviteit van 100% bij de detectie van 4 ILC met behulp
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van MRI, terwijl met mammografie slechts een van deze vier tumoren werd gedetecteerd 
(sensitiviteit 25%) [46]. Dit suggereert dat MRI screening een toegevoegde waarde kan hebben 
in de vroeg detectie van ILC.
Voor optimale detectie van ILC in een screeningssetting is het essentieel om te weten hoe een ILC 
er uit ziet op mamma MRI. Er wordt vaak gesteld dat ILC zich vaker dan IDC presenteren als een 
aankleurende gebied zonder duidelijke massa. Helaas is er opvallend weinig wetenschappelijk 
bewijs dat deze stelling onderbouwd. Dit is, tenminste deels, het gevolg van het feit dat de 
beschrijving van laesies op mamma MRI, zelfs met gebruik van de BI-RADS lexicon, last heeft 
van een sterke inter-reader variatie [47-49]. Een directe consequentie hiervan is dat het simpele 
onderscheid tussen een massa en een aankleurend gebied zonder massa zeer moeilijk gemaakt 
kan worden (de ene radioloog zal een afwijkingen een aankleurende massa noemen, terwijl 
een andere radioloog dezelfde afwijking als aankleurend gebied zonder duidelijke massa kan 
beschrijven) .
De frequentie van de presentatie van een ILC als aankleurend gebied zonder massa varieert van
5 to t 69%. Het samenvoegen van de data van de verschillende studies is door de heterogeniteit 
niet mogelijk [27].
In de grote groep ILC die zich wel als een massa presenteert wordt ongeveer 85% beschreven 
als irregulair en gespiculeerd. Een irregulaire en gespiculeerde massa is dus in feite de meest 
voorkomende presentatie van een ILC op MRI [27,43,50] (fig 4). Niettemin zijn er zelfs ILC die zich 
presenteren als ronde massa's met een scherpe rand [43,50,51]. In gevallen van aankleurende 
gebieden zonder massa, kan de aankleuring beperkt zijn to t het traject van een ductus, maar 
ook verder uitgebreid zijn to t segmentale, regionale of zelfs diffuse aankleuring (fig 5).
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V
Fig 4: Drie voorbeelden (Rij A, B en C) van massa vormende ILC in de rechter mamma van drie 
verschillende patiënten op respectievelijk mammografie (eerste kolom), subtractie MRI (tweede 
kolom) en maxim ale intensiteits projectie van de MRI (derde kolom). De massa's zijn allen irregulair en 
met name de massa bij A is steri gerpiculeezd. Alle massa's waren ook zichtbaar met mammografie 
(rechte pijlen). Het additionele tumor focus bij patiënt C, meer anterieur gelokaliseerd en op deze 
plaatjes alleen zichtbaar op de MIP (gebogen pijl) werd echter alleen met MIRI zedetecteeidi
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Fig 5: Drie voorbeelden (Rij A, B en C) van aankleurende gebieden zonder massa in de linker mamma 
van drie verschillende patienten op respectievelijk mammografie (eerste kolom), subtractive MRI 
(tweede kolom) en maximale intensiteit projectie van de MRI (derde kolom). De aankleuring was 
respectievelijk regional (A), segmenteel (B) en diffuus (C). De tumoren bij patienten A en C waren 
palpable maar mammografisch occult, de tumor in patient B was op mawmojrafie gedetecteerd, 
maar de multifocale verspreiding was alleen op MRI zichtbaar.
Het aankleuiingspatroon van ILC is minder vaak bestudeerd. Sittek et al. en Trecate et al. 
beschrijven beiden dat de maximale aankleuring relatief laat werd bereikt en dat het uitwassen 
van contrast in de late fase van aankleuring minder frequent voorkomt [41,52]. Catamella et al. 
beschrijven zelfs dat de aankleuringscurve doorstijgt (wat meestal wordt beschreven als een 
type; 1 curve en suggestief it voot een goedaardige laesie) in 37 % van de ILC [43]. Twee studies 
die gekwantificeerde parameters van contrast aankleuring evalueerden, beschrijven ook dat de 
geobserveerde waarden in deze studies veel lager lijken dan de waarden die in andere studies 
worden gerapporteerd met betrekking to t IDC [51,53].
192
Nederlandse samenvatting, algemene discussie en conclusies
Zonder de aanwezigheid van studies die de morfologie en het aankleuringspatroon van IDC en 
ILC direct met elkaar vergelijken, kan niet bepaald worden hoeveel ILC en IDC nu werkelijk van 
elkaar verschillen.
Dit soort studies zijn wel verricht en besproken op verscheidene internationale congressen, 
maar helaas to t op heden niet gepubliceerd.
Newstead et al. presenteerden een vergelijkende studie over 22 ILC, 257 IDC en 83 DCIS op 
de RSNA in 2005 [54]. Zij beschreven dat 55% van de ILC zich presenteerden als een massa, 
vergeleken met 76% van de IDC en slechts 16% van de DCIS. De tijdsduur to t maximale 
aankleuring van de tumor na contrastinjectie was 2 maal zo lang voor ILC als voor IDC (270 ± 
112 s vs. 131 ± 90 s), als direct gevolg hiervan was de aankleuring van de tumor op 68 seconden 
na contrastinjectie lager in ILC dan in IDC.
Mann et al. presenteerden op de ISMRM 2008 een vergelijkende studie tussen 33 ILC en 103 
IDC. Van de ILC presenteerde 75% zich als een massa, terw ijl 84% van de IDC zich als massa 
presenteerde [55]. Er was een matige interreader variabiliteit voor de differentiatie tussen 
een massa en een aankleurend gebied zonder duidelijke massa (k = 0.41), vergelijkbaar 
met in de literatuur gerapporteerde waarden voor interreader variabiliteit van mamma 
MRI, in het algemeen. Er was geen verschil in de interreader variabiliteit voor ILC en IDC. De 
maximale aankleuring was niet anders bij ILC dan bij IDC (360 vs 382%), maar bij analyse van 
de aankleuringscurve zonder gebruik van een computer was de uitwas van contrast (relatief 
specifiek voor maligniteit) minder vaak zichtbaar in ILC dan in IDC (48 vs 84%). Wanneer 
wel gebruik werd gemaakt van een computerprogramma om de meest verdachte curve 
te detecteren, werd dit verschil echter beduidend kleiner. De uitwas van contrast werd op 
deze manier vastgesteld in 88% van de ILC en 94% van de IDC, wat suggereert dat dergelijke 
computerprogramma's met name bij ILC een toegevoegde waarde kunnen hebben (fig 6). Dit 
verschijnsel wordt verklaard doordat bij ILC doorgaans in een kleiner gebied van de tumor d it 
karakteristieke aankleuringspatroon zichtbaar is (<10% van het dominante focus in 64% van de 
ILC vs. 30% van de IDC). De resultaten van farmacokinetische analyse lieten ook zien dat ILC over 
het algemeen langzamer aankleuren, maar niet minder. Dit wordt in meer detail besproken in 
hoofdstuk 6 van deze thesis.
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Fig 6: MRI beelden van een 40-jarige vrouw met een sterke familiar belasting, die zich presenteerde 
met tepelvloed. Het mammogram liet dens klierweefsel zien met multipele benigne calcificaties en 
was dus negatief (niet afgebeeld). Microdochectomie liet LCIS zien. Vervolgens is een MRI verricht, 
waarop een multifocaal ILC over eert (gebied van 4.7 een zichtbaar is. Hoewel het grootste deel van de 
tumor continue aankleuring Uetzien, was er toch een klein gebiedje waar het contrast snel uitwaste. 
(A: T1w FLASH 3D acquisitie met hieroverheen een kleur gecodeerde map van de aankleuring 
(zie hoofdstuk 10 voor een afdruk van dit figuur in kleur), de cursor is geplaatst op het door het 
computerprogramma gedetecteetde punt met de meest verdaehte aankleuringscutvei Bi subtractie 
beeld van pre- en postcontrost MRI, C: maximale intensiteit projectte, hierop is het tumor gebied 
(dubbele pijl) duidelijk zichtbaar. Voorts is er een lymfe klier in de rechter mamma zichtbaar (pijlkop) 
en een fibroadenoom in de contralaterale b o s  tgebogen pijt). Dl doot de machine gedetecteerde 
meest verdachte aanjieuringscurve (correspondetend met de cursor in A)t.
Tenslotte rapporteerden Dietzel et al. op de ECR 2009 de resultaten van een vergelijkende studie 
tussen 108 ILC en 347 IDC |56]. In deze serie waren ILC iets; vaker irregulair begrensd dan IDC 
(62 vs 55%), hoewel d it statistisci neet significant werd bevonden. Belangreker was dat interne 
necrose in de tumor (en dus een ringvormig aankleuringspatroon) minder voorkomt bij ILC 
dan bij IDC (3 vs. 15%) en dat oedeem rondom de tumor minder vaak aanwezig was bij ILC (30 
vs 45%). Tenslotte rapporteerden zij ook dat het uitwassen van contrast minder vaak zichtbaar 
was bij ILC dan bij IDC (57 vs. 73%). Beide tumortypen zijn vrijwel altijd iso- to t hypointens op 
T2 gewogen MRI afbeeldingen.
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Samenvattend:
• Vrijwel alle ILC zijn retrospectief zichtbaar op MRI.
• De meeste ILC presenteren zich als een irregulaire, gespiculeerde massa, maar de 
frequentie van een aankleurend gebied zonder vorming van een duidelijke massa 
(tussen de 20 en de 40%) is iets hoger dan bij IDC.
• Ringvormige aankleuring en omgevend oedeem zijn minder vaak aanwezig bij ILC dan 
bij IDC.
• Contrast aankleuring bij ILC is trager dan bij IDC, maar niet perse minder, wat er toe leidt 
dat een groter deel van de ILC niet het typische uitwassen van contrast laat zien.
• Computerprogramma's kunnen mogelijk helpen de meest verdachte aankleuringscurves 
te selecteren. Niettemin is de laesie morfologisch meestal verdacht en deze zou, ook bij 
afwezigheid van een karakteristiek aankleuringspatroon, niet moeten worden gemist.
Overeenstemming van de MRI bevindingen met pathologische analyse van de specimen 
b ij ILC
Omdat zowel de mammografische als de echografische bevindingen niet geweldig 
corresponderen met de bevindingen bij pathologische analyse, hebben veel studies zich 
gericht op de correlatie van MR bevindingen met pathologie [35,37-40,43,44,57-59]. Globaal 
kan de aanwezigheid van multifocaliteit goed worden voorspeld in 80-90% van de patiënten. 
Caramella et al. rapporteerden een kappa coëfficiënt van .87 voor de detectie van multifocaliteit 
in vergelijking met pathologie [43], wat kan worden vertaald als een uitstekende interreader 
overeenkomst (ter vergelijk: mammografie en echografie scoorden beiden een kappacoëfficiënt 
van .22 , wat kan worden vertaald als slechte to t matige interreader overeenkomst). Niettemin 
komen, ook bij MRI, zowel overschatting als onderschatting van het aantal tumor foci voor. 
Overschatting kan het gevolg zijn van aankleurend LCIS [44]. Rodenko et al. beschreven 
in een serie van 20 patiënten 2 gevallen van tumoren in 1 kwadrant, die radiologisch waren 
afgegeven als multicentrische aandoening. Dit onderstreept dat het essentieel is om histologie 
te verkrijgen van op beeldvorming geobserveerde afwijkingen alvorens het chirurgisch beleid 
te veranderen [59] (fig 7).
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Fig 7: MRI geleide mamma biopsie van een multifocaal ILC in de linker mamma, na negatieve 
mammografie en niet geslaagde echografische lokalisatie. Er wordt gebruik gemaakt van een 
computer programma (DynaCAD, Invivo, Orlando, USA) om de naald accuraat te positioneren. Bij A 
is een natieve sagitale T1 opname van de linker mamma zichtbaar, de naald is op dit moment gericht 
op de cursor. Bij B is een coronaal subtractie beeld van beide mammae afgebeeld, waarop de laesie 
wordt gelokaliseerd. De laesie bevind zich midden tussen de kruisende lijnen. Bij C wordt de biopsie 
grid afgebeeld. Er is zichtbaar waar het naaldgeleider blokje moet worden gepositioneerd (paarse 
blokje met rondjes) en welk van de gaten gebruikt moet worden voor de biopsie (gele cirkel) om zo 
dicht mogelijk bij de optimale biopsie plaats (rode cirkel) te komen (zie hoofdstuk 10 voor een afdruk 
van dit figuur in kleur). De noodzakelijke biopsie diepte kan worden afgelezen aan de onderzijde van 
het scherm. Met gebruik van vacuum biopsie is ongeveer 95% van de biopten conclusief.
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Recenter beschreven Onesti et al. in een serie van 10 ILC dat 5 tumoren in grootte overschat 
waren (gemiddeld 1,2 cm) [58]. Het leeuwendeel van de studies beschrijft echter een 
uitstekende correlatie tussen MRI bevindingen en pathologie (tabel 1, fig 8). In 2006 was het 
helaas nog niet haalbaar een meta-analyse uit te voeren op de aanwezige data als gevolg van 
sterke heterogeniteit [27]. Momenteel zijn er, door de publicatie van de studies van Caramella 
en Mann, 7 studies die Pearson's correlatie coëfficiënten vermelden voor MRI afmetingen versus 
afmetingen bij pathologie (of voldoende data presenteren om deze te berekenen) [43,44]. 
Omdat een van de nieuwe studies een extensie is van een eerdere studie zijn er zes studies, met 
in totaal 220 patiënten die nu voor meta-analyse in aanmerking komen (tabel 1).
Table 1: Gerapporteerde correlatie coefficienten voor MRI afmetingen versus pathologie 
afmetingen van ILC.
Studie N Pearson's correlatie coefficient
Munot et al. 20 0.97
Kneeshaw et al. 21 0.86
Francis et al. 22 0.87
Kepple et al. 33 0.88
Caramella et al 57 0.88
Mann et al. 67 0.85
Wanneer nu een meta-analyse wordt uitgevoerd volgens dezelfde principes als in 2006 is er niet 
langer sprake van significante heterogeniteit (Q = 9.75, (p = 0.084), I2 = 49 %) en daarom kan 
deze nu wel uitgevoerd worden. De geschatte correlatie coëfficiënt is 0.89 (95% BI 0.84 -  0.93). 
Dit is veel beter dan wat er bereikt kan worden met mammografie o f echo, zelfs in de handen 
van ervaren specialisten.
De slechte resultaten die behaald worden met conventionele beeldvormende technieken 
kunnen, althans deels, verklaard worden doordat met MRI vaak tumor foci worden gedetecteerd 
op enige afstand van de primaire tumor, die mammografisch en echografisch niet zichtbaar 
waren. Dit soort additionele tumor foci is aanwezig in ongeveer 32% van de patiënten en deze 
kunnen zowel multifocaal als multicentrisch zijn gelokaliseerd [27,36,40,60-62].
Samenvattend:
• De overeenstemming van de MRI bevindingen met pathologie is goed.
De correlatiecoëfficiënt bedraagt 0.89.
• Additionele tumor foci, welke alleen met MRI worden gedetecteerd, zijn aanwezig in 
32% van de patiënten met ILC.
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Fig 8: Beelden van een 37 jarige vrouw, bekend met een BRCA2 mutatie. Op het mammogram (A) is 
een isointense gespiculeerde massa zichtbaar met een maximale diameter van 2,3 cm. Bij echo (B) 
is er een hypoechogene massa zichtbaar met zeer geringe posterieure akoestische beschaduwing 
De maximale tumor diameter bedraagt echografisch 2,0 cm (B2). Op de MRI (C; C1: natieve post 
contrast T1 acquisitie, C2: subtractie beeld, C3: maximale intensiteit projectie, C4: aankleuring versus 
tijd curve, corresponderend met de cursor in de andere beelden) blijkt er sprake van een multifocale 
tumor in een gebied van 6,9 cm. Als gevolg hiervan werd mastectomie verricht. Bij pathologie bleek 
er sprake van een multifocaal ILC in een gebied van 7,3 cm.
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Consequenties voor de therapeutische benadering van ILC
De goede overeenstemming van MRI bevindingen met pathologie en de goede detectie van 
additionele tumor foci heeft een enorme impact op het therapeutisch beleid bij patiënten met 
een ILC. Omdat de primaire therapie bij borstkanker, zowel bij ILC als IDC, meestal chirurgisch 
is, verandert de therapie vaak in een uitgebreidere operatie. Het chirurgisch beleid verandert in 
28% van de patiënten (95% BI 20-39%) [27,36,38,39,59,61]. In 12-33% van de patiënten wordt 
toch een mastectomie uitgevoerd terw ijl initieel een borstsparende operatie was gepland 
[36,38,39,43,59,61]. Een therapeutische wijziging richting minder uitgebreid opereren komt 
ook voor als gevolg van betere afgrenzing van de tumor, maar in een substantieel kleiner deel 
van de patiënten (ongeveer 5%) [43]. Als gevolg hiervan is geschat dat in totaal in 15-20 % van 
de patiënten als gevolg van de MRI de primaire therapie wijzigt van een borst sparende operatie 
in een mastectomie [63]. Daarnaast kan preoperatieve MRI patiënten doorverwijzen richting 
primaire (neoadjuvante) chemotherapie, of juist van chemotherapie toch naar chirurgie, 
waarbij MRI ook kan worden gebruikt om het effect van de chemotherapie te evalueren (fig 9). 
Ongeveer 88% (95% BI 75-95%) van de beleidswijzigingen worden achteraf correct geacht na 
pathologische analyse van het specimen [27].
%
Fig 9: Twee subtractie beelden van de mammae van een 47 jaar oude vrouw die zich presenteerde 
met een T4 ILC in de linker mamma. Bij het initiele MRI onderzoek (A) is een grote diffuui groeiende 
tumor zichtbaar met betrokkenheid van de huid (pijlkop). De patiente 'werd initieel behandeld 
met neoadjuvante chemotherapie. Op de controle MRI (B) is helaas zichtbaar dat de tumor hier 
niet goed op heeft gereageerd, maar in plaats daarvan is gegroeid (terwijl patiente veel dunner is 
geworden. Verder is ook de ingiuie in de huid durdelijk toegenomen (gebogen pijl). Als gevolg van 
deze bevindingen is een nood mastectomie uitgevoerd.
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Samenvattend:
• Preoperatieve MRI veranderd het chirurgisch beleid in 28% van de patiënten met ILC.
• De primaire therapie wijzigt van een borst sparende operatie in een mastectomie in 
15 to t 20% van de patiënten.
• Gebaseerd op pathologische evaluatie van het specimen is 88% van de door MRI 
geïnduceerde beleidsveranderingen correct.
Het effect van preoperatieve mamma MRI op de u itkom st van de behandeling in patiënten 
met ILC
Tot dusver is er geen bewijs dat suggereert dat patiënten met ILC die een MRI hebben ondergaan 
langer blijven leven dan patiënten zonder MRI. De 2 studies die zijn verricht naar het effect van 
MRI op het voorkomen van recidief en verbetering van de overleving hebben beiden niet specifiek 
naar ILC gekeken, bovendien konden deze studies niet aantonen dat MRI resulteert in een 
verbeterde overleving in de hele groep van patiënten met borstkanker [64,65]. De frequentie van 
recidief na borstsparende therapie en radiotherapie is thans gedaald to t 0.6-1% per jaar. Dit lijkt 
acceptabel, we kunnen dan ook nauwelijks verwachten dat preoperatieve MRI in alle patiënten 
dit getal verder doet afnemen. Het impliceert, dat in ieder geval een deel van de additionele 
laesies, die met MRI worden gedetecteerd, na incomplete chirurgie adequaat worden behandeld 
met radio- en chemotherapie. Toch zijn de gerapporteerde re-excisie percentages, noodzakelijk 
na niet radicale tumor excisie, waarbij er meer dan focaal tumor in de snijranden aanwezig is, 
onacceptabel hoog (29-67%) [66-70]. Daar komt nog eens bij dat 16-48% van de patiënten die 
initieel borstsparend wordt geopereerd uiteindelijk toch een mastectomie ondergaat omdat de 
sparende operatie niet radicaal was [70-75].
Deze feiten zijn natuurlijk uiterst pijnlijk voor patiënten, die ook al om moeten gaan met het feit 
dat ze borstkanker hebben. Bovendien wordt het cosmetisch resultaat slechter na re-excisie dan 
wanneer de operatie ineens slaagt. [76].
Omdat het duidelijk is dat MRI de beste, momenteel voorhanden zijnde, diagnostische modaliteit 
is voor de evaluatie van ILC is het niet de vraag of de tumoruitbreiding goed is afgebeeld, maar of 
de behandelend chirurg in staat is deze informatie te gebruiken voor het optimaal behandelen 
van de patiënt. Het grote percentage behandelingen dat wordt veranderd naar aanleiding van de 
MRI is alleen acceptabel als het patiënten direct verwijst naar de optimale therapie (borstsparende 
chirurgie of mastectomie). Hierbij moeten patiënten die zonder MRI voor een mammasparende 
operatie in aanmerking waren gekomen naar aanleiding van de MRI niet onnodig een mastectomie 
ondergaan. Daarvoor moet de chirurg in staat zijn om met de 3D MRI beelden in plaats van de 
2D mammografieën te werken. Dit vereist training en kunde. Het is bovendien essentieel om in 
gedachten het 3D beeld te converteren van de MRI positie, in buikligging met hangende borsten, 
naar de chirurgische positie in rugligging. Hierbij moet in gedachten rekening gehouden worden 
met de beweging van het mammaweefsel in alle richtingen.
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Pas recent is de eerste studie gepubliceerd waarin re-excisie ratios retrospectief zijn geëvalueerd 
in 267 patiënten waarvan 99 patiënten een preoperatieve MRI hebben ondergaan [63]. 
Honderdvijfenveertig patiënten ondergingen primair een borstsparende operatie, 90 zonder 
preoperatieve MRI en 55 met preoperatieve MRI. Re-excisie was noodzakelijk in 24 patiënten 
(27%) zonder preoperatieve MRI en in 5 patiënten (9%) met preoperatieve MRI. De oddsratio 
voor re-excisie zonder preoperatieve MRI is 3.64 (95% BI 1.30 - 10.20). Met andere woorden, 
dit betekent dat patiënten die geen preoperatieve MRI ondergingen een meer dan 3,5 maal 
grotere kans hadden een re-excisise te ondergaan (in een populatie waarin zowel radiologen 
als chirurgen gewend zijn om met MRI te werken). In de groep zonder preoperatieve MRI was de 
kans om uiteindelijk toch een mastectomie te ondergaan 23%, terw ijl d it in de groep patiënten 
met een preoperatieve MRI slechts in 7% het geval was. Het uiteindelijke percentage patiënten 
dat een mastectomie onderging was zelfs lager in de groep die wel een preoperatieve MRI 
onderging dan in de groep die geen preoperatieve MRI had gehad (48 vs 59%), hoewel dit 
de statistische grens voor significantie niet haalde. Tenslotte bleek dat de totale behandeltijd 
(ongeveer 42 dagen) niet afhankelijk was van het wel o f niet uitvoeren van een preoperatieve 
MRI, maar wel langer werd wanneer re-excisie noodzakelijk was.
Momenteel zijn er slechts 2 andere studies gepubliceerd die het effect van preoperatieve MRI 
op het chirurgisch bereiken van schone snijvlakken hebben geëvalueerd [77,78]. Geen van 
deze studies heeft zich specifiek op ILC gericht. Pengel et al. hebben 52 patiënten met ILC 
geïncludeerd, waarvan de helft preoperatieve MRI had ondergaan [78]. De snijranden waren 
meer dan focaal niet vrij (de indicatie voor re-excisie) in 3 van de 26 patiënten (12%) met 
preoperatieve MRI en 5 van de 26 patiënten (19%) zonder preoperatieve MRI. In deze studie is 
de totale re-excisie ratio (veel lager dan in de eerder beschreven studie door de grote fractie 
patiënten met IDC) in de groep patiënten zonder preoperatieve MRI meer dan twee keer zo 
hoog als in de groep patiënten die wel pre-operatieve MRI ondergingen (10.6% vs. 5%). De 
auteurs verrichtten echter geen statistische analyse van de re-excisie ratio. Bleicher et al. 
rapporteren niet voldoende data om gegevens over ILC te extraheren, maar rapporteren over 
de hele linie geen reductie in het percentage positieve snijranden, noch in het aantal patiënten 
dat uiteindelijk mastectomie onderging [77]. Blijkbaar was men in deze groep dus niet in staat 
de toegenomen kennis, verkregen met de MRI, om te zetten in profijt voor de patiënt. Dit maakt 
de noodzaak voor training en ervaring in het gebruik van MRI, zowel voor radiologen als voor 
chirurgen extra duidelijk.
Samenvattend:
• Preoperatieve MRI bij patiënten met ILC kan mogelijk het percentage re-excisies 
reduceren van 27% to t 9%.
• Preoperatieve MRI bij patiënten met ILC leidt niet to t een toename van het uiteindelijke 
aantal mastectomieën.
• Preoperatieve MRI bij patiënten met ILC verlengt de totale behandelduur niet.
• Het succes van preoperatieve MRI is sterk afhankelijk van de ervaring van zowel 
radiologen als chirurgen met mamma MRI.
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Evaluatie van de contra-laterale mamma met MRI in patiënten m et ILC
Naast het stadieren van de bekende tumor heeft preoperatieve mamma MRI een tweede 
doel, dat mogelijk zelfs belangrijker is. Volgens Arpino et al. is een synchrone tumor in de 
contralaterale mamma aanwezig in 20.9% van de patiënten met ILC, vergeleken met 11.2% 
van de patiënten met IDC [79]. In totaal wordt geschat dat preoperatieve MRI in ongeveer 
4% van de patiënten een synchrone contralaterale tumor detecteert, die niet zichtbaar is met 
andere beeldvormende modaliteiten [80]. Het zal niet verbazen, dat het percentage synchrone 
contralaterale tumoren bij patiënten met ILC, alleen gedetecteerd met MRI, bijna tweemaal zo 
hoog is als bij patiënten met IDC. Momenteel wordt d it geschat op 7% (95% BI 4-12%) [27,34­
37,39,57,60,61,80] (fig 10). Dit is onafhankelijk van de grootte van de ipsilaterale tumor en 
maakt dus duidelijk dat preoperatieve MIRI geïndiceerd is in alle patiënten met ILC, niet alleen 
de groep die initieel een borstsparende operatie ondergaat.
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Fig 10: Subtractie MRI beeld van beide mammae van een 48 jarige vrouw die zich presenteerde met 
een palpabele zwelling in de linker mamma. Bij mammografie en echo (niet afgebeeld) werd een ILC 
van maximal 1,5 em gedetenteerd. Op MRI is een multifocale turneerzichtbaan oven een gebied van 
3,4 cm (pijl kop). Belangrijkee nog is dat de MRI een tweede ILC in de contralaterale mamma laat zien 
(gebogen pijl), welke middels controle echografie ook histologisch werd bewezen.
Hetishierbij wel belangrijk datmenzich realiseert dat de specificiteitvanMRIbij het screenen van 
de contralaterale mamma slecht 50% bedraagt [80]. Histologische verificatie van middels MRI 
gedetecteerde laeeies is dus essentieel (net als de verificatie van iedere lansie in de ipsilaterale 
borst die het chirurgisch beleid sterk zal beïnvloeden). Echo controle kan echogeleide biopsie 
mogelijk maken in ongeveer 50% van de patiënten [81,82]. MRI geleide biopsie is een veilige, 
snelle, eenvoudige en conclusieve manier om de rest te evalueren, maar moet wel eenvoudig 
beschikbaar zijn [83,84] (fig 7).
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De kracht en de zwakte van door middel van MRI gedetecteerde contralaterale carcinomen 
is dat het in de regel kleine tumoren betreft. Het is voor mammacarcinomen in het algemeen 
onduidelijk in hoeverre deze contralaterale carcinomen de prognose beïnvloeden in de 
aanwezigheid van een groter ipsilateraal carcinoom en data specifiek voor ILC zijn volledig 
afwezig. Contralaterale tumoren worden, anders dan additionele ipsilaterale tumor foci die 
hoe dan ook met radiotherapie worden behandeld, wanneer zij niet worden ontdekt, niet 
behandeld. Tegelijkertijd kan adjuvante systemische therapie, wanneer d it wordt gegeven, 
misschien voorkomen dat de contralaterale carcinomen ooit klinisch relevant worden. Men zou 
verwachten dat de incidentie van metachrone contralaterale tumoren afneemt in patiënten die 
preoperatieve MRI ondergaan ten tijde van de ipsilaterale tumor detectie. Helaas rapporteren 
de twee studies over d it onderwerp hebben conflicterende resultaten. Fischer et al. rapporteren 
een reductie in de frequentie van metachrone contralaterale carcinomen van 4% naar 1.7% 
als gevolg van preoperatieve MRI, terwijl Solin et al. een incidentie van 6% contralaterale 
carcinomen rapporteren onafhankelijk van het al dan niet uitvoeren van preoperatieve MRI 
[64,65].
Niettemin wordt adjuvante systemische therapie alleen over het algemeen niet gezien als een 
curatieve techniek voor mamma carcinomen. Omdat recent is aangetoond dat vroege detectie 
van tweede tumoren (zowel ipsilateraal als contralateraal) in het asymptomatische stadium bij 
vrouwen met een mammacarcinoom in de voorgeschiedenis de relatieve overleving verhoogt 
met 27 to 47% [85], kunnen we momenteel alleen maar aannemen, dat vroege detectie van 
contralaterale carcinomen met MRI inderdaad de overleving van patiënten verbetert, hoewel 
de omvang van dit effect niet duidelijk is.
Samenvattend:
• Preoperatieve MRI detecteert mammografisch occulte carcinomen in de contralaterale 
borst in 7% van de patiënten met bewezen ipsilateraal ILC.
• Het is niet zeker of preoperatieve MRI het voorkomen van metachrone contralaterale 
tumoren vermindert. Voor patiënten met ILC is geen data beschikbaar.
• Er is indirect bewijs, dat vroege detectie van contralaterale tumoren leidt to t een relatieve 
overlevingswinst.
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Huidige status van mamma MRI bij patiënten met ILC, tekortkom ingen en toekom st 
perspectieven
Tot dusver hebben meerdere studies laten zien dat MRI goed in staat is om ILC af te beelden en 
dat de MRI beelden beter correleren met pathologische analyse dan enige andere, momenteel 
beschikbare, beeldvormende modaliteit. Het uitvoeren van MRI beïnvloedt het diagnostisch 
denken van de behandelaren en beïnvloedt het daarop volgende therapeutische handelen. 
Het feit dat MRI het therapeutisch handelen beïnvloedt staat bekend als nivo 4 bewijs van de 
waarde [86]. Niettemin betekent d it niet automatisch dat de patiënte er ook beter van wordt, 
wat bekend staat als nivo 5 bewijs. Op dit vijfde nivo is de reductie in de noodzaak van re- 
excisies de vroegst mogelijke uitkomstmaat, die kan worden geëvalueerd. Daarnaast vallen 
ook bijvoorbeeld een reductie van ongewenste neveneffecten van therapie en een reductie 
in het voorkomen van locale recidieven o f metachrone carcinomen in deze categorie. Zelfs de 
ultieme winst voor de patiënte, namelijk een verbeterde overleving, of beter nog een toename 
van het aantal 'quality adjusted life years' (levensjaren gecorrigeerd voor kwaliteit), valt in deze 
categorie. Dit is niet voor niets vaak de primaire uitkomstmaat van goed opgezette studies. 
Slechts zeer recent zijn de eerste studies die nivo 5 parameters als een functie van het uitvoeren 
van preoperatieve MRI analyseren gepubliceerd [63-65,77,78]. Slechts een van deze studies 
heeft zich specifiek gericht op patiënten met een ILC [63]. Deze retrospectieve studie, waarvan 
de resultaten in de voorgaande tekst zijn besproken, laat zien dat preoperatieve MRI in handen 
van een behandelend team met ervaring in het gebruik van MRI het percentage re-excisies 
kan reduceren. De studie heeft het effect op tumor recidief, het voorkomen van metachrone 
contralaterale carcinomen of overleving niet geanalyseerd. Ook kosteneffectiviteit van 
preoperatieve MRI is een nog niet geëvalueerd onderwerp. Voor al deze zaken is slechts indirect 
bewijs beschikbaar.
In andere woorden, het nivo 5 bewijs voor het uitvoeren van preoperatieve MRI bij alle patiënten 
met ILC is slechts van gemiddelde kwaliteit en vervolg studies zijn essentieel. Bewijs op het 6e 
(en hoogste) nivo, dat stelt dat het uitvoeren van preoperatieve MRI in patiënten met een ILC 
goed is voor de maatschappij als geheel en dus afhankelijk is van een kosteneffectiviteitanalyse 
vanuit een maatschappelijk oogpunt is volkomen afwezig omdat d it nooit is onderzocht. 
Niettemin ben ik van mening dat het momenteel voor handen zijnde bewijs voor het uitvoeren 
van preoperatieve MRI in patiënten met ILC substantieel is. De consequenties voor patiënten 
zijn groot. Preoperatieve MRI kan niet alleen de kans op een re-excisie verminderen, maar 
leidt mogelijk zelfs to t een verbeterde overleving. Aan de andere kant zijn de nadelen van het 
uitvoeren van preoperatieve MRI bij alle patiënten met ILC, wanneer preoperatieve MRI correct 
wordt toegepast, beperkt to t de kans op een additionele biopsie. Daarom is, gebaseerd op de 
momenteel voorhanden zijnde data, het uitvoeren van preoperatieve MRI in alle patiënten met 
ILC sterk aanbevolen.
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Toekomst perspectieven van mamma MRI, een bredere k ijk
Hoewel de waarde van preoperatieve MRI in patiënten met ILC duidelijk mag zijn, is d it slechts 
ten dele waar voor patiënten met andere typen mamma carcinoom. Bij patiënten met een IDC 
zijn de gerapporteerde re-excisie percentages veel lager en hoewel d it percentage in ervaren 
handen waarschijnlijk teruggebracht kan worden door het uitvoeren van preoperatieve MRI, 
zoals gerapporteerd door Pengel et al. die een reductie van 8 naar 2% positieve snijranden liet 
zien [78], is deze winst van een geheel andere orde van grootte dan bij ILC. Hetzelfde geldt voor 
de detectie van contralaterale tumoren, de frequentie is met ongeveer 4% slechts de helft van 
die bij ILC [80]. Als gevolg hiervan is de mogelijke winst in overleving kleiner. Niettemin zijn deze 
aantallen ook nog altijd te groot om geheel te negeren en het zal daarom ook zeer ingewikkeld 
zijn om een MRI te weigeren indien een goed geïnformeerde patiënte hierom verzoekt.
Daarnaast is het duidelijk bewezen dat screening met MRI en mammografie bij patiënten 
met een lifetime risico van 15% o f meer, meer carcinomen detecteert en de frequentie van 
interval carcinomen reduceert [45,87,88]. Uit een recente meta-analyse van Warner et al. 
blijkt bovendien dat de toegevoegde waarde van mammografie in deze situatie slechts heel 
beperkt is [89]. Daarom zou feitelijk screening met MRI geprefereerd moeten worden boven 
screening met mammografie. Omdat recent is gebleken dat MRI minstens even goed is (en 
misschien zelfs beter) als mammografie in de detectie van DCIS is d it niet langer een argument 
om mammografie boven MRI te verkiezen. Dit wordt in meer detail bediscussieerd in Appendix 
1 [90]. Vanwege deze resultaten en de wetenschap dat het lifetime risico van de gemiddelde 
Nederlandse vrouw met 12-13% slechts beperkt lager is dan het lifetime risico in de geteste 
hoogrisico populaties [91], is het logisch om aan te nemen dat MRI in de nabije toekomst van 
de mammascreening een belangrijke rol zal vervullen [92,93].
Een van de beperkende factoren is altijd de beperkte beschikbaarheid van MRI geleide biopten 
geweest, maar tegenwoordig is deze techniek veel breder beschikbaar en zou momenteel 
toegankelijk moeten zijn voor iedere mammaradioloog [83]. Indien de screening vooral wordt 
uitgevoerd met MRI, dan is de discussie over de zin of onzin van preoperatieve MRI natuurlijk 
obsoleet. De meeste tumoren zullen dan immers door middel van MRI gedetecteerd worden.
De belangrijkste beperkende factor voor uitgebreide implementatie van mamma MRI in de 
huidige radiologische praktijk is de nog immer hoge kostprijs van het onderzoek. Het is daarom 
essentieel dat de kosten van MR-onderzoek omlaag gaan en de scanprotocollen sneller en 
beter gestandaardiseerd worden. Dit is helaas nog werk in uitvoering.
Een meer experimenteel idee is het gebruik van MRI om de prognose van patiënten met 
mamma carcinoom te bepalen. Het feit dat mamma MRI een techniek is die zwaar leunt op 
fysiologische principes maakt het mogelijk om fysiologische parameters in tumor en normaal 
weefsel te observeren. Omdat er veel verschillende methoden zijn om een tumor te analyseren
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(b.v. contrast aankleuring, diffusie, metaboliet kaarten) kunnen verschillende aspecten van de 
tumor biologie worden geëvalueerd. Het zou daarom mogelijk moeten zijn om het gedrag van 
de tumor en de potentie om uit te zaaiien te bepalen. Het grote voordeel van deze techniek 
boven de standaard pathologische analyse is dat de hele tumor geëvalueerd kan worden in 
plaats van slechts een aselecte steekproef. De recent gerapporteerde correlatie van contrast 
aankleuring en necrose met het zogenaamde"driemaal negatieve" (oestrogeen receptor negatief, 
progesteron receptor negatief en Her2/Neu negatief) subtype mammacarcinoom is een eerste 
stap in deze richting [94]. Studies naar veranderingen in aankleuringspatroon, water diffusie 
en choline spectrum bij patiënten die worden behandeld met neoadjuvante chemotherapie 
zijn een tweede, reeds meer geaccepteerd, voorbeeld van deze mogelijkheden [95-100]. Een 
nieuwe dimensie hierbij is het gebruik van contrast aankleuring en diffusie gewogen MRI om 
reeds voor de aanvang van therapie de tumor respons te voorspellen [101,102]. Dit zou in de 
toekomst misschien een beter op de patiënt afgestemde chemotherapeutische behandeling 
mogelijk kunnen maken.
Ten slotte kan de betere evaluatie van tumor uitbreiding, zoals mogelijk met MRI, ingezet 
worden voor het optimaliseren van behandelprotocollen. Vooral het gebruik van radiotherapie, 
essentieel bij de huidige mamma sparende therapie, maar op zich wel een behandeling met 
(ernstige) bijwerkingen, zou misschien kunnen worden aangepast of zelfs niet verricht hoeven 
te worden in patiënten waarbij op de MRI geen additionele tumor foci zichtbaar zijn [103,104]. 
Daarnaast zou MRI gebruikt kunnen worden voor het geleiden van niet-operatieve focale 
behandelingen van mammacarcinomen, zoals Radio Frequency Ablation (RFA), cryotherapie, 
laser therapie, gerichte echo of vacuüm excisie van de tumor [105]. Toch zal het waarschijnlijk 
nog lang duren voor d it soort behandelingen als volwaardige alternatieven voor chirurgie 
worden gezien.
206
Nederlandse samenvatting, algemene discussie en conclusies
References
1. Holland R, Mravunac M, Hendriks JH, Bekker BV: So-called interval cancers of the breast. Pathologic and 
radiologic analysis o f sixty-four cases. Cancer 1982;49(12):2527-33.
2. Holland R, Hendriks JH, Mravunac M: Mammographically occult breast cancer. A pathologic and radiologic 
study. Cancer 1983;52(10):1810-9.
3. Peeters PH, Verbeek AL, Hendriks JH, Holland R, Mravunac M, Vooijs GP: The occurrence o f interval cancers in the 
Nijmegen screening programme. Br J Cancer 1989;59(6):929-32.
4. Porter GJ, Evans AJ, Burrell HC, Lee AH, Ellis IO, Chakrabarti J: Interval breast cancers: prognostic features and 
survival by subtype and time since screening. J Med Screen 2006;13(3):115-22.
5. Garnett S, Wallis M, Morgan G: Do screen-detected lobular and ductal carcinoma present with different 
mammographic features? Br J Radiol 2009;82(973):20-7.
6. Hilleren DJ, Andersson IT, Lindholm K, Linnell FS: Invasive lobular carcinoma: mammographic findings in a 10-
year experience. Radiology 1991;178(1):149-54.
7. Adler OB, Engel A: Invasive lobular carcinoma. Mammographic pattern. Rofo 1990;152(4):460-2.
8. Krecke KN, Gisvold JJ: Invasive lobular carcinoma of the breast: mammographic findings and extent of disease 
at diagnosis in 184 patients. AJR Am J Roentgenol 1993;161(5):957-60.
9. Le Gal M, Ollivier L, Asselain B, Meunier M, Laurent M, Vielh P, Neuenschwander S: Mammographic features of 
455 invasive lobular carcinomas. Radiology 1992;185(3):705-8.
10. Evans WP, Warren Burhenne LJ, Laurie L, O'Shaughnessy KF, Castellino RA: Invasive lobular carcinoma of the 
breast: mammographic characteristics and computer-aided detection. Radiology 2002;225(1):182-9.
11. Helvie MA, Paramagul C, Oberman HA, Adler DD: Invasive lobular carcinoma. Imaging features and clinical 
detection. Invest Radiol 1993;28(3):202-7.
12. Tan SM, Behranwala KA, Trott PA, Nasiri NA, Moskovic E, Brown G, King DM, Sacks NP, Gui GP: A retrospective 
study comparing the individual modalities o f trip le assessment in the pre-operative diagnosis o f invasive 
lobular breast carcinoma. Eur J Surg Oncol 2002;28(3):203-8.
13. Uchiyama N, Miyakawa K, Moriyama N, Kumazaki T: Radiographic features of invasive lobular carcinoma of the 
breast. Radiat Med 2001;19(1):19-25.
14. Mendelson EB, Harris KM, Doshi N, Tobon H: Infiltrating lobular carcinoma: mammographic patterns with 
pathologic correlation. AJR Am J Roentgenol 1989;153(2):265-71.
15. Newstead GM, Baute PB, Toth HK: Invasive lobular and ductal carcinoma: mammographic findings and stage at 
diagnosis. Radiology 1992;184(3):623-7.
16. Dummin LJ, Cox M, Plant L: Prediction of breast tum or size by mammography and sonography--A breast screen 
experience. Breast 2007;16(1):38-46.
17. Fasching PA, Heusinger K, Loehberg CR, Wenkel E, Lux MP, Schrauder M, Koscheck T, Bautz W, Schulz-Wendtland 
R, Beckmann MW, Bani MR: Influence of mammographic density on the diagnostic accuracy of tum or size 
assessment and association with breast cancer tum or characteristics. Eur J Radiol 2006;60(3):398-404.
18. Heusinger K, Lohberg C, Lux MP, Papadopoulos T, Im hoff K, Schulz-Wendtland R, Beckmann MW, Fasching PA: 
Assessment o f breast cancer tum or size depends on method, histopathology and tum or size itself*. Breast
Cancer Res Treat 2005;94(1):17-23.
19. Veltman J, Boetes C, van Die L, Bult P, Blickman JG, Barentsz JO: Mammographic detection and staging of 
invasive lobular carcinoma. Clin Imaging 2006;30(2):94-8.
20. Butler RS, Venta LA, Wiley EL, Ellis RL, Dempsey PJ, Rubin E: Sonographic evaluation of infiltrating lobular 
carcinoma. AJR Am J Roentgenol 1999;172(2):325-30.
207
Chapter 11
21. Cawson JN, Law EM, Kavanagh AM: Invasive lobular carcinoma: sonographic features of cancers detected in a 
BreastScreen Program. Australas Radiol 2001;45(1):25-30.
22. Chapellier C, Balu-Maestro C, Bleuse A, Ettore F, Bruneton JN: Ultrasonography o f invasive lobular carcinoma of 
the breast: sonographic patterns and diagnostic value: report o f 102 cases. Clin Imaging 2000;24(6):333-6.
23. Rissanen T, Tikkakoski T, Autio AL, paja-Sarkkinen M: Ultrasonography of invasive lobular breast carcinoma. Acta 
Radiol 1998;39(3):285-91.
24. Selinko VL, Middleton LP, Dempsey PJ: Role o f sonography in diagnosing and staging invasive lobular carcinoma. 
J Clin Ultrasound 2004;32(7):323-32.
25. Skaane P, Skjorten F: Ultrasonographic evaluation o f invasive lobular carcinoma. Acta Radiol 1999;40(4):369-75.
26. Watermann DO, Tempfer C, Hefler LA, Parat C, Stickeler E: Ultrasound morphology o f invasive lobular breast 
cancer is different compared with other types o f breast cancer. Ultrasound Med Biol 2005;31(2):167-74.
27. Mann RM, Hoogeveen YL, Blickman JG, Boetes C: MRI compared to conventional diagnostic work-up in the 
detection and evaluation o f invasive lobular carcinoma of the breast: a review of existing literature. Breast 
Cancer Res Treat. 2008 Jan;107(1):1-14.
28. Paramagul CP, Helvie MA, Adler DD: Invasive lobular carcinoma: sonographic appearance and role o f sonography 
in improving diagnostic sensitivity. Radiology 1995;195(1):231-4.
29. Evans N, Lyons K: The use of ultrasound in the diagnosis o f invasive lobular carcinoma o f the breast less than 10 
mm in size. Clin Radiol 2000;55(4):261-3.
30. Mesurolle B, Mignon F, riche-Cohen M, Goumot PA: [Invasive infra centimetric breast lobular carcinoma: 
ultrasonographic features]. J Radiol 2003;84(2 Pt 1):147-51.
31. Golshan M, Fung BB, Wiley E, Wolfman J, Rademaker A, Morrow M: Prediction o f breast cancer size by ultrasound, 
mammography and core biopsy. Breast 2004;13(4):265-71.
32. Pritt B, Ashikaga T, Oppenheimer RG, Weaver DL: Influence of breast cancer histology on the relationship 
between ultrasound and pathology tumor size measurements. Mod Pathol 2004;17(8):905-10.
33. Tresserra F, Feu J, Grases PJ, Navarro B, Alegret X, Fernandez-Cid A: Assessment o f breast cancer size: sonographic 
and pathologic correlation. J Clin Ultrasound 1999;27(9):485-91.
34. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB: Diagnostic accuracy of 
mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. 
Radiology 2004;233(3):830-49.
35. Boetes C, Veltman J, van Die L, Bult P, Wobbes T, Barentsz JO: The role of MRI in invasive lobular carcinoma. Breast
Cancer Res Treat 2004;86(1):31-7.
36. Fabre DN, Boulet P, Prat X, Charra L, Lesnik A, Taourel P: [Breast MRI in invasive lobular carcinoma: diagnosis and 
staging]. J Radiol 2005;86(9 Pt 1):1027-34.
37. Francis A, England DW, Rowlands DC, Wadley M, Walker C, Bradley SA: The diagnosis o f invasive lobular breast 
carcinoma. Does MRI have a role? Breast 2001;10(1):38-40.
38. Kneeshaw PJ, Turnbull LW, Smith A, Drew PJ: Dynamic contrast enhanced magnetic resonance imaging aids the 
surgical management o f invasive lobular breast cancer. Eur J Surg Oncol 2003;29(1):32-7.
39. Munot K, Dall B, Achuthan R, Parkin G, Lane S, Horgan K: Role o f magnetic resonance imaging in the diagnosis 
and single-stage surgical resection o f invasive lobular carcinoma of the breast. Br J Surg 2002;89(10):1296-301.
40. Schelfout K, Van GM, Kersschot E, Verslegers I, Biltjes I, Leyman P, Colpaert C, Thienpont L, Van Den HJ, Gillardin 
JP, Tjalma W, Buytaert P, De SA: Preoperative breast MRI in patients w ith invasive lobular breast cancer. Eur Radiol
2004;14(7):1209-16.
208
Nederlandse samenvatting, algemene discussie en conclusies
41. Sittek H, Perlet C, Untch M, Kessler M, Reiser M: [Dynamic MR-mammography in invasive lobular breast cancer]. 
Rontgenpraxis 1998;51(7):235-42.
42. Brem RF, Ioffe M, Rapelyea JA, Yost KG, Weigert JM, Bertrand ML, Stern LH: Invasive lobular carcinoma: 
detection w ith mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol
2009;192(2):379-83.
43. Caramella T, Chapellier C, Ettore F, Raoust I, Chamorey E, Balu-Maestro C: Value of MRI in the surgical planning of 
invasive lobular breast carcinoma: a prospective and a retrospective study of 57 cases: comparison with physical 
examination, conventional imaging, and histology. Clin Imaging 2007;31(3):155-61.
44. Mann RM, Veltman J, Barentsz JO, Wobbes T, Blickman JG, Boetes C: The value of MRI compared to mammography 
in the assessment o f tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol 2008;34(2):135-42.
45. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, 
Warner E, Yaffe M, Andrews KS, Russell CA: American Cancer Society guidelines for breast screening with MRI as 
an adjunct to mammography. CA Cancer J Clin 2007;57(2):75-89.
46. Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard 
AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de 
Koning HJ, Rutgers EJ, Klijn JG: Tumor characteristics and detection method in the MRISC screening program for 
the early detection of hereditary breast cancer. Breast Cancer Res Treat 2007;102(3):357-63.
47. Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, 
Barclay J, Schnall MD: Development, standardization, and testing of a lexicon for reporting contrast-enhanced 
breast magnetic resonance imaging studies. J Magn Reson Imaging 2001;13(6):889-95.
48. Kim SJ, Morris EA, Liberman L, Ballon DJ, La Trenta LR, Hadar O, Abramson A, Dershaw DD: Observer variability 
and applicability of BI-RADS terminology for breast MR imaging: invasive carcinomas as focal masses. AJR Am J 
Roentgenol 2001;177(3):551-7.
49. Stoutjesdijk MJ, Futterer JJ, Boetes C, van Die LE, Jager G, Barentsz JO: Variability in the description of 
morphologic and contrast enhancement characteristics o f breast lesions on magnetic resonance imaging. 
Invest Radiol 2005;40(6):355-62.
50. Levrini G, Mori CA, Vacondio R, Borasi G, Nicoli F: MRI patterns o f invasive lobular cancer: T1 and T2 features. 
Radiol Med 2008;113(8):1110-25.
51. Yeh ED, Slanetz PJ, Edmister WB, Talele A, Monticciolo D, Kopans DB: Invasive lobular carcinoma: spectrum of 
enhancement and morphology on magnetic resonance imaging. Breast J 2003;9(1):13-8.
52. Trecate G, Tess JD, Vergnaghi D, Bergonzi S, Mariani G, Ferraris C, Musumeci R: Lobular breast cancer: how useful 
is breast magnetic resonance imaging? Tumori 2001;87(4):232-8.
53. Qayyum A, Birdwell RL, Daniel BL, Nowels KW, Jeffrey SS, Agoston TA, Herfkens RJ: MR imaging features of 
infiltrating lobular carcinoma of the breast: histopathologic correlation. AJR Am J Roentgenol 2002;178(5):1227-32.
54. Newstead, G. M., Arkani, S., Abe, H., Schnidt, R., Sennett, C., and Yang, C.: Dynamic Breast MR Imaging: Comparison 
o f Kinetic and Morphologic Characteristics o f Malignant Lesions by Tumor Type and Grade. RSNA 2005.
55. Mann, R. M., Huisman, H., Veltman, J., Stoutjesdijk, M. J., and Boetes, C.: Morphologic and dynamic differences 
between invasive ductal and invasive lobular carcinomas o f the breast. ISMRM 2008.
56. Dietzel, M., Baltzer, P. A., Herzog, A., Vag, T., and Kaiser, W. A.: MRI o f Invasive Lobular Carcinoma - Prospective 
study comparing Invasive Lobular and Ductal Carcinomas vs. benign lesions in 891 cases. ECR 2009.
57. Kepple J, Layeeque R, Klimberg VS, Harms S, Siegel E, Korourian S, Gusmano F, Henry-Tillman RS: Correlation 
o f magnetic resonance imaging and pathologic size o f infiltrating lobular carcinoma o f the breast. Am J Surg
2005;190(4):623-7.
58. Onesti JK, Mangus BE, Helmer SD, Osland JS: Breast cancer tum or size: correlation between magnetic resonance 
imaging and pathology measurements. Am J Surg 2008;196(6):844-8.
209
Chapter 11
59. Rodenko GN, Harms SE, Pruneda JM, Farrell RS, Jr., Evans WP, Copit DS, Krakos PA, Flamig DP: MR imaging in 
the management before surgery o f lobular carcinoma of the breast: correlation with pathology. AJR Am J 
Roentgenol 1996;167(6):1415-9.
60. Diekmann F, Diekmann S, Beljavskaja M, Bick U, Taupitz M, Blohmer JU, Winzer KJ, Hamm B: [Preoperative MRT of 
the breast in invasive lobular carcinoma in comparison with invasive ductal carcinoma]. Rofo 2004;176(4):544-9.
61. Quan ML, Sclafani L, Heerdt AS, Fey JV, Morris EA, Borgen PI: Magnetic resonance imaging detects unsuspected 
disease in patients w ith invasive lobular cancer. Ann Surg Oncol 2003;10(9):1048-53.
62. Weinstein SP, Orel SG, Heller R, Reynolds C, Czerniecki B, Solin LJ, Schnall M: MR imaging of the breast in patients 
with invasive lobular carcinoma. AJR Am J Roentgenol 2001;176(2):399-406.
63. Mann RM, Loo CE, Wobbes T, Bult P, Barentsz JO, Gilhuijs KG, Boetes C: The impact of preoperative breast MRI on 
the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2010 Jan;119(2):415-22
64. Fischer U, Zachariae O, Baum F, von Heyden D, Funke M, Liersch T: The influence of preoperative MRI of the 
breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14(10):1725-31.
65. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD: Relationship of breast magnetic resonance imaging to 
outcome after breast-conservation treatment w ith radiation for women with early-stage invasive breast 
carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26(3):386-91.
66. Keskek M, Kothari M, Ardehali B, Betambeau N, Nasiri N, Gui GP: Factors predisposing to cavity margin positivity 
following conservation surgery for breast cancer. Eur J Surg Oncol 2004;30(10):1058-64.
67. O'Sullivan MJ, Li T, Freedman G, Morrow M: The effect o f multiple reexcisions on the risk o f local recurrence after 
breast conserving surgery. Ann Surg Oncol 2007;14(11):3133-40.
68. Smitt MC, Horst K: Association of clinical and pathologic variables w ith lumpectomy surgical margin status after 
preoperative diagnosis or excisional biopsy o f invasive breast cancer. Ann Surg Oncol 2007;14(3):1040-4.
69. van den Broek N, van der Sangen MJ, van de Poll-Franse LV, van Beek MW, Nieuwenhuijzen GA, Voogd AC: 
Margin status and the risk o f local recurrence after breast-conserving treatment o f lobular breast cancer. Breast 
Cancer Res Treat 2007;105(1):63-8.
70. Waljee JF, Hu ES, Newman LA, Alderman AK: Predictors o f re-excision among women undergoing breast- 
conserving surgery for cancer. Ann Surg Oncol 2008;15(5):1297-303.
71. Dillon MF, Hill AD, Fleming FJ, O 'Doherty A, Quinn CM, McDermott EW, O'Higgins N: Identifying patients at risk 
of compromised margins following breast conservation for lobular carcinoma. Am J Surg 2006;191(2):201-5
72. Hussien M, Lioe TF, Finnegan J, Spence RA: Surgical treatment for invasive lobular carcinoma o f the breast. Breast
2003;12(1):23-35.
73. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ: Infiltrating lobular carcinoma-- a 
comparison o f diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004;13(5):389-96
74. Morrow M, Keeney K, Scholtens D, Wei J, Steel J, Khan SA: Selecting patients for breast-conserving therapy: the 
importance of lobular histology. Cancer 2006;106(12):2563-8.
75. Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, Ku NN, Baekey PA, Cox CE: Tumor biology of 
infiltrating lobular carcinoma. Implications for management. Ann Surg 1995;222(4):549-59.
76. Al-Ghazal SK, Blamey RW, Stewart J, Morgan AA: The cosmetic outcome in early breast cancer treated with 
breast conservation. Eur J Surg Oncol 1999;25(6):566-70.
77. Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, Morrow M: Association of routine pretreatment 
magnetic resonance imaging with time to  surgery, mastectomy rate, and margin status. J Am Coll Surg
2009;209(2):180-7.
210
Nederlandse samenvatting, algemene discussie en conclusies
78. Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, Bartelink H, Rutgers EJ, Gilhuijs KG: The impact 
o f preoperative MRI on breast-conserving surgery o f invasive cancer: a comparative cohort study. Breast Cancer 
Res Treat 2009;116(1):161-9.
79. Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma o f the breast: tumor characteristics and 
clinical outcome. Breast Cancer Res 2004;6(3):R149-R156.
80. Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, Warren RM, Ciatto S: Magnetic Resonance Imaging 
Screening of the Contralateral Breast in Women With Newly Diagnosed Breast Cancer: Systematic Review and 
Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management. J Clin Oncol 2009.
81. LaTrenta LR, Menell JH, Morris EA, Abramson AF, Dershaw DD, Liberman L: Breast lesions detected with MR 
imaging: utility and histopathologic importance o f identification w ith US. Radiology 2003;227(3):856-61.
82. Linda A, Zuiani C, Londero V, Bazzocchi M: Outcome of initially only magnetic resonance mammography- 
detected findings with and w ithout correlate at second-look sonography: distribution according to  patient 
history o f breast cancer and lesion size. Breast 2008;17(1):51-7.
83. Floery D, Helbich TH: MRI-Guided percutaneous biopsy of breast lesions: materials, techniques, success rates, 
and management in patients w ith suspected radiologic-pathologic mismatch. Magn Reson Imaging Clin N Am 
2006;14(3):411-25, viii.
84. Veltman J, Boetes C, Wobbes T, Blickman JG, Barentsz JO: Magnetic resonance-guided biopsies and localizations 
o f the breast: initial experiences using an open breast coil and compatible intervention device. Invest Radiol
2005;40(6):379-84.
85. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW: Early detection o f second breast cancers improves 
prognosis in breast cancer survivors. Ann Oncol 2009;20(9):1505-10.
86. Sardanelli F, Hunink MG, Gilbert FJ, Di LG, Krestin GP: Evidence-based radiology: why and how? Eur Radiol. 2010 
Jan;20(1):1-15.
87. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse
H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, 
Klijn JG: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic 
predisposition. N Engl J Med 2004;351(5):427-37.
88. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani 
SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM: Screening with magnetic resonance 
imaging and mammography o f a UK population at high familial risk o f breast cancer: a prospective multicentre 
cohort study (MARIBS). Lancet 2005;365(9473):1769-78.
89. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D: Systematic review: using magnetic resonance 
imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148(9):671-9.
90. Boetes C, Mann RM: Ductal carcinoma in situ and breast MRI. Lancet 2007;370(9586):459-60.
91. National Breast Cancer Organization Netherlands: Guideline for treatment o f patients w ith breast cancer. 2008. 
Kwaliteitsinstituut voor de gezondheidszorg CBO, available via http://www.oncoline.nl.
92. Hall FM: The rise and impending decline o f screening mammography. Radiology 2008;247(3):597-601.
93. Kuhl CK: The "coming of age" o f nonmammographic screening for breast cancer. JAMA 2008;299(18):2203-5.
94. Uematsu T, Kasami M, Yuen S: Triple-negative breast cancer: correlation between MR imaging and pathologic 
findings. Radiology 2009;250(3):638-47.
95. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY: Predicting pathologic response to 
neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. 
Radiology 2009;251(3):653-62.
211
Chapter 11
96. Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, Gribbestad IS: 
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced 
breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29(6):1300-7.
97. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW: 
Neoadjuvant chemotherapy in breast cancer: early response prediction w ith quantitative MR imaging and 
spectroscopy. Br J Cancer 2006;94(3):427-35.
98. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood 
M: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR 
spectroscopy--a pilot study at 4 T. Radiology 2004;233(2):424-31.
99. Pickles MD, Gibbs P, Lowry M, Turnbull LW: Diffusion changes precede size reduction in neoadjuvant treatment 
of breast cancer. Magn Reson Imaging 2006;24(7):843-7.
100. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW: Role o f dynamic contrast enhanced MRI in monitoring 
early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 
2005;91(1):1-10.
101. Iacconi C, Giannelli M, Marini C, Cilotti A, Moretti M, Viacava P, Picano E, Michelotti A, Caramella D: The role of 
mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: 
a preliminary study. Eur Radiol 2009.
102. Pickles MD, Manton DJ, Lowry M, Turnbull LW: Prognostic value o f pre-treatment DCE-MRI parameters in 
predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. 
Eur J Radiol 2009;71(3):498-505.
103. Prosnitz LR, Horton J, Wallner PE: Accelerated partial breast irradiation: caution and concern from an ASTRO task 
force. Int J Radiat Oncol Biol Phys 2009;74(4):981-4.
104. Tendulkar RD, Chellman-Jeffers M, Rybicki LA, Rim A, Kotwal A, Macklis R, Obi BB: Preoperative breast magnetic 
resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer 2009;115(8):1621-30
105. Kaiser WA, Pfleiderer SO, Baltzer PA: MRI-guided interventions of the breast. J Magn Reson Imaging
2008;27(2):347-55
212
Ductal carcinoma in situ and
breast MRI
Appendix
Carla Boetes 
Ritse M. Mann
Lancet. 2007Aug 11;370(9586):459-60
Appendix 1
In today's Lancet, Christiane Kuhl and colleagues present the results of a large prospective 
assessment of the comparative sensitivity of mammography and MRI for detection of pure 
ductal carcinoma in situ (DCIS) [1]. It is widely believed that mammography is more sensitive 
in detecting DCIS than is MRI. However, Kuhl found that the sensitivity of MRI for DCIS is much 
higher than that of mammography, especially for high-grade lesions, which are thought 
to be more prone to progress to invasive carcinomas. Almost half of all DCIS lesions are 
mammographically occult, and high-grade lesions w ithout necrosis are even less likely to 
be detected. Although these results were unexpected, the pathophysiology of breast cancer 
provides ample justification for the findings.
Before the spread o f screening mammography, about 2% of all detected breast tumours were 
DCIS, yet autopsy studies have shown that almost 9% o f women have undetected DCIS [2]. Since 
the start of screening mammography, the incidence of DCIS has increased nearly ten-fold, and 
about 20% of all tumours detected at screening are now pure DCIS. On the basis of circumstantial 
evidence, almost all invasive carcinomas are believed to begin as DCIS lesions. However, the 
time course of transition from in-situ to invasive carcinoma is unknown, and whether all DCIS 
will ultimately evolve to invasive disease is unclear [3,4]. Nevertheless, treatment o f DCIS by 
complete resection, or, when breast-conserving therapy is used, radiotherapy, is deemed 
appropriate for all DCIS lesions [5].
On mammography, DCIS usually manifests as microcalcifications, which are caused by necrosis 
and subsequent calcification of debris. These calcifications are usually very small, but need 
to be bigger than 100 ^m for mammographic detection. Only 27% of mammographically 
detectable DCIS lesions present with soft-tissue changes on mammography [6]. Recently, 
digital mammography was shown to outperform analogue mammography for the detection 
of breast cancer. However, in a large study by Pisano and colleagues [7], only 60% of in-situ 
lesions could be detected by digital mammography. Despite the increase in DCIS detection 
by mammography, many DCIS do not contain observable calcifications, and will therefore be 
mammographically occult.
The assumption has been that DCIS cannot be detected by MRI, because MRI does not visualise 
calcium and cannot be done at a sufficient resolution. Yet contrast-enhanced breast MRI visualises 
neovascularisation. Normally, the contrast agent is confined to the intravascular space, except in 
places where the vessel wall is corrupted (eg, by neoplasm). In DCIS, neovascularisation occurs; 
however, the vessels formed are more mature than vessels in invasive carcinomas. Therefore 
the typical wash-out patterns, indicative of malignancy, are often absent. Instead, more subtle 
asymmetric enhancement patterns can be seen (fig 1). In high-grade DCIS, microvessel density 
is higher and consequently enhancement is stronger, which explains why these lesions are 
more easily identified on MRI than are low-grade DCIS [8].
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Fig 1: Maximum intensity projection o f subtracted contrast-enhanced breast MRI
In the right breast, non-mass-like enhancement corresponding to area o f grade-2 DCIS is visible.
M RI has a higher sensitivity for DCIS than mammography [9], and about half of contral ateral 
carcinomas detected on MRI are DCIS [10,11]. Kuhl and colleagues' results should therefore be 
expected theoretically.
That only 20% of tumours detected through screening are pure DCIS is disappointing, when 
one keeps in mind that most breast tumours probably evolve from DCIS. The observation 
that MRI detects many DCIS lesions that go unnoticed on mammography implies that some 
invasive carcinomas can be prevented by timely intervention on the basis of MRI findings. As 
such, MRI has the potential to increase survival when used to detect breast cancer. However, 
currently MRI is considered an adjunct to mammography, and all series are biased by the fact 
that there needs to be an indication before MRI is done. For instance, in Kuhl and colleagues' 
study, one in eight women had findings that demanded biopsy. These results would not be 
expected in the general population. Despite the high recall rates, 52% of biopsy specimens in 
Kuhl's study showed breast cancer, a figure that is also accepted in screening mammography. In 
MRI screening of high-risk patients [12], MRI also doubled the recall rate but the rate of detected 
lesions per biopsy did not change— one in three biopsies was positive for cancer.
These findings can only lead to the conclusion that MRI outperforms mammography in tumour 
detection and diagnosis. MRI should thus no longer be regarded as an adjunct to mammography 
but as a distinct method to detect breast cancer in its earliest stage. A large multicentre breast- 
screening trial w ith MRI in the general population is essential.
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Dit proefschrift had niet kunnen bestaan zonder de hulp van vele zeer gewaardeerde collega's, 
vrienden en familie. In de volgende alinea's wil ik enkele van hen speciaal bedanken. Niettemin 
weet ik wel dat vrijwel ieder gesprek dat direct of indirect over de mamma radiologie in het 
algemeen is gegaan en over de waarde van mamma MRI in het bijzonder, heeft bijgedragen 
aan de ontwikkeling van de ideeën die in d it proefschrift zijn uitgewerkt. Ik wil dan ook iedereen 
bedanken met wie ik deze gesprekken heb gevoerd, ongeacht wat u daar als gesprekspartner 
destijds van heeft gedacht. Voor mij was het bijzonder nuttig.
Tussen alle personen die expliciet geholpen hebben met de ontwikkeling van het proefschrift, 
steekt Carla er natuurlijk met kop en schouders boven uit. Eindelijk Professor C. Boetes, je hebt 
het meer dan verdiend en ik heb een diep respect voor de enorme hoeveelheid werk die je er 
voor hebt verzet en natuurlijk voor de offers die je er voor hebt gebracht. Ik ben er heel trots 
op dat ik bij je kan promoveren en ik hoop ook hierna op een voortzetting van de vruchtbare 
en intensieve samenwerking. Je was echt de ideeën generator, het ene onderzoeksvoorstel 
was nog nauwelijks uitgewerkt o f het volgende kwam er alweer achteraan. Ik heb onnoemelijk 
veel van je geleerd, zowel praktisch op het gebied van de mamma MRI (niet alleen door het 
onderzoek, maar ook door de ontelbare presentaties die we samen in elkaar hebben gezet), als 
in het algemeen; hoe de wereld van het onderzoek in elkaar zit en hoe belangrijk een goede 
samenwerking is om uiteindelijk een doel te bereiken. Ik kan me nog goed herinneren dat je 
bij een van onze eerste ontmoetingen zei: "Ik ben wel een drammer, daar moet je wel tegen 
kunnen" Ik kan me ook nog goed herinneren dat, toen ik je daar later aan herinnerde, je zei: 
"Ja, dat is waar, maar ik ben niet de enige...". Voor mij, hoe gek het ook klinkt, een teken van 
vertrouwen, en dat is dan ook waar ik je misschien nog wel het meest voor wil bedanken; het 
overdonderende vertrouwen dat je altijd in mij hebt gehad.
Beste Jelle, professor Barentsz, je rol was natuurlijk altijd wat meer op de achtergrond. Ik heb 
me nu eenmaal niet met prostaat MRI bezig gehouden, waar jij en de meeste andere klinisch 
onderzoekers zich op hebben gericht. De mamma onderzoekers waren een clubje apart, 
zelfstandig functionerend, en ik heb altijd het idee gehad dat je dat wel prima vond zolang 
wij de onderzoekslijn maar netjes in de lucht hielden. Toch was en is je inbreng vanaf de 
achtergrond zeer belangrijk geweest: Je hebt altijd gezorgd dat het mamma onderzoek niet 
vergeten werd, maar mee kon liften op het enorme succes van de prostaat MRI. Jij was en bent 
iemand die met een goed doordachte opmerking hele theorieën kunt doen wankelen en die bij 
mij op dezelfde manier met een simpele opmerking dingen helder kan krijgen, waar lange tijd 
het kwartje niet wilde vallen. Ik ben je ook dankbaar voor je commentaren op veel van de in d it 
werk opgenomen manuscripten en de verschillende projecten die we hebben uitgeschreven. 
Je wist de teksten steeds weer net zo te buigen dat ze beter over kwamen bij het beoogde 
publiek, een kunst die ik nog steeds in mijn vingers hoop te krijgen. Ik hoop ook dat we samen 
ooit de kans krijgen om het onderzoek naar de stadiering van axillaire klieren met MRI contrast 
uit te voeren, er valt daar nog heel veel te winnen.
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Beste Jeroen, dr. Veltman inmiddels, met jou als mijn directe voorganger had ik heel wat te 
bewijzen. Je scherpe en analytische blik aan de ene kant gecombineerd met het uitgesproken 
pragmatisme aan de andere kant, maken je niet de meest voor de hand liggende onderzoeker, 
maar wel een voor de kliniek uiterst waardevolle aanwinst. Wat immers is het nut van onderzoek 
zonder enige klinische consequentie, het puur weten om te weten? Jouw pragmatischer 
aanpak zorgt er immer voor dat het uiteindelijk de patiënt is die er beter van wordt. De immer 
droge commentaren, gebaseerd op een achtergrond van zeer gedegen kennis dwingen je om 
met beide benen op de grond te blijven staan en het uiteindelijke doel voor ogen te houden. 
Ik heb altijd met heel veel plezier met je samen gewerkt. Ik denk dat we elkaar, in ieder geval 
op wetenschappelijk gebied, goed aanvullen en ik ga ervan uit dat we samen, ook al zit je in 
Almelo, in de toekomst nog mooie dingen kunnen doen.
Beste Henkjan, dr. Huisman, ik heb je wel eens beschreven als de vertragende factor, niet 
mijn eigen woorden overigens, maar, hoewel ze misschien verwijtend klinken, feitelijk een 
enorm compliment. Jouw fysische achtergrond en de daarbij behorende drang om alles to t in 
de puntjes kloppend te krijgen heeft mij, als haastige dokter, soms mateloos gestoord, maar 
tegelijkertijd enorm geïnspireerd. Je hebt me ervan doordrongen dat zonder degelijke basis 
ieder onderzoek wankel is. Ook hebben de eindeloze discussies over het nut van ROC analyses 
me ervan overtuigd dat ons vak veel minder zwart w it is dan de meeste mensen denken. Het 
blijft een kwestie van keuzes maken, afkappunten bepalen en weloverwogen besluiten nemen. 
Ik vind het heel bijzonder dat juist discussies over een CAD applicatie gericht op het eenduidiger 
maken van de analyses, en eerlijk is eerlijk je hebt een fantastisch systeem ontwikkeld, dat soort 
inzichten bij mij hebben losgemaakt.
Beste Roel, Stijn, Thomas en Monique, bedankt voor jullie gezelligheid in de dagelijkse 
onderzoekspraktijk. Ik heb altijd veel plezier gehad in onze discussies rondom het senseo- 
apparaat op onze kamer, vooral als ze niet of, zoals meestal, slechts zijdelings met onze 
onderzoeken te maken hadden. Jullie zijn, juist door de enorme verscheidenheid, een geweldig 
voorbeeld van de typische onderzoeker geweest en samen een enorme bron van inspiratie. 
Heren, heel veel succes met het afronden van jullie theses, Monique heeft dat al niet meer 
nodig.
Beste Mechli (drs. Imhof), beste Roel (drs. Mus), als mammaradiologen pur sang wil ik jullie bedanken 
voor de beoordeling van vele van de MRIs die gebruikt zijn in dit proefschrift en voor de vele mooie 
voorbeelden die jullie me hebben laten zien en de wijze lessen die hieruit te trekken waren. Daarnaast 
bedankt dat jullie er nooit een probleem van hebben gemaakt als ik voor de een of andere studie 
weer eens in de weg kwam zitten en het DynaCAD station weer eens gebruikte voor dingen waar het 
eigenlijk niet voor was bestemd. Roel, heel veel succes met jouw onderzoek in de nabije toekomst, ik 
zal helpen waar ik kan en ga ervan uit dat de 3D echo een mooie toekomst tegemoet gaat. Ik heb veel 
vertrouwen in een toekomst voor de MRI als screeningsmodaliteit, maar denk wel dat we daar nog een 
tijdje zoet mee zijn. Niettemin uitdagingen genoeg, zowel klinisch als wetenschappelijk.
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Beste Yvonne, dr. Hoogeveen, bedankt voor je altijd aanwezige enthousiasme, je immer vrolijke 
gezicht en je enorme drive. Je weet de dingen gezellig te maken en maakt onderzoek doen bij 
de radiologie to t een feestje. Bedankt ook voor alle taalkundige correcties, het is toch heerlijk 
als Engelse manuscripten worden beoordeeld door iemand die de taal ook in haar wortels heeft 
zitten.
Beste Arend (prof. Heerschap), Tom (dr. Scheenen), Dennis (dr. Klomp) en Jannie (dr. Wijnen), 
bedankt voor ju llie steun bij de pogingen die we hebben ondernomen om de MRS in de 
mamma-diagnostiek te betrekken. Ik ben nog lang niet zeker of die rol er in de toekomst echt 
gaat komen, maar het b lijft het proberen waard. Het was altijd bijzonder verhelderend om jullie 
met technische MR vragen lastig te vallen, alhoewel sommige antwoorden me soms met meer 
vragen achterlieten dan ik voor het antwoord had. Ik denk niet dat ik ooit precies zal begrijpen 
hoe MRI werkt, al denk ik het aardig te beheersen maar gelukkig weet ik dat ik altijd op jullie 
terug kan vallen, waar jullie ook zitten.
Beste professor Wobbes, als steunpilaar vanuit de chirurgie heeft u een belangrijk aandeel gehad 
in enkele stukken van dit proefschrift. Uw commentaren waren altijd helder, bondig en snel. Ik 
ben blij dat ook u zo opgetogen werd van mooie plaatjes. Ik heb uw vriendelijke en enthousiaste 
houding altijd enorm gewaardeerd en hoop dat het pensioen u bevalt. Dr. Theo Ruers, ik wil je 
bedanken voor de steun bij de ontwikkeling van de PREOP studie. Je hebt me geleerd hoe een 
goed studievoorstel eruit moet zien. Hoewel de studie geen succes is geworden, ik kwam op 
een gegeven moment echt in een ethisch conflict met mezelf, was je een geweldig voorbeeld 
van wat ik me voorstel bij een klinisch onderzoeker. Drs. Margrethe Schlooz, bedankt voor je 
altijd vrolijke inbreng in de oncologie besprekingen, je altijd optimistische kijk op de zaken en 
je passie voor optimale patientenzorg. Ik ben heel benieuwd naar jouw onderzoeken aan de 
chirurgische kant van de soms vage lijn die onze vakken scheidt.
Beste Peter, dr. Bult, je was altijd de gouden standaard. Ik ben blij dat ik bij je terecht kon als 
ik wilde weten waar we nu eigenlijk echt naar zaten te kijken. Er is niemand die de analyses zo 
grondig uitvoert en ik denk dan ook dat de correlatie en outcome studies nooit hadden kunnen 
lukken zonder jouw enorme inzet.
Beste Kenneth (dr. Gilhuijs) en Claudette (drs. Loo), het was me een waar genoegen om met 
jullie te werken aan de outcome studie. Het was zonder jullie support en enthousiasme nooit 
gelukt. Ik denk dat we hebben kunnen laten zien dat we als radiologen, mits de omstandigheden 
optimaal zijn, werkelijk kunnen bijdragen aan een beter behandelresultaat voor patiënten met 
lobulaire carcinomen. In de toekomst hoop ik met ju llie ook nog eens een blik te werpen op de 
lange termijn uitkomsten.
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Dear professors Kuhl and Kinkel, it was an honor to  work with you on the creation of the European 
guidelines for the performance of breast MRI. Thank you for the sharp and punctual criticism, it 
was appreciated. Without your help it would have been impossible to create a document that 
was so well accepted by the European radiological community. Did you know there even exist a 
literal Japanese translation, that is brought in circulation by the Japanese radiological society?
Beste MR laboranten, bedankt voor alle mooie scans. We beklimmen langzaam de piramide 
van de "levels of evidence", maar wanneer het misgaat op de onderste tree kan de piramide 
nooit stabiel zijn. Jullie hebben gezorgd voor de enige basis waarop radiologisch onderzoek 
kan bestaan, namelijk goede beelden, jullie inbreng is dan ook onmisbaar. Bedankt ook voor 
alle keren dat ik weer eens in 25 minuten een mr-punctie wilde verrichten. Ik weet ook wel dat 
dat niet lukt en ben jullie zeer erkentelijk dat de reactie altijd beperkt bleef to t slechts een klein 
beetje gemopper.
Beste collega assistenten, bedankt voor de steun en het vertrouwen in de afrondingsfase van het 
proefschrift. Ik doe mijn best mijn steentje bij te dragen in het regelen van de assistentenzaken, 
maar ben jullie ook dankbaar voor het begrip dat die niet altijd op de eerste plaats kunnen 
komen.
Beste Emile, Florens, Hans, Henk, Joris, Jurrian, Maarten, Michiel, Sander en Tim, bedankt voor 
de vriendschap. Ik ben blij dat, ook al is er veel veranderd in de afgelopen 10 jaar, deze basis 
altijd is blijven bestaan. De ma-di-wo-do-vrijdag etentjes zijn nog altijd een welkome bron van 
afleiding en inspiratie. Het wordt bovendien tijd  voor een volgende bruiloft/vrijgezellenfeest.
Lieve Matt, Sytske, Zita en Imke, er is weinig belangrijker dan een familie die achter je staat en 
waar je altijd op terug kunt vallen. Ik weet me van die luxe verzekerd. Ik ben heel benieuwd hoe 
ver jullie komen met het daadwerkelijk lezen van dit proefschrift.
Lieve Patricia zonder jou was het nooit wat geworden met d it proefschrift, je bent een bron 
van inspiratie als geen ander. Je liefde is een belangrijk ingrediënt van deze teksten. Je hebt 
er bovendien voor gezorgd dat ik mezelf niet in het werk verlies. Met Tycho hebben we iets 
fantastisch neergezet, daar kan deze studie niet aan tippen. Lieve Tycho, je zal er weinig van 
mee krijgen, maar je hebt me een deadline gegeven dit af te willen maken en dat was een 
bijzonder essentiële bijdrage.
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Ritse Mann was born on July 24th 1979 in Wageningen, the Netherlands. He graduated from 
secondary school in 1997 (Pantarijn, Wageningen). Thereafter, he started his medical study at 
the University Medical Centre Utrecht. During his second year in medicine he also followed 
medical biology courses and obtained a propedeuse in medical biology in 1999. He finished his 
master study in 2002 with the study of aortic distensibility using SSFP MRI sequences in healthy 
volunteers. His internships were concluded w ith an internship in radiology, during which he 
also concluded the distensibility study. After his graduation in May 2004, and after a well spent 
holiday traveling two months through western South America, he started working as a clinical 
doctor at the emergency room in the Amphia hospital in Oosterhout, which he exchanged
6 months later for a position at the ICU in the Amphia hospital in Breda. In August 2005 he 
started his research on breast MRI at the radiology department of the Radboud University 
Medical Centre. He was involved in studies to the many different aspects of breast MRI, but his 
main focus was on the value of breast MRI in invasive lobular carcinoma of the breast, which 
culminated in the present thesis. After almost 2,5 years of full time research, he started his 
residency in radiology in January 2008. Currently he is still working as a resident in radiology, 
doing breast MR research on the side.
In early 2000 he met his wife, Patricia Poll. They lived together in Utrecht from the end of 2002 
and got married on the 27th of May 2006. In November 2007 they moved to Nijmegen, where 
their first child, a son named Tycho, was born on the 22nd of November 2009.
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